var title_f14_15_14576="Central lung tumor PA";
var content_f14_15_14576=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68761&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68761&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Central bronchogenic carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 344px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patient with advanced lung cancer. Chest radiograph shows complete atelectasis of the right lung.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_15_14576=[""].join("\n");
var outline_f14_15_14576=null;
var title_f14_15_14577="Waist circumference measure";
var content_f14_15_14577=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F77584&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F77584&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Waist circumference measurement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 357px; height: 468px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Measuring-tape position for waist (abdominal) circumference in adults. To measure waist circumference, locate the upper hip bone and the top of the right iliac crest. Place a measuring tape in a horizontal plane around the abdomen at the level of the iliac crest. Before reading the tape measure, ensure that the tape is snug, but does not compress the skin, and is parallel to the floor. The measurement is made at the end of a normal expiration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Heart, Lung, and Blood Institute. The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart Lung and Blood Institute, Bethesda, MD, October 2000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_15_14577=[""].join("\n");
var outline_f14_15_14577=null;
var title_f14_15_14578="Esophageal foreign body";
var content_f14_15_14578=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76887&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76887&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Esophageal foreign body",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 428px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The PA chest film demonstrates a coin in the esophagus. Deviation of the trachea as a result is also noted.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Alan E Schlesinger, MD, Department of Radiology, Baylor College of Medicine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_15_14578=[""].join("\n");
var outline_f14_15_14578=null;
var title_f14_15_14579="AKC eyelid changes";
var content_f14_15_14579=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F56670&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F56670&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Eyelid changes in atopic keratoconjunctivitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 267px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAELAXwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDjBHE4eAuwC/OzdCapyqpXEEhOeM1oStH9taOOLEbffz6VSnkiJZEi2HoBjqa+cPuCjHYG6udhYLtGCas7Li0yjt5qdhV2DTNkKukqktzjPNT/ANnTySIkWZHcgKoGd3FNtlpWRgK6MGzFsPXgdamt7VU+Z5TnPFaWqWhhjaG5jMM4HpWJJFJbRN5ZLtjoearfQl2WrNK6ngiHTII6etZm95pTtYIuDgE+lVo787GSVQJPXH86icu77uM5yABWipW3Ic1LVFuJLjzy2HKnnPpWzFLZW1upk3bmHJHY4rEe+nWJcNjHGaqSSgk7/nJ70cjluK9tjVN69rP5sDmW2JxtJ5FE2rm4cRxoqAnGaz7eGNo2k3nI5ZfUUHyMOUwvYZ60ckdieZodLKBKcxgIPvdCfzpzpbSLmPg+xx+lUi6htzFm9j3quxO7IHFaKnfYmU7Fxrh4gEQ7lX1FPgluWZjCGZj1wMkVTQ7+WPNbmhzJDvAleIkYJHFKdorYun7zNLRNIvJwWW0cyMQqtIwTntgHrWvH9rg3Sy+TvQEgZxyD6VQutXzDGzXZM0Rwh5J/z71Ob+41OPbaxb51x87DgDvn3rnavqdEU9jUi8Swx2R8+AryASPX0qX/AIWGkEIt0ty8QOVLDO2sZPDM9/sZ5GaQZ3cYQD2q5beDlkmVBlz1yRwR7Uko9S3BPcS68b6rc3DrBM6wN0UcYFMim1m64t9SkQSddu7P44rvdB8HWUEZSS2jM5GdzH2rs9G0CzgkGVQuO64wD70tL6GM8RSprY8i0vRJwGh1O+ufskzjzxFFmQ4/uk10dr4QhulP2YXUtrG2B9pUbtv4V6O2lWsrSH70hJy+RzVuOwS3tEQKjHPy4P5/nT3OeeO/lOFtPDemWwVmSNXUABVUEE+9bkem2jgR20ESoeQAOQe9dHa6fDI20xqE6YIBx/8AWrUtrJIZDheOxxQqbexy1cb5u5zum+GbSTc11MYNxxsVByPTpUUfhq3jSVbdiy7sDcOvPpXbJENo2ovHTIpkVsA5x948mtvY7I4/rs7t3OUk8O74hHu3Qrztz37/AIVBbeGmto90LYz0B/pXfR2nPJGfemz2cmflwRjsat4fQhY+e1zgxoUs8gWd3bb0fufxqEeGXjjQ5UsDyCM5/Gu7itW8smQEn39akNrlQcdeaSoMv6/NbM8p1TwyiSyM0ccauMDaM/p2rlNY8IK6Epbx7wD85HBr3xrJWB3ple4HWs+9skcHbGGUdNw6VEqUkjqpZpJaM+dU8PWrItvcW6kk5yqYI7Hmnz+ArCWdI1c2sLPg3bE7Uz0LAcgV7BeaNZlkQxSeYDkeX1T6elZAsJUebEjPA3BOfmrLnaPRWMVRaHkt/wCGfE3h1ZUtJRNbjkqRvUgj7wyOhFcxPq1zEvkXVsIiOuz5f0r3qV/Ks/JkL4yQFI4K+3vXM69oWnSWySGGOaORDtYN/F/Sq5k9zSnVb3PJIdWfGxZ5AO4Jq3LrRmfEj+cQuBI3BHtV/WfBhtlSSHzRE67gzAHHvx1FcxNaT2Mq/aoX8s917j2p8kJbGnPJas6GHxHKuTJ5ZJXb07Vo2/iJlhCKIgxOTIwO4+2awbG10a5lRTfyxL1bKfMPYD/69dPe6H4UhiiawvdXnkXHmCdUQY5yVxnrxUygkHtE9NyaXxFLcJGEg8zEQBfbwD9fSqZ1KaSbYxAiyCY93Q/X0rc05fCEkLBrTVoE8kLtivN2+Tn5yCOntVzRtI0m6eSDS44FJUh7i/HmBeM8ADj0zz1FZuLfUSqKO6aK1n4gWKylEFnbrkjfPIu9vTCVo2uqm4UsqBJj8kUb24KjPB+pp+lWEdlfwrFYxLfKCy+bIQiYGN2D0POR+HFaWgQ389nJFFqWmwMJSrLdz/O3oeR90+o54oSbM5zirsqw+GNS0cLepFAyHZtDSAyAdQzD+Eetaqz6w7PJ9s0+BnYswJYbj0J4Ht+lZeryX0bymdYjK+CHgkDRrjgZ9uOlQQ21ptI1CHUbq4B+aSC6VUP04PFC02M2nNXlZnDa2LppeYhH3J9M02f7HMyKjL5hUbu3NS6kZLmMlZ0ZQcA+v/16yogFVoZYzvI4PHNVJ2NbWNaGzWYKIT0+9npW1pkiabexzSY3oOM8/pXKWU08TsqOW4yMdTTNQ1yRJAs8IVu+BxTh5DbvudP4okXVLs3MjJk8DHAA9q5e8t4II28yYKTwCayNSvp2ZSjMqMBjFZryPM4Lkt9TWqpuerIcklZC3iRbv3bEnNLESFDcgjqR3phAUEllwaI7oxxvGo+VvWt7O1kYaKRLcYMYbJOeoPrSWsKSRzlTukRdwX19aqEkrjPHpU+nXC2t3FM54Vhkeo70OLUdA502QiU8HHNMdTuz0B5wK3fFukrpd5FJbndZ3aedCw6YPOP1BrA3h1K5yw7CqjrqjKT6MkOACGPP86YSeAAPrSKrZ5q1b2zS8KOcZ60NpbjgpT0RAiM7ADqaspbTOWVQTg4q/YW/lzKWUGP+I+1athCfMDMGK54ArGVXXQ7aeGVrsq6Zpm2aNbhWDNyARgYr0HRLJVI8tSWI+4pArCitjI7OseU+6Gc8j866bTbZTGic7V6unP61k03qzqlFRjY3NMjYpI6OmZFI29Se1b+n2UVtdLJHGocgfJwR/wDWrN0KFo5Qk4UKQQox/XtXV2UEXn+Z5XnyLkKjAYx61m97Hm16nLdFm0to23SEKHfjrU8FuhgkHCjHQD73vTvJZ4I5ZIwufuhe31rVt4hKFZGbao6mrjC+h5k6ltTNh0/fEw+YLjHBwRmryWYQrhflHUk5xV2GBdpPJzwamitlXJJy3XbnrWsaJzTrtlaC2HJVcE4z71pQ22VBz+dPjXfEPLAH9KnzjC11QppHJOo2MS2RfWnosagjgU1k3jG7GaiTKjbkNjua0tboZ6vqTbkPB4PrSq4CnJ6Vn3VwkUwZQzY+9jtTgjyMrwghCMsG6n6UubUrk0uy0Zh1PCioJrpUTcoOwHk47Ux7dmm27isYGSKSVHMZDNgcAf41MnLoUoxHx3CHIzjdz0qrcSI0zLE2PlzuPQVLKoCF5ANgHWs6C9guZJUVkAUfMp7D1qJytZM0hC+qKe2I3khLkoBhucVWnhhkVkAO3qpx3q8xs/M3nLoeNsfQ1VYrFAoZXTqeO/pXK0dkWYdzpUYdJZSB3BHrXL6r4f8ALlkeGRVzkheoNegCNJIP3o+9z71nahGlyIoShIBx17Vm0dtHESizz1YntoDFfRSS2xyQiPgD3X0NYN9aWsti0M6k5PI6YHPNeh38ZRUaJV8oZTkYzWVqukQztmOMiQqG4PAHf86nY9CFZPc8a1/wlPaEyWQ+0wYJwnzMAOvHpXMB5YiVDsMdiTkV7Zb31/pImt4G2RykCTAxkf3d3UD1+neudvPD8GqTCODe1xIcKO+ffue9bwq9HqE6N3zLQ88hv50ACyMMehrY0/xJeWJ3QSnpz2z+VVtc0JtPjhlWVJ9+7eEBzHhiAG474z9Kxi2OCePWtOSE9UY+1nB2kdSviO8up980+DnPTGfxrqNM1iCUNDLdRqhwSojyVOOoPb/69eXqx/Cp4JniYFGwR0HrWcqHY2jVUj1qXUdO85P3t1LsBXdPINijHYKBnmteHxRp9tDHFbxpMgUZYrjnuOD0rzzw7rJgZZLiCKWEkb/k4I7g46A+orQk1GGRyyQwhSeFAbC+w9q5paFuEZaMrPLZKmQWGR061RuLmJ4yA3yg8cVSlk8liDt29uetRObeXiTqe4OM1py3Jc+xDNK8LCRJgQT0zTGuVu93nvgAZHGM4FVJkjVcgkn09KgZ14A610xppowcmjqbS2tbzQbqNnxPB90Y5OBkf1rl1cZG/IBoimeOQGN2XPBwaSVlLZ4z7VUYcuhEptjruFoZShOQQCCPSouQtWbsNGsal0YYypHp6GqwkKnIIB+mauN2iHZMWNvmGcEVHK6xknI29ajmkCJuY4FUTI1wSG+729q0jC+py1sSoLlW5rXOuXN7pVtpsgBhtnLRseoHpUMUfII6elMtIcx8gbl/lWlZ24kdVIznt0zUTlGCsjXDUZVHzTJ1th5Mbrzn17VpaXaLIQu4ISMHNamlaX50YQxltnWtqz0aL/lomV6ggda4nNyPahBR3KWm6diVk44HPPWtuPSpZGWO3VQWHBPat210NmaEmMKZwGUqRxjrXd6f4bjVUWQtIw6+ooS6IyrYuFJHksmhXQkKjcZEGWGe1dn4dWK5tEtdjCY/fBGB+Br0FtAtQVMcYVe1Mj8L26QPI6t5mcqVetVCTOKpmUJxsznILVbRsYUEr90nOPWulitRZNDJNIUldAVGecelZdzpnks8kjF2L4D56cVjxXN7caqjXNwTbxjaq55IrNwsZNOsrp+p6JDGsk7KoPlYz0q3DEFxxtHSo9HO+2QKMAjOW61Nvw5B7c10RglqeNOTu0XI4wSVBwDyeOtJMVU8euKx4L53ndFYblbnPQVYuZ8nlgSO/pWntI20IdKSeppwIw5jwKc8btk+Zt7dKyfO/ds5lCquMjuTUMl0WB8twzU/aLsL2TbNZCUbbI2MfrUUtzBiV2YqoXjB61kR3MkiM6DLIcY7GsvxBLIzW8Fy6JHJ83ydcVnKrZaG1PD80rNmZZ6/do92FdAEcks56c10Ph7xIusKZInGUO04I/PFclp2kLqcuoKZFgtZAXDkY4H+NbNl4ZtdOht7mG4Ci4YfPux8v0HWsKU6jd1sejiIYezT0kdQt2zXDRFss54OamWJUUiSTeecgckGucngaO8muy6z2yYI28Hp3/HPSrtndtM5MWApXJ/wro5+558qWl4l1I4nXi4IH90t6VElvbp5RkjUb2wz+orJubwm7WBIW8kZLtjkH+tT32vWdlZxqsJnnP8ABjgD3PaoU4yL9lPRR6mhfqlywW2VdkfTacVh3r5Zo5WZxHyccfSn6RqX9sPcSeSIio/hP4cetN14i3DWdtZusDAO9w45ZvTNTO0veRpTg4S9m9yM38dlbZvoma4yCEHTBrOknWSdJ8yKjLwccg/4VN/aW7y4LiJXkwR8oySO1VLmXyrWUrw0jgY9vas7aHVCFnqtWVNTkjhgaFlcjhgvQjPXmsa7uEtllgimlDr93eOPcCtPVZnuZllmwAqr8/HPtiue1FLmORri8AiSRflBHBHv6ZqGl0O+jHSzLF4sEwACk79oYj+LvmqNxpNvMkptyU+bPUjj/GtDTke5s0eFgC3AUgZx611tjpEJsykw2sn8RPQ+/tSSdwqVlSPOdc02W6iRL8RyMqgF0G0svQZ7E46GuTm8DDWI4YdDjkW/V2e6knIS3hiJwpLdQAACWxzuPpXreqaeY7Mi3Qs0YILDvnpn0ArkLm2uGj23kQEaqP3sZ6fX2qleOpUWqsbHkniLSbHSL5rax1iPUinDvHbPEm7uAW5IznnHOPeq+mfZJJRFepJsP8SNtI+telS+FLLVpDFJctbXfmNuuHG5PLA6IgGXkPoSB71wGraSlndSeXLJFEC3kvOhBkAPByuRk47ZHvWqqKSs9zJQdN2RN9im025HlsLiJk3/ALo84Pb6j0rotP1izhtwjLL1/hGPz96wdB1hoJEjlCnttIHI74PbqeK7ux0TQtStUubd7iDdkOnythgeepz6VhNNPXc6FJWPJJC7ElsknuaaSGXrtYUxm3AKT096YTg9a77HE5E2zKH5un4VE2B6UgJB/wAaU4K+9Mm9xvPQfrS98mik3D8aBN2HkjquSPeoJJQvTJPbihmJ4/SoZFOenOaqKMKtV290hbdNnecYPFT28OB05NEUXIJrRtIDI6qOpPWnOdkZ4fDucuaW4ttDjkjP8q6LStPMqphcMORgcn15pbHTHFrFJtDKTyR0U5710/hqIrJsV1RJTsDMORXBOfM7Hv0oKESbSHezmjEcavGvJB6HmumXF/fK4QJJJjeBhVA+lZ9lp5W7KqMxgg7c549c+tei+FdHtBBLNMCpVdwI6D/E1Kjd2IxFaNNcxe0rSgnkytztx8rjPArpbe3OcqpRs5zjGB6CqXh1POillQE7RznvW1DIAOcYxwRXRTirXPnsRVk5NDPJkCkEbsdz3p6QiTCEYbr1q4r+aNu3Cr2xVZ32zElce1bWscik2TT6dBdxGKTI46r2Nef+I9B/4m9mYnKtE2XGfvCvRbaZGXagO+snxPDBcBWjbN7GuUx1bnpSqxTjdG2Erzp1LdCWCTy49q4AAxWXeamIHJZhsHB45xVRNRBsJJOURB8xY9DVG5VZ4Fk87KkjDYx1/pXO58ytE6KdC0vfLj6onn/Ij5kGFJXr9KnP2yGLz7srFApO3u30rlL+7EQBWVpJFGE5+7zVTWpbi/0aITXbvKxPG7gCsm2tzsWGva2iNzWtcFrpT3satLBvEasxwQfTFZGheJVupDGwYF2wO+K4fU3vIIpbW7MjxEZGBkD39qs6BcWMVjBNHNIZ9xEqMBgem01mm2zuWDhGm1uey6VqdhZwkOzGRuXYjgVm+KLi1vHKxzLsCEb165P9a4qTUh5c22ZVVQSNw6+wrLW/ZpEdW4QfMCO/9a3c7rlOWngLT9pfU9JiS2/shMzjzIVCxxHHzfWlN40MQBgiQY5PUCuJOppcorAssijAHv8AWqv9s3sci+U7MY3B2PyDihytqhrBye53sl/JHsYqm1uiEYyPpSq89yFSF1hb7zFR1PoK4ObxBd3d959wVyeAo4UfSr0WrtEjv5mM/MoDZNNyvuJ4SSXmenW1jbwWQutQbdcOud38sCoZZ7IafPHAFmuHUgfLkVy2i620tsd5L788k5wKtwSbpVlTqc455+uKpOO0UcEsPOLfOxlppbw3KyhyHU52qePpijULjVTDI8srT4b/AFYwoX0+tXzOFnjY5KZ+YjrVaRixmcjqeFI7fSomna0WaqTcryVzE32+p3IjtHmivVGSpHDf3se1UPtU1peTRtsk25RCzZGe/FXLpZIJwLcjzZfmwnDc+9Zc2iwPOJb6ea3SP5Qqc+YxPQ+g96jU7ocvXYW2jmlk8yYboY33sz/oOab5yXcs7s/mhSvynkk9OB7VHqtzFcoHKtGwdQgU8ZHTioIYWtZ4ictvGMnjbmkmnsbJXV2bWmrAkyHDbQSo29eK0b+8ubR1hkwY5R6ZI/GsiBfKt3ljyAD1U1E2pT3tzmViJIzlWIHyj+tUjF0+aV+hv/aJYJFFwMR7QxA4D8cE+1ZbXi6Xqm67s4LuKUf6hiR82ehxwOKgTUJdSW4uby4ZygEap07YH4UXP2c2lvOnzbA2UbnPGCaH5CjTtpLqIYrSK4mJtfJtpNw8tmzsBPr3xmsDxF4Yh1K1uY7bCyoysXkywCkcDdztHtiuoeEzwQyZA3nCbsY9OT2qe+H2P7JdJD+7aEANJjLqRjoOAPTOTwDU8oe0adlueL6/4A1C2jSe1ETwyK0sMQOJZEBOWAwM4xz0I9K5o3N5CfKljSRk4y684r2bxYqqIJ4WaKYrl1jc4YdjwRzzVjSrPwnrVsbnxWtxLrCtsmljA/eYAKlv9rBA/Cq1lpa5XtHCPO/wPnZrdtgcMpU+9REEHGCRSZweMinbyP8A69d1mc10xB78/Skz+dP35A4GPak+Q8KDn0FAeg0gmj2A6U7bkZPC/wA6F5OAeKLktDAjMQqKxJ9B1qQxERhifn7rjt61ZiQRoH3tvz0FIFeeXLEszfp6VLkNUyOOFg2CvOcGuj0Ow3DedpL9FJx+dQ2unHajRncWAJLHGDXSRWoidFjBIYDaDjqev4VzVKnNoj0KFLlH2riALGy/ITkehPStnw/ao86iQM24ZJPGOetMtreCYm1YFj/E3bPtWlo8bQzOrLzGnI9hWWx1t6M62ws44oxPlSfMVVVhyyjufb61pS6hmaUKCsUp3bVPXBqGCdm0tU2jzUJ5xxtI4GKS2dP7LSXbmRH2OTjBH1p2PMl7zvI6iwDLaEWU43Sr8yg9RV/TJZSjGZSWX17/AIVz+k3SWDq6shWXHJGNv1FWdQ1WSzuUMssbQlv9ZGvQn1q1K2pwTpSlJxR1XnOFGw4z0qqbotM6u4BC7ueDWENVZIMoXlVvusecGuU1DUrtrneNivu2ruGRzjpVSrE0sE5NnYvrKGT9y4L+3+FY2vXk1lc29xbySmQKQ5YcD2Has3VL2MXdpgiK4K5cL1atE6xDcaRNZOgfzEyHbqD7VN+eOrOqND2bUkrrqcOfFN811dR5QxNlZc8rk9wPWruha2sdsts2ZAuSzMCcr7CuT8Twol4zQR+Ww6jHFZto9zFKWtxIWI5xyKhaHsewhKOisenXUkCIcKSCMk96xjqISeMk4VGyVxnNcpP4gupl8uSUAg9Peqx1JkALBSeuMZp3FHD2Wp0Wt+IJbxpUIXYx2lAowVzyK5xH2OEgUIAeAKybjUmNyrZxt6AUltqiLMQzDdnipvqbRUYKyOshme5JUYRtvBY8cVX+1SxzuHKlfYelZo1GOfAD9McjikN9AuHdwB/P/CmrD0NWDU3imDIB0/i6Zqe71psAk/P0ridQ1tBIvlYPr6Gp7e9imKvNLgj8s0NNMlODZ0kN7O28tzk9MVbtblp5AhUAg4x/9esOK4aF9p/i7mtPSJEa4UAcr3Ap6MqSVjvNHDw2ZGxeOeB9761s2l0yNsdNuOnFYdheQ+UAGwRwQD1pW1HbvZsHuAewp7Hlzg5t6HWtcNksxOwjHKgmsm6vGcsrbgSSADXPT+IDtIV2AGQB7VlXGtb3By2CccUnIVPCSW5vX80ghxGTxgFsdqWXVbgaXLZypFLG38bL8y564NczcayyICRgE5U44qnNqyNcFi3ynnFTc6lQvujUuEXy9yAhM96uW72/2UySLlw23Jbnb3+lY1rqOFKMwfJJAI7VB9rmbIXjjuKZo4N6HcyasiWK2okdCr/MNo2KO2O5NZ2oTBxHz8g6ZGc++a5jzDKDggkj8a0YtwOJSJG6YP3QKp6szVBQ1RcjuwZog0mADgd8Dvn1rZguYpBcM0aC4uEEaK+FVFUdcep9aybe0iXZIwZyr7gqjr/9atM26C4PEG+4beuTkAH+H2o5epnU5Tn7m9v4HMbB1RvlUHpt9u3410VlNJceCpWjttwtZDG7Z5Kk8ZHcjJrA1a7ae+/eKkh+6F6Djpg+nvUuma5ItjewLjE6iCUrx91sgr78Yz6GpW9h1YOUU0tbov8AizTWewtJLFzLGYRlSMMGxz+tZFvZPeQrO0VursMMArDkcHIB68V1JuAdNW3x+6kw2xjkjaP71Zek6/pdpZCC804zTo7bpfN2+ZliQSPoQPwpSWuhhGU1C1r2Pm4dPSlz27/SkAP+NSAEYwK9FnIlcVIyYZGY4xggeuTiheASvB9qlSQpC6DBMhG5SMjA5/nT0tjgNIwB647AepP9Khu25aj2GwWrzknBA5PC5z+FaFhYi6zAht4SPmaeZyAgA6cdSfQAnpSxybliiAyegHTP+ArYsNOt/sPmzzvBMOVgEeQ3Pc54x71hKozdU0ZEdiqk+ZJvz90Lx+Yq7YWYaQMVUHd06ZHatn7IDHGVIaMAjAXG7nr+vfmtHTbZWdYiA0kmQvHvWTk3ubRp2KNhbGeTMcbMep29QK6I2pMojZXiIfDKy4ZeORjqK67w34fu7qynazFuGSIuS5IJI5yD/e9O1Fjpv9sXpnkRxI3HmM5LOe7nJ5b3qUtClXim12NzTtJtxYJCqJkgBc4OB3P+etUvE/hqe2WO9sYjPFgmRUGW2+uK6jT4BbiKEj7hCkgZzj/PWupUTizuBEUAGDGwGXQ/4V0U4KS1PKnjJ0p3Wp4z9sj8iP7KdrsBy3ana3rCz36y2UTW/mxDzBuzlh1IpPH2l3ObjWrUwBvNzPAsmHz0Loo7cZNcQNSWWNZN48wc4PT3rG1j2aNONVKaPQrL7ZqVhMtjbmeWJNwGO3ufWnX3iSW6sI7bVrQLd7Qo2jAUDpn3rk9H1a5itJlt7mWAE8lGI3c9Kmk0nVddM13bFp5lKhoif3j54XA7+lTZ3E6EVK87JLY6fTNaeBFScb49m1VU9/U1W1y/uUsi0MihJME5UErj09K5mKa4tLtra4RoriLKSRP8rKfQirl7OtzEbck/JngdT3q0h+wipKSKz3klxumncmRjnvn8Kig1uSAEMWZh69qrAxKxUDJXoRk1halceWW3/ePcCm7WOlRT0Z0UMh1W+Yy/LEvLN3J9Kffp9njYwFWRhgjGDiuf0/V4vJKFyhznrVTWPEdvbQYEu9umB1NOL7GU5Rhq3ZHP67etDcMVfGOfXBrGGvzbMNk1m6lfPeTFm4X0qma66eHjy+8tT53FZnOVR+yeho3GrTSH5QBnuapvcSu25nbPsahPWiuiNOMdkefUxFSo/ekWEvblPuzP+dObULph80zEVVpKfJHsT7aotOZ/eTNcSscs7Grlnqs9sw5DDv61nUUShGSs0OniKlOXNGWp2dl4lEwEb7g3vXW6DewDLO+D3HXdXkI45B5rRsNWntjhjvT0rjqYXrA9nC5w/hr/AHntdpLvlBV2VOxqS51BVdlLY3HlvQV5pY+M0t49vlSgeg6VXuvE5uOiNn1btXN7Gq9Gj0fr+GevMdrqd4qMUWXnpn2qlBeGPKvJu9xXM2+p/bZVRlBIHGGAwPxq358SqFZZk6EMw4PHB/Ks5U5J6nTTxFOorxZ0dzeqIAqZ34yxI61TSGW8nDpkIBjBOMn1qjZ3FtPKsd3epbwjnf5Zcj8BUmu+Va3C/YNUg1GF0D+bEjRlCRyhVhwR7cUuWXU0547Grd3g0+YwsyNKoGfLO4EHnrVu21KCUGMltrcbu4rhGkPPp2xTopn3BVY/StORoOddT0ex+yRXMZvLtIIckljlsD6Dn/69amlLJrkk72Il+x2xAchc+XnpuYcAk9q860+zmmdS4Yxk4JHWvrHwTZx2nhvTNNtAn2VYs8IF3nqS3qfetKUOdnFj8T9WipWu2cBb6Hqy222AGOI8bAQxHvzyTWppFmlzOkFxBMu1SGcptfd3+XsvvXoV7bMhIjC7h0JHFZn2y4tLqCYoJYc/vFVPmK+1bunGL1PH+vTqp2R57rXh+3H7vZHAVBZWB7ZxkHqO3FcdBYPpt25kO+JmwkgHIOeM+mfWvTvEKedNM8Nm5iG6QMBuO0nAz6CuTvmSSCWBoChc4Kgc+59vauWaSeh6WHrScdSjquoPBZqoYPIBlWAH5Vh6tbpaXzJaXMl5A6rIs0kXlMcqCQV5wQcimWwmgvJFvpsiFt1v8vDd+fcVXkuReTyz3qySTO5JdyQWHrWTOhRs9DyYoVJDAg+9SNEwRWI2qwyCehq0loxVfkWNe8j9BxV2EQhw9rG0cQXb5jsGZ/w6CuyVSxxxgZkVtKeURifUitHTIj5uAm6XOOein19qtWsQZf3oZu/zc5zWnaI8aCKJBGrnPTv71zzq82hvCmkVobZbeYtuDSsMlh0FaENt5lwWYl93OWIyB744H0FT/wBnRvcQrF+9mJ53qMA4+vP6c1rW0CQSJ5aZYjCBeNxzy30rO3c0SILWCa4Z4lH7pBuYDg4H8q2rbR7m2mgaa2aGFphHlyN2SocEjOeVINbFpZXfhxbO8KFLq4DTxsHHyAdsdQfY8c960dJ0qKO0/tm4ML3nmB0VgCDznGPQc59aq19CHVtqtv1Nu+cadbXNlaspbUEQqEOSsZHKk9ua2fClstrdqWjBwpXZ+HSuMs5Fn1h3yAgbCnbt788dq6DTroHCbzjd8zN92P8A3vSri7ST7HFWptQce+5txSlroqkQCQ/PvTn92Tjn3B9K2bfV1t0HmiQlxlQFBJ9K4LxF4giBjk09xDc2mYJGjIxMj/dIHfocmr3hvU83aS3Mka27JsYPyOePlNaRqWehzVMK5Q5pITxvo/2q0uLuztkW9RzJI6sAyRhcsgXo2c54rxDU9Hgt4otQSeMW08hjMEjfvIz13bf7vvX06PsbRo3lidgvloxj3Mvv7fWvHPHOipaeIZZjGDbzDo65wuOce/8AjROF1dnflmKb/dP+vI4nTdjOzQuxA4G4YDVvfbJESMpK0TxMG3RMQwI6c+x9K5HUYnsJN7JIlrIx8oFhnA9aI9VRghPRT3rFO257EoqRoX93LcX09xJJNLNI25pZTlifUmmpePGpG4tk9CelZ5uFkYuzDk4wO1OaQxxqwBfJ4A70X6j0SsR3eqMuVXOQPoa5jVtTdt2W9s1pX8cp+8oDnjisSXTJ5Z0EiEKDyc1pSipPU4MbiHTg1EzZrx9mdx9PSs+SRpCcn867geH45rQqYuepb0qCLwbKZAYGL98MAcD8K74JLofNV5ym9WcaImOMLnPpW5F4U1Ca2WWFVYEZIz0r0LSfDOm29usl6rMU67uhHtXW6dc6fKgsYE3s6nb0Cj26frW3K7HHzxTsfPN7Yz2b7Z1APtyKq16/r+kPE00d1AgMowseQ25fWvN9V0SazlbyVaSIDO7FTe25Vr7GPj2o7VM0Ei4yhGen4UnkybQ23AJxTuTZkVTw28krhUUknpmpraylkKkKGzwBnqa6XSITawsJ1CEYA+nvSb7FJdzmf7PuSzARMSoy3HA/GqxRgxBHNesaaIrqeWzVTuVA4JACsD2HrTb/AMOQTwBxDGzt0XpVJO1yXJXseXRW7yH5Bk1dh0u5dQyR7vpXZp4bW2kVjGA4H4VpRWSIqkBATxjHSpZrCxx2j6Fe3M20Qnk4zXXS+GJoJIgJHjG0ZaRcANjJHGfoDXq/w50AQFJjEpz/AHhnp14r0S50Gzu4zFJEGBHB6bT61xVYuT0PVw+Jhh0k0fKsulSSTSlIsopzn0Hrmkj0CSWVUiAfOeAemByTX01c+CNJkAlEG12UHA6E+pFYkHh610HUUvmgjnhgcS7WbALZ4HT6H8KwcJRPQhj6U0+Vanz3eaLd2T4vLeSD5BIBKpUsp6Hnse1b/gbwxHqcv2i9ysBO1B3kP+Feh65pF742vrjWLmSEQmRV8tgVaQAcBR2QdMk5JrpvC+iol9CEyi8LskTCrQt7Gs8RGEOZ7r8GaOjeFLXQpIZ9PiSRmH7xpSFGfQf41051Wz0lJFWKdGIBSMgfLnqPp3qeO0upmlWSRmhjPPlKDnj0qnrB+yJCZkSOAqQUxweO/vXTdxWh4Eqnt5WqO5q6rcxNZW0qzIN8igMBkL3OR14rGulE4knEhEecAEdV9faokllihSWN182JcxxyDIZfSoTeSTR+Y6hGbmSOMYVCelTOdxU6ThsQXbTRqYxL5cTKDhW685+b/Peub1qOHy7slctIgYuD09x61t6tMFtSWdecBQO49a4rWNTM0mwhNrL5ZKqACvf6Hiuecuh6OGg3qclJPDNqV3FdRySFIgsTI+wCXsW4O4Y6jjr1qGJJJC5RQF3e/oK09FitrCXUf3bS2k64w6hiuTg4PqFJIPqB1qrNZzwysmcLwUJBXcpGVYexBB/Gsnc9JNXsedyRElcRvsx8pI4b6U/TrXdKfPIWMHPTOP8AGtq3tEVmDSeY7YO51x+XtT5Lc7sIrduW4xz+lVzOxCgQLblpcxr8oAGc4IrX0y2jYiNlcljxgDI/PtiktdPniBM0QRMEqT/PHetPTbSUzRuSIDImTI3DBfbP86lLqXsSWWmxwXSpHIGlI2s3QIvc896vaVCJdYcQnfHDwZMjBOO309KPIURNHBCfQdweep9ea6fR9Ln0++NhMipJGVLbMPjeM89s+1P0M5zUU7mlpmnzLOLmOHNwwJRpRnB7H6jrWfNEy3U9oJMGPMYIbIb/AGgR6nNdZdoywxhS8Sx4yVJ5A9PSuWlBGrXMgDrGZsozJlRnov1HpWslyo5KM3Ntss+HNFne92KyLIJAocDqT6j6Cr2v20nh8zyQBGhYhGY5657epHQ/hWpo9wQ/2gyxho23lMAHHqPXrVbxrqdtcST2TvuiuVVo8qdu7oSPQ5x+VXyrluZe1qTrpNadTiP7HW/06WW2mh+0xyMZkPVQehHqKqWupyaey2N3uSYPtkTGR6g/yqW7WXSWmtpUaG4dGjd94xnHDD2x/OqVldKPsfmRfaImfM434aUcZCn+E4GM1i12PVinJO+q6HoUPiEr5bIGgXaFkkBHzkDtzVPxNqEet+UpU7IVIRm6lq5LUdU0576QWdtJZwbsxqzbto/n15pzapZQQ5cB5m5DMenvVRbSs9jnjhVFqaWpz/iGyWzY+eokRhgE8/nXD39ukDFvMCr7nj8K6Txb4hSeIR7c4HAJ5rhJZJLyfcxJ9BSS5jtlU5I2e5cS6i3Ebsjpwuc1eS/lZRHaxFePvNVfT7EuwEa7mPcDNeh+GfAlzeuXuAY4Au4t1wB/OpbV9DGVZpXk7HP+FPD0+q6ggcscjk9gK6zxH4VFpGjRgEAc7RjNeoeG/DKaVCgMZbdwq8AKM5+b1NaOv6cktqfkXJPfvXTRvHVnjYrFKpLljseBWFuiB0lPzbuRnGfxq+ssOnAPChJBzweBnGP61p6zozW87yAL5eeRnp/9aqiwCXLEKU27uV5x9K64y6o4KkSoxF7KI2jkmkfIVWbOB6fhVSPTJNJUTTku+MAEgt7j2FSvMsTAWYKkHmU/e/CrlpbrcwsmAxc/OScFuPWtoyucko2JbDUhq8ipJbxpl8IyrlnwOP8AGqus+FmmcNaKGEig5yBj2NWVt2WVEtNkRQfMem045/SqkviNtNR7GGcbyCSzDP6+9OVlqZxbvocm/h+F9VXdGSFbbxgA/SptT8IQQIuSYy3AO7gt/jW7ZX/nLbvKpAzuO1ev/wBaq/iPWleJNuWCSeahbquPSk4PlLVT3rFG30GytbICYFZdpxkZCHPXNL/YdrfIpa7ZXVsg4AUc1eh1GPUvIa92fvAQJU4XPXn3rJaQreXEVvKHjU9Cc8+q+lNKK3C8nc3IdNisGG+RQR8pZG4+me1OWVnYsg+cHBx9ar2gSXBEL+YwCnJzv+oH41tixjaAMDsYHa0ZHOBzxTlJJEwg5Myi00iyb/nbuvUY9qveHtNW9ugGztXtV5YxJCqJFznrjBP1rrfCGigOCCPtCncMDgjtzXJUqWPRpUuVczOi8J2EtpZiOLaOSHB+bnPABrpJJHQF4AC7/LtbjBx0pFtylzKUbYCBldvXjvUF5OTMLZBtkXDSsP4FPT8SelYRvHcJP2krk+mytfXAwvZQqgfdHvXK+LMTHy5ZQbUyP8w4LheCcehPAPsa62aNbC1TSbKQQ3EwMlxL18mM/eY/7RyAPrXOa1cWl7dNCFKW1qgiEYbPTp+QpVNVbqa4b+JzJaFDSd6mJLeJdhGQrdj7D1rprLTZLwytNcyw7OAIwCrZ9ag8PadDfGdeY4VABMeNx9AD2rqVSO2hWKNfkRgMAf5zRSp31exOKxFpWjuIyRWNpvAKwpy5AJPu1Ylq1xqUXlo0ckDMX3tz8pPCj0OPWulkYG3fJABBHPauUsfM028nXZsijznP3WJGePStZ6Ndjlo6pvqX76xWGFVUnB6DPQVzlwnl3RWEMisN3HOR/hTNZ8ROygttkdXEbQL971BHtWRq95NFaS3zbocDKjuuelc9WcXsejh6FRfF1KXjK+ktFt7hIwqsCAVPBI4Off2ry3XdUEavcNvwWyQp5PPatTxNrYMbefPsVRn7vTOP1rj4IRr94Ybdnjzj7OhTcZXyAAfQY3Hv0965/idz2YQVGFnudx4Fgm8QW5/cnylkZpfmwBGBk89zgGvQJ9Ggv7iW5v7kMzuRFtOxRGp2qFGDgcVneGfDg064Ok27ztDCqNNc7cERyKCxO0kDPQKck967YW9vFbW8T2srbEIG6MA7dxIz74I/GlK551ev7y5WePS6dd6hqEFqpaebAXy4yGCnoFJH0+lGoaONMxLdmEzvnEcTbtp6c9xXe3ZsrW4mtbGURWwkxJKoDbCBhiqg5YZHGTWHqGlLJiSJ8uTgbzksfb6f/WolvY6YVua3RHLxzQrKhuE3QKNzIV6njH61ZVGuLwugDLIcYY5+br/SoPscl1IkEe5QxI+Y8nHX61uaMi2+pxW4VFXaWDEAZOR3p7I6JOyub/hzSbTzlNwXxGctIg3ENtzxWhYWl6t9c37W6LaMwVhFkrH+B5AJyc+pp9ncPHaeVETLGZRmKNSWftlR3Pt6VqRTssatZybYXXJYYww9CD1HXNawimrHmVKkrvzJZp/Nt5lABDqFyD071zmvXscFi8UcUrMbtZpD1UgLtwf6VZ1WxOmWSTWc0k0eQWbdwSeeAfTOPauae6j8yX7S7FpMYGcA1cptaNF4ejF+8tUbUTxzBGBTAGcBsMR3BNVbueOaWKwaOaWFTkFiVKEjse44qpZ6pBAWhjcpKDtG5Rg+1Yt5rktjqb7p2WRSXQr9zP0/H6VFzrhRk5afI9M02Swut9nqWnWt1aSBSsksSLIiHAO8jpz/ABd68z+IUGm6f4gaDw0XaKM/vFZsxKePlQ9T3zmtP/hLrOTSoLdLd4rjyws77uDtOcL7HPeqeuLZzWkaDaXKcBWDBcjuR3q3JONrCw1GVGrzSvZ9OnqcDNqMizbiPmU7thHHXpWVe6q5MrudzMeOeAfatbVZI7YO7kMRwCfX6VxNzOZHx7+n+cVmotux6dSairizTtPMply2TkhTgn2rf0DQp7uQIBtd+uB90fTtVTw1pbXl0p2naOSe1e7+GfDkFvAjR5iY85U5Zj2P09qmpO3uo4atRQXNIreBfB8USh5UXOPlZgAR/SvWraxhjiRAuVU8cdfrWVpyYPlIqOANxzz+NdDEQVGQR6CtcOk9WfPYyvKpLUXYAMYB9B6Vn3kbeXJ5ce4dff8ACtFgSMEdOcetMkUnORj8q6parQ44uzPP/EVhJIQdm7HDJjgjHU//AFq81u7OWOU+U3DsTt5/PmveHhV98bYAAOM9BXC61oZnDLkI6NhRnAI/vD8e1YKbgehTcZqzPOo7QF1k4XB5z0Jx0qVoGyCu4ysCOThSCOT9cZrVvLCS1dkmXkDGQM5FQxxDziUc8YBGegrojVMZ0WRWoVVlWRQmQCp7D0BJ/wA81xmvW3mX9q3Z3JUoORjrn2rsrvbJKcYUgcjHH41nG3zdRCNQxTlSCOOc1q5cyOdU3F3Ma+VYo47dM4VAxJGPU/1rI+xvI0rZGSwZs9geK6bUrWRiZERRt+9jnk1STTpvJy2WBXbwcfnVymmRGlIz9NCRrd20kWfNXC47NjqPxqbw1p8cDzR3AJaVRyDgjHtWhb6WAUwzZBHHXArfhjVYSSw3kYAI6ColUS1N4UJPQfpGkulysYiyWPXIGPf8q9E1bT9IFnsukeMxR7UEcQ5bqeT1rkPDmpiyv4mKtJ5f8LYCnPr7V0kVq3iK+ubxLaW5vFVRIqjbFER2HcjGPfrWUql0brDtO70SMrRtME9xkKMMQvTpXcWVnDb+UsSEMvUjqKzYQ1rYtIF28ZBb5QSPr9KybnxRMzFLKJnZsKWC9DXO5LdnUqM6ukdjsb3UbexPmNveV2CBEP3j6c9PrWHqesRxW3nSAhoyCiRYG6Ttz3we9chNc3huRcXMsYk6KhblR35qhe3E2pXCW0kksm75VigAXJ9u5qXNs6qWAUbNs7Kz1NZw8NuwupFT7Reyg5QzEYiiBzztJ3HtkDrisnRLiH7QRdu2cEgDAyfr9aw5Lx9Lt5rBrMw5ZQqFiCD3Zh3yOlb3gDw9Nq9xM92H+xR/efeAyN22/r7VD1aSNpUoUacpydkegeFUd4XkgZVUjkkfKG9vXtW8Ld4zuSUvOcZMh+Xj0HasPw5pTaZqMuDJ9lIIUHkKTXRzTRxfMxwFG4/TpXZTXu6nzuIleo+XVMy9ZaYaTc/ITcLIu1VOA+CCMfhmuB1fXPtskuN+1QqADopJ/Wus1q7MVrN56yL5rbkUnkLjrXnWqyL5UyQMPLXDYb+L/CuavPWyZ6OApK15Io+JNVjuih8sJcJ8vmJxuI9ayL7X3Ni/nMCo+Ug8/hVe9AkjKiUvMzYAboR61xviS5aRfL80liSAgH3ef8BXM9T3Y04xj6GDqdw+oX7FXlkTooY/yr1L4X2EaWV55gDX9zCY4YnBG0gqVYY5zjPH865/QPBwfSZ726uVjMKp5q+Wcwlnxtb3IwePXFe7+G9Eh0a+02X7JBGUs9gaOTcTtByWGOXOTzx0xW1r6LY8/EVlCLb3f6alzSIDaXazXVzETLKivNGgXO2McY9FIUA+9a9tAr2cDXDl3KkjPUDceDTUs0jt2OQ8ituVSOAeDjHfkVLb2z3FtDIxmLlfm28c5NUotaWPFnNS1OO8O2T32iW8TCNbVGeSIqodnLHk4GM59elQalBHHZXAKZmYhUbGAOxH513HhyJhpqP5hVGHzMAAQo4wAOg9B2Fc34ujBi/duWmBJyWB5Hc/TmplStBSOqnX56zj0ucDZWk9xfM0Q3ImQo4HPcn0FVtatJLe4Fx99QdrBem0+np7V3Oj6TBb26xA75CNzkH7xPNPv9Ljns23L5i7gF55HaiFPmR6CxSU/IxdEuVu5YrkyN5sW3aOmcdz/hW9rN7A2oRT2AxHKubqIKV8uX+8O2D3A+tcvFpEliJTFMDIp4V+CfXgc1JdX94LVJhAERV2uUbcD6nFUoOKaFKlGc1KLNO5Lu6K7fLn5F3cD35/lVK40uCREkXcdmQwOCcnuPQ1j/2o+xJGIKkbQwPT8PpV5tWkREDkY+96/n60ubua+znG3KYGp6RIhmMYEgQgMyHHPX5fpXLajZ3NvIv2gMcdA/Uj/PpXaahNdkK8UoVJCRGj9QOpbPbmrmn6nG1rcxXUMEm9FUSSLuYYOflPb60WTOyNWcI3tc86tJ4/NcFwmR8ytz/+qn3utRR2LqsmR0wp6+31rW8X2ltLdxRWMYku7iVYYo4yMySucBQfc4rgPGcOtWeriw8SIsd5aRJCsSsjbEAwq7k4OBxzzQou9ip4iKt3L0sA1Pw1f6k0yW8dnIqBpZMGeRukUSDqQMszHoK52zhWSYbvu9T71dvfD2q6ba211qdjLaRznEKXACSOuM7hGfm2/wC0RjNW9P0reFkhcBieI3IycfyFNtRVkRTbqPmbudJ4YeCEKEYMedoPQe9e3eGrRYrdXi3+c6878dcdPT+orwmK1aGSMXEJjkPKg9D9DXZaJf3tltFtcSvBjJhmYsh7/UVysnFUHUj7rPb9MZZI9xJBIw2SM8cdu1aYdV6kDnpXlMXjQtCkcNuIlGWkZ33ZXP8AAe7d/pXTaT4kgvreP7XIlvLnIWZWUvgcH0H58V0U63LpY+fr4GpH3mtDsJpgIt44A7etRJcRzpmNgxPTHb6+lZN5qKC1yis0rLvRNhYHt+K89as2iQxGN0faCMl933+P15rVVW5aHL7LljdliclCEKgkjgen1qjNbg7ii5LDGH5x64rRkaFU+bk9MkHIomhCIAQWZz9MD3olG4oy5TjtS0hFUsiu0YXOerKPf2rlbvw+TMZbXJDLuznB9OPSvWVgVZt0hG3qe3PvWRe2EQlfYvyYBIU4wSeSPwqXBx1OqniL6M8o+wXkMLSNCzqR3Haqy2xjl3sgAI7DH5V6f9gktUmaUr5RciONxuwvbJHfrWLJd6bLO2nyjyblSBtkXr34Pce9NVF1NlHn+FXOO1BbcxzGKEIgK+W4BBAxgjH61Ui3BXRFyvckV6SfDouEcKiRonOMdzVS90eOC1BiiXIIyc8Y7k05S0uODhex5/HbTGfaqDYTw34Vr6fpLy3CB32qMc+px6elas1vDCWkaQHk4Xj5j2wKZBcSCCHeirI5x8zdQDw3FZ89zsULrQvDRbGCSCaUl0R8so/u+ld5barbSWAjt1eztFG0QQ48wjuS38I9+teeXOrQoJjZEuwXa8zDH/fI7VzE+sOJUWbcVc8qW4atE7PUl4KVdLme39bHU+KNQs/tTRWrxy54RAWZI89gT1PvVAwXS2aTupKOcqRgVjzX73l1brF5KxjhVReFGeck9frXYWe+O3EhB2jg72DAfh2NJas6pR9hBI5qewkuAzujALz71b0mwubfU9OWWNLSR3BErruGw+o611lhF9umhhiuY4zNlAwXGDjOD61Ru7W5a7jS1Jnu7ZgNynIU5PbvQ1bUz+suV4PQu3NlZpqlvcXULPnmQStvLAdwO3tW0919plSC2hZ7ZfmO5MOB2AqvpOmz3l67CVopFUhmlTO49wO3pV69W80W1AiQSGQbd4H8XrSs7X6HmVJptRvdmoJ5Ds+0K6A4Kx5H5k1HPq1nO8lvCjMNhZpCMBP/AK9UdQ1eEaS9wyrHdBlR1bqP/rVxd5qr+dNHbsUSVCGLA8iqnV5dFqZUcI6urVrFnxJetdxRguxKJhSD71yN1PCLp4Q42hD82PY/pVu8aVjvk+SNV3sCea5TxDqYSYQwcb2DEqM7a47uTuz3cPSUVyooa7d29nEED+YxHBx1NZfhOCC41pbu+ciGEkKoAJZsE81RvC8sxkkEhkPTjgKO9eq/B/RPtFlcX1xLbIm5Au+ISMNrL6jjdnt/dq46s0xNVU4XZuaNoc0NvawTxI8FuqXMysxy7upKsxPYZHA9K9EsrRbW5Cx4dEi7nIGcms2wQXaXO95jHKUjdmIAyM5AHYYx0roSiku2Hx91QO+BjmuinG+p85ia0pOzIXiWQuQjrINvORkAD+Rp0azMg3bWxwCCP8aguAGO5n2iSReVBBwD1x2xVq3khES5U88jKj+tUrN22OZ3SKGi7Y7II25gW3ZJwCfUis3xuWj8mKJVWaZ87887QOePxqVS8aArkP1HPBHaue1fUJr7X4FmDEbP3IYYG3PLfjjrWTqr2fKdlGk5VefpqaumQKsccshUzfpV5oPNU2u77PuUyBz0CjqeP5UGZVt2EcZ2qoJIX7vpn1p6y25t3ectKjjKhSFIP1rekuVClKTdzlbzwOmvL50F/JBqEYwqK5Xcvrn86xLO3mtfPsLqUl4NyE7sOhHXdnqP6V6P9vSMWRWFmuNuGQfKRx6jvXG6qZLmeWSfeTIwL7xgkAcZ/wDr1Tilqjsw9epO8Z7dDg9S0q4FlJewq8dqEaUtsOAqkBmx2GSOuM5rl4PE11biXb5M9qgy3mMEIGccc5z7Yr0HVtPFxaLE6O3ylI0yOQTklvbjIFeazaakWoyQPDB5lwhihmuJvLht3JH7yQ4Pygbh9SD2rCpGx7NOfNBt6mpc+KoraZobiKW1mCgMk8bIyggHoRkcf0rF1HxbkAWnzlc4AXAHvk1zF4bia5kmupJJ52bLyyMXLn1LHk/WoljZjhQSM46UlFdxpvsWTqd+bxbvz2Wdc7WAHy5BBwDx0J5rU8Ja5P4baSfSrGxOosR5V9cRedJb9P8AVKTtDH+8QT2qrYaRczyhREQB1J4Aru/DHhGWaRCIccZ3uwUY+vb8OaL9hTpQabqbHKCw1jXNTlvbuaa6u5iDJNcOWdvT3wOw6V0Np4YuIogJrmNWbqmzcf511q2LW+baBkZQwGYjgHPU46mtW2sbqzulM1urMXDqIyu72HHSpavuL2kaatHQ5i30DVJVUp5c8fAKzRYBxwOR0PvU8ehXUbF5YZljBw/lneB7dj+OK768eeKeJWSQzsN/L5J9Bg8VJBP5ty6TpsjPzFW+Y59yBzScUczxc7Xsedx6JqE8jQafEzqDuB3qrDjrg/5NdHFbapDYPDcS2tnKq8yXK/fbjjg4z9a7O10yK4BljJhB5wOfxqjrGnRTRtDcr5gIBUuuRn8e9S6elzJ4z2kuVmPpWs3NiqtcSJPEvyiRgHUDtt7iuyg1a1mgWYNEjgjG8ZBPpnsa87bw/PbMJbCUkdWQOvJ+h49OKaL2TTrmPzGBDjBt/uFWx15BBzmoTlHYmrhqdbWL1PYFljRg7swI5GeRio1uovtW1nL5AKsT971A9xXnml+JpBHuDGVVwqxMAGP1Hce4rYj1Zby32ELDuJU+ZgKWxluSflxWvt32POlgpQep2dz5c5PlSMNwxle3rWRqMvlSJsZW2kmRAMNjt9R615imv6oL2ZYpneErgCST5gmQchhx2961G1/U721lUWqNGANhuJVZlPXIwM8cc8U5VubobLLp02tU0d3dFj5ckcqm3ZeSB1B6HisG/t4XjU7UV1zIJG+/7++PauKs9a1CwmkWARzI53yne5XJ7DBxnr/9equq+K53miLRugTO4DLbiSPpx7VDlzHTTwNSMrJnosE4ti0c8zYVPkRjkE+3t9a53xVq2fLs4HGCd5C9e3HsOtcpN4sm+1xMA7yyDCgr8n0FRXt3eTyKs6eSNxMjg/O3r9KNbWN6WCcZqUiTVdYm+0rEgjYSNsWME5PoRU+nwzXjhkbe6DLn0FY8JtwtxK0YJDbEJ6g9Sa2tG1X7JGWXGNuCcfe/xNXBdTslBxj7iJUsoFlZLmUiI8kAc/X/AOtWZ46gttE060lzI1xPuNvuHVP7xHb/AOtXQWmr2hW7llWNZcCRGfgtg9B6GvPtajutf8Ri5wSJGCqjHqKqTshUlNzu9Ejf+Hulz6qPOZW8pB+8kJwMnsPevTtM0iPzbSOLy40RP3ss/wA6uR1IHYVR8G6B9hsAIJlwzDcSMqG78V3VrYR2sQQ+fLKynI25X/AVpThpqeVjsZebUWc7qFpp15HEIoWtkSQBpIDuz6tTJPDtnZ3SXOnXD3ML/eXdtfg+oxmuog0gx2vlFU5O7K8Ee2aisbO2WGR2Z0kBOCxxtquTujgWKaVoydi3bSQ3MWyNi8I+cZPzKawdd1Kax08yJumSVvkVzlkx1JpJbmTT7hLxEys4I2dA4XqfauG8RapLeXMtz8sTsf8AV9QRWVWrpbqaYXC8879B2o6zNcq4ZNy7sM+eM9qghihfatzcJEokUMucnb17Vz7yCfUoIPMeOJmUOFHC+9SwNLY6hcC3uYN9sS/nt8wPYY45PPSuW99z2vZKKtHQv6hq/nPfW0J3W8jEqp4Ax/EfcCvONSv2cTLCVaN+PNx/CPStnWr51i8uRmEk5wXx2zycCsCN4luYPOUHLDCDuoOf1PFPqbwioLQne1udSvJDdMXuI/LgPy4HCcDjgEKAPfmvdvDemLE9tHY29ylqy+Z5c6BWRcYYjHY4xXnXgvSLybVraW9gVrO6lPmqWG5wTy6jqMdAa9s0yy/s4SRxXM7wxKVTzG3YOBx6j6VpGN2eVmFZRtFFlVeGOFI4/Lx8wDHPOP8A6/6VZwY4GRc4QEoT1I/yTSrGqGIAnI5IAzkY6fpTIS0ifeJiC4OFBDHk9faulaaHht31IymZQwHVl2ZGc471ZW5ALYR8E5FNyB8x6KoxkZ70hkRGKsOR0wDgj2pr3dmJ67nPtdhFiYIZmc7FHQZPA5/z0rkNfuP7P8RGHCr9niVCV4DuWJLf0/4DW8+JbyGAbA8iEbuw4+9k9DWRrUdu3iJLW0XZIsRgkZmH7zPfJHBI79q5XrHU9nDpRl8jfsrqO5jH7z52GByPlP0qrq28IqhywwTgdPaseKK7ErxkMVjzgxgPgg8g49OnFTRwXV1ISS+UX7oBb5s8ZB6fnVxlpZleyUZc19DUNlO9hHcmRlXG5fM43CqM0JMm+3LXKvgH0B9arJa3ZnQnzgjk7hv2jOMkAema6HR8Wmbi5TMbr/qxwPQGtoO5M26ave5jXtqq24i2KZXOTkcH/PNYN7oSJbtM9ursSDkkcmu/nRfsqyOV3KMQ5IAX1zXP6vFc3FuqO7BDk9eWPtVySKoV5XsjgbzQLa4haQxxqI1y3QZ/xrno9HVrpRaxHB+UHGM/hXpkfh39+j3jM5C5xuyPy9KuNoiRIBYFE/jcYAOBzkCsuQ9BYyMdL3OCtdLZNitG0aqcEbeCfc+vtXWWQkskHlsiuycAADGPb+VWxqNnAHM6yNMr7Io9uQPUn375pLeA3B868jjubRQQm0YZD/Oo66EVKrmveWhStoVvJf3P7olgGG773+B61s6ppaiygSEzBuNzF+c+i+1aIt7ZtMa5a1JunO1XJ6fUVatdOeGZZ3RmVshS2DlqajfQ46mJ1utLHLRaDfRiOVZJpJCQSc52r/drUGmTmSOOJmDMp3sWyEz/AFrsYbWRLclk2qOQFbk8d6zontfM3PCoiDbWkByaHTUUYfXJT+Q7RbCS0Qxgrt/hHerV5JtYjax29gORTo1s57k+TO8ajBUnkMKlngUYR23SMeNxxkfT1rWKsrI45TvO8jjry6imOJB5agkHPBB9Kkj023ykd8HMEqZGUDgehIPUflWtbeH0uHljnmQOuSVzvZfw61WIRQLZH81UOQcVhyPdnb7WL92DKGneHdAjnU6jFNaPJzDIJiqk98H8uDWB4xsL7Qb+KO7d9QtHA+zzyLnPoCR3HpXUXOmtfny5AZFHO124z0z9cCqz2LJELdbu5SCM7zbOdycdSD/L3pOOlrGtOq1Pmcr+X+XVHnkGrQLcZZzC4Bwzc4J7EelXYr1LoyIt1CoAO5iCPX05rR1ie2jlnjgQyhWG3zMMx/pRa6fDcRL9qtIlY4xhByO2eKhxR6DnG3M1Y5i4by1dI7yKQHAIGQTx7gdOn4VlG5it0GwHO4HbnO/8a7W7sLaN3CacrkHA8w9P8KNO0ve4BjSI4+9Go6fU0WNVWildnEwpe3MhmWJ/O6xrjoM9s8VpnSZpIt1/clSRnCdueee9dq2jrbxSSLLIWHIyoP1z9Ko6RA+pXCPPEFh3fKB1wD1rVRRP1hSTktkc7a6YrqseP3a8cn5jnv8AWrF3p8VtDmxMv3vl807s8ciu01SGOGbdBGFUEKCB17VnTwN/aiQyKY1Bz0ztFS3YiOJctTm9LgRpHWaFzcbsDf8AdrpNF8PLPqUTbAHDhsN930xXUaHoiG9+0wgS2sDcsw5YeoH51vXOieVMLmxy5ZixTIHX3rSMG1c4sRmKu4xdrkg0drGBFsCqInLAjlj/AIVp290vlgSPsfHNZcWruQsMqkNjDE9/enPOrWpZVA28FgOlaqpFfCeNKM5fGWrzV4YcLG6hjzlulc8msQNIxvmbH+sKjnDdqy9QuELysWK8AYT17Vy+qyFVaQZiVBgk9CR2rlnXk3c9DD4KLVmbOt6uWkVpmK7MlVOMKP8AE1xVzK7yugX6ZHWopZWu51Bk2LsK88gEVEdSZrCWIsgET5DD7zHHTPpWGrd2exSoqmrIotM1nI77yN3yMAO3WqX9oeTLM+CHYbI1jfaAc/ePHP0pl9eOW+z+a2SdxA6KfWqdzKkKQBrfeN5CvkkSAdV/z600dD21IPN8yZHuJXY8KVUbmxn+Ef410elWlsHuNUlhhMCSmO3gll3yyPtzyRgYUEEnpk4FQ6H4efV7omFRagL5rvMxKQJ6nAJ68CvUdC8PWlpDYQteQapK+BiWJmSNfmcKoIBUH5Se/WtIo48RiIw0J/BOlfZIIJwUkmdhBLJJgtGxYHYBjuMY7DNd2ARMycRsRllXleeMY/Cq8QXKzbYPJT5jtc8n7q49eOOambdBB+6hLTsu7y8ZySc9M9vat4xsj56tVdWV2OlZpJZWT+DhiDjj/wDXUhHlIuQuB8oyOnrSW6utmm9VDFctjue/H1FSOTtzyehAHX61aXVmDfRCI+WkXqiAZJ4B/wD1UjJvwzF1buOeKijEYaSLcAXIZ+M5HQf1qYSlcr8428dQKa1WonpscpbmN79GlyyIpwOnbgD8a5nxXaPpOpQ3qviGdhkk5w38OfY+ldb9i/1T/NhSGyOD16CpbzSVvtGuYQpxcKwHmKGUH69j1wfpXMoOSaZ6lOuqc1K+mzM7QWmuhATHCq7hIcnah7nJ/CuhumgW6kkaFpBIMbYwURRwcN6nNcN4YkuJLOUSMdqxhORyxHGf0rqdOkaSQeZlnAHzMSwHHbNa0p6JMnE07Tb7FZLFlLPGAVPLF+1WCRswyndn6Vqq8ZAB24I/Cs+4mgAkdACEJGf/AK9b8qWxiqjm9UUb6UxzosihuMHAHHvVe5bzl3MyKqHJyecD2/pVuWRFgdk4nIPXnnPSp9Iskae3V4kyx3kY68d6Xka8yjG76GRAZHchg8e35lXGc56VjTWt0940rySCWAhjtz0H8P612XiW+srC6lllk2lkUHAPbPArhdW1q7vSWhzEobG1R8xX3qZNL3TqwznU95KyY6/t1ivWukZmVugAyNp+8D+Nbtq7W+m2xypQYTGPmcnpWNpptJtOaKEOGkXEoP8AGfX8KrJO+m3SR3GGhABDSHIP09BWHNys6JRc1y9UdpaWRczTyTZnPyyRjkIOMAVraf8AOEyCiqBsU54Fc3Y6zbDe8NyPMZh5tufmyfRW7j3ro4NRhMkRjzGgYo6txtPoa1g4nl14zW6Lt7PIUC26BXfOSTyB64rOl04SwIFiclmDPn5QSaIr23ub4yRtgRkkhfvEdOfb3rTW9t76FdjTeUeHIUgfTPpV6S6nN71K1kVtO0eO0Ty1mLSEYKOuRge/r71JfxC1tXW4eQwn7kv8SP2FJLdjTbmETcWjApGx/h49aW5uTfvFDCymNsltwyDjpin7qVluK85S5pbGXqcF/FfI8EWZ5ovLM0bbG3E9/UYFLZaNLpabppo552XHzDjj3q9fXU0YgCMJHiYu+0dOCAMVl6bcnVpxLebtpcqCG4wOw/lWbUU/M3jKbh5dSw93BGEM+EduAAOlZGr6hZzAWr5M4bbhRwB14NdBe6Y0jR7iscakcRjJA9K5LVtA+y34eKSX7N5vzShfuBv8eaU1I1w7pSer1GWdl/phSO2XzUOFKnJPHX8iK0b7SrmCN5ZQU2r1JHAP+etWrO4gNzP9ltJjGsWxSDh29TntzQ13d2CmC3gSTB8x0mBbOB93OanlilqaSqzctPxOcb/S7gCJR6EDv7D1reg0+5gSRIbVisQ3MeAAah0TSZL7UJLmUNDF5pkZYl27GPPHtk+9b+s3tvYaX5Kyl5Ze+cnGeST9OKIRsnJirVnzKnDU4DxbqDz6YlnBFHmSRS0ithkXuMd6uaJpoSPEBxCDgnuT6motWgt2RUuEUJP91l5xj/IrQt5Ui+zLHFIHdcy8fKFHAIxRe71OqUrUlGBsXelCz024lV4ZhswQD0P+zWDahZFhnkRypG0kcYbt+ldfaCzij2zEfOMiQ8A07T4bWG2uYd6mKf5TnAwDVOCb0PPjiHBO+oaSWMLLbum5U6dPwq7DM/2ZWI8pzwoxwfxrMhRNOZ2MoZlyG3dCB/8AWqvcSNJ5Xmuyo7HCkHGPanz8qMHDnd1sW72S3jiUyIvmrnGwfzrEe/DS+U8h2txsUd6sapr0EFsIoLVmzlDkZyf51xGsam6WkEM1osMitnzlzuOfX3rCpNX0O3DYeUt0T32oRwXEkokZ543AWMDOa5bxbqktzMYyTG2d+zPC5FRX1+67p9pbf8uSME/T8qZpelaff6Rc6jqU8r3pfEFsowhUDlmb0z2rFK57MKcaVpSM5IJJSMO0cW3ezsMZ9h71Vu5AHmdAkcRPybvUDuBzW0Wlt4LhXaJJljEkQeTZtA579/QVyhTe/n3Rlyxztzjj39Kq3Y2UrltbXUGgF69nPLbSkr9oaEqjN6BvX+QrW8P2EN3ILVLOVZZ2COhmDc+3oP8ACq2kLc39m9rHDFJaJJli8hHlbuMKM8knpwa9h8J+F4tGu4zaoZLW2TYZHwzSzEEHoMgLxxWkY3dkceJxKpRd9+g5dNtrTSotE0uwuoUuXQTyMP3jP6nJGQD9BWhMhg1eOWDY0oWVGlj4LMflGfoB0/nWgfM/tEyCbMVsS77Tz93pz15qjFKsFzDKV86aUF3wQAG7j0wBj8auWjPEU3L+u/8AwDUuy0V1FbW5RPu5jWPJfAySMdAPeoYJjJN55QHIYbhxj/ZzS6cs8ck7TnzJZMhSDyqH1z39quqFCRJEGVQmBhRjAPQ+9Vbm1MG1HQmBHlkL1xkc5x2prSKwwAcr6HHOKb5x37T8xI4IAGOeh/xqrPLNGTmQcuXKlfurjOM1pKSSM1FssiWNMl24UdTjJPqDT5Zn3AxhSCO4qkZo3kIaMvbpyXRwVHHOfbAq0ZAMCMkIBx8ppKem4ONiALE0q43LIiEOpHcGlCl4jEUZ1IwoA+9nt/WqsKuswmbJUNhscmr0qA242NklR1GGXjrn3oi7mj0PMPt2oaJr90lj/rdxMeMY+bnG3kDqa7TSJQI4hcMUuEUNKHG3rx+PPpXN67LLb+K4rm3td7TQDfz9506/mCDj1FdJYXQvUt3uTF52Qx5+4MdOKxp6SaPSxD5oRlbdGlq4CRxXK27OQpK5UOu49OntmsVI3nj+VFViDJtA2qWPt05qLVtWmUC28pTBCSxUEkSHPX1qaBjcpuETMCRlfT2ArounIwhCUIXZVivSdNl3oGkjI5JAPXmtbQJ1iuR57h8+2MVzGqxPbSXMbSScYwhG07c5Bx9KuQ6m9mLW4ypww52cEH69etTez1Np0ueHu9S54vW3ufJHlkXDSPMZOPu9B/KkttAtJ9HBjgt/tJzHvkUllDdWA/vAcj3rl9V1+a/8RESokQhjWMI2exOfx5zgV03hzW4WuFTzlhaSM/O4BB/Oo5oym7lTpVaVFW6amNc6dNoOqT2lpK10kcYcmT7wXHT6+1YPiDV7SWB4ZM4TDg9CMj3rd8R219oWqzXlwbiexudgS5YrgysCSvH8PHcVw+qJdzS/aQUEaZKZAJA9KzqJ3aO/CxVS0276b+ZpeH57GfRrtVB/tHz0WEkkZj/iyenpXY2x+0QLJCgeRAEnTzdx4H3iP8K8X/taW2vmzj+6SoxzXWWtzf3Fu81qBIsREsksWVaEZ2gsfcnjHNZxfQ3r4a7vc7LTJ7G01SRkmbMr7IxzhD6NnqM8VvNeaneX8kGkSiCNBtZ0AOc4/wA5rjvD1ol1q0cj5ecA5dnOGOflx9D616FcWUsFu8aJHFLncP4Tu653Dr3rSm3K9jy8VyQmlu/MrGx1aS3fTpBKwX5gZmDL+daXh1ZLD7ZaXRUtCwC/TGRj2OazdLja+ijaLV5p5MsGiMmTG3+71/Oorm7vWvDGkBa8ZAMPj5hj27e1aJ8tpHJKLnenp+QzXLto2R7e6leOaQ5PlgBh6Y745q1bamos1jngEcgATbgbdp6EDrWfdW0t1p6JcFYkV9x29VPPyj8arQRnkyZLx8DfzWcptO5uqcJQSfQ9BsH3WETK4dtuCa5/VopAtzdqR5TuokVj8uOgIH6ViWOu3FkoYKWXftKYyD6Y/wAKb4g1S5uoliELJEhDTOgJBA/z+laOtGUTCnhJwqeTOjsAqXqxiSW3kePf82Pmp2pWL+bbyB/M8ty5c8ZzwAfxNc1BLJIYxu8xsbY1J/DNbp1KSe2RblHRo/lZRxlvWkqkWrCnSlCSaZNLa3L3EkNtKVt1wJnQ8s3Xiq914eknk3xMNrH5g6gAfQelSJd+VbOyMpSQg4JwQajmvlvoWRpWVVX5VXgs3+FO8HuTH2ifulqytbJbOPT3eIuEIYMudzev4URaXpsdlMYDJ5kA/eSM/wB0Yyfw9qzdQaA2ccumFmuARhNvf0Hv61nw6wqIbe6ypnOWz0UZ7+tNzitGilSnJXi2dVa2iPp8abx5Djcuev1FZEpm0uYsGR1DYAbkHPtWTeT3Vk5khcy2z5ZFB+6B/SuU1fxBKS6vN87AvIwBPGeAPTionUVttTehhJze90zr9WvrSFBJPDMWb5tqDGD7e1ZE3ipZbdTKokVE+WMt90+ua5TWNcdrbbANsZXbtJycf/XrnUjuHjWVpEMpIKIDnaCcZb0FYOUmejSwUVH3zrYtVeyukvJnjlXdkox+77fWqDajNql2HG9lXOzYM4J9DWRc2Hlq0k863JibhUyFPsF6mrZsZ7GxS5IWGKUYEGcSsvqf7o71Njp5ILVbmjI0EwH9qRqqwjbt3DJcdj7Vj6lfPcpC0KqsQzGI41+UBRzntS2unT6qI5JmWGwRyHfgceue/wBas+IdesbXTm0jTYEh0tn3/Ngynj+J/T2ppdydpJLX9DlNR3tLHJOxSMHMce3K4/vGpNC+33d9HZ2sD30Ukiq9vFyGBHqOhrQ0iy/4SPSUtlfZbx3uPOK4YZX7uepHB4xXqvhDSFguLRYxbrZWsDsWhLDY56qTwS4BHzdOapK+iIxGIVKLZmeENJNs0kN9CJJVmzK867WRUXO0njHOPqK7KG+t9NH2RHDmWTcPMBVi2OuPQkfTFSWtlbNAJGnl8y5k3OrkYPPXHXpSwWzzmR7qxSQO21JhtbKjoSp6YwPrWkbrRHi1aqqybkUn1GXLw7XjdCzyFRuUDOQGz1BOAcdq0LWyxE0t3HCfN2YIIwATkKCf5+lV/KgULAj7ysJ8xlAXKn+9n04xWom5R5KY2MQijacYC8kH3ogr/FqZVJWVo6FmPylZ3wrcgcjt7UMwySgwij5VPc56/wA6RN22RgFLAjBxjGOAMUyOPyyWYksyjqOhzW/ocw0yzblYx7kHQrjv2/L+dR5hUqJF2u+QAMjcSRnOOalkGJJJCh3FgFOcFuQPwrMtpkciaIpKpZo3O35lwx+631/nWcpW0ZpGN1c1I5UeUFRtLLhhwenA5/zxVgSDaCVQ5HBzjiqZ2xuqgEE8nC4/L09KshCwBILHHfHFWpMzkkZcFxkrJIoIdckDpn0qyGaBVLfMhG1lBBOPr0zVCzkMtmIsgIckc5HvU0dw7qEDMYiM7UblQOpP/wBeohI3lHU434iRXNrBHqFix3RY5A7dwPcZrJ0DxGkUQSX51ccuB39T7muw8Q2IurGeK2kdoRndF/EQOuCfb3rx3R44k8QvpV9KbdsmJX7A4+Rj7Zxn8azmmpXPYwihVo8suh6XP5epTI0coCyOMbSOPeuu8PC1+3lBIcRjCnHJxx/KvFdE1GWC82OyZic5IbIJHBINdjcz6hHZtfwwzC0XaxmA6Nn1/H9a1hU6snEYRtcl9Da8cNcf2tDHKIzHLmISLgEBQScj2z1rDke4vbaS13IREg54BYg9vX1rq0urnU9GLoxu1QAA/Z2z0ycN1yMYJ6Vy6SJcX1xJI7CNXyu0Af5FOcru/cjDtqHK1rE57XrYjVVjspZbmZYftEjBSxh55z6YqAP5s8k7XsEJjdQUYH95nqygDHB65x1rW8ffYVtItUtzeR30dwsaOqbEliKgtux3B79xWXZWOmarepcao0io6hpDbcFew47kfrWMo62PSpTvTUnf7tSbxlrNzdabpVlDI/2e1DMr4b5yerHP9PWqMV8LrTEaUH5Tg8Y6dPrmo9Wk0rTtfCEy6hpUJ5VXMLyL6A9qxk1m1h1Of7PC8WnyO3kxyvvZF9C3epk7O5rTppRSivP7/wAbmv450bSYvscuj3M9x5hUT749vluewHp/nJpvhOT7HHqfmXRNiqhHiWXZ543djg8g4bHoDTLXU1a/gS91GbTNPnQxNPFD5pwvzJ8vU/MAK3PEemXn2i1m1jUEF/f20b+UY1doSGwgLrxk9Dx3x71CvZyJcuVKlN3/AD/L/htO51NhYXWnada3MvlbJoxsmXk4J4Jx39q6ObWpLzT4clEnI2hEU/Mfr2NcJ4c1W5sbC+sBD9r8lWE9sj+YAT/GMZ/IdKr2WvXMUCRI7IykkRuANv51rCouh51TCyqSbdm0zr7ERObYpaPHMjMjSpwSRzye9XtRu5ESafULuH5AGTywVfd2wa5VtckuJNpl8uQfNhOM+36VS1fxHLqN2Int7KN9oVTyPwAzT51axP1WcpJtGld6qJgrXFyyWzkkzNGwGCcHBA60l3dPagvay+fGTgNtIyOmQDzWfpGvTafbeTGonlYFFC5ZVB64Xt061oW915VjPc6y9v8AvjsjXq6le4/DisnqbODg9tPzJdHu7p7hJYI3nMYJAAwAR3zXZyXkl/oVwt2IbAY2O5feSev3fevO9K1+MrJbW0gEbsSzDC5+ma1JLmymtpTPMIULbVJ5cj1IFEKnJoYYig5STatYuWYkWJZWcDnhwe/qKsRam8jOgXGPllPTNcq3iZrGF4RbxyLIBtlmH+p56isC68TR6fJM9zdLIJB8nlrnnsajmfQ1WFlO7kj0yR7WeCVbe+hRBwXPJL5+6P8A61YUWqy2lzMtrtllIKdM59x9f61wuieMLSxhbPmO7EuTt53HnIPY+9P1P4gC7QJFEA6g4dFw2fc1XNfUuODlFuNro7LTdbvobsC2TfdSE5jAyVHfn+H3qh4qnBleVJFecnc6xAlUP93NcJeeN7t41jDlCmQCo55681DZnW9bjZdJtp2ikwkjs2FY+5JAou2jojh1CXO7I0rzUZHQxQSyOv3XYn5foBVD7fJArRKHmdj83Hyk1HHY3dtIq3J8sx8ndgD9O1b/AIdgRZXug8fUZkf5UQ+w6mix0NqKuZ1rFdzjzLpFWJxkeYcDB/ix1NX7aFPLnW0kVlQfPP8AdUDtnPf2ror/AE/Sr2ZEt5GlDgmWeQHauFyQAR16Y9KzUbT7SR4YIGeKSHyoY5H3jef4y3fBxTsYKtzLRGO15HYwechaW+Y8ysd20eq+lVori6vneW8doopOWzy7jr1Paq+JEvYB5ckhSUQz3CplEc/wjtwOfWpbbT/EVxdwXUEDiOKYQK8iDg84+U9qRo7LUi1fWsKscVyHTAO0chR2A9frWr4O8Jtr8Uc2pQy/ZLmUKhVSZiRyzJjjaBxzmuni8DWl14ptPL3TTErPdsU6y/ebCAABc446AV30dzHPeTIm+JxCYYhHHgICdz7R05459KpLqzgr4vljanv+RR0Tw/bRW96yjdDCTHEiqqeWxwMgdegA/Otyz0xbae4jfMpQBUO7DbMAtwO5Y9/Sl0t4RYoUGQzMoVjk5BwCfc+tWSGJlDoqy7fmJzjPccfWtUo2TPHqVZybuxkWwRTR28b5lJA/2V9z2q1GoCR4ARV4BH8j602MMVcYb5j/ABcZXtUsjYhQIoPOVGemOelaR7s55O+hUuY8faZgoEkrgFvUL0X25qwi7o4I8kbFyAR0PbB+uaSMAHZsbDLjJ6ls07eu7yskN1wBmkt7g3pYMjYqlz0wcjg+9MvPmjCqWXHOe59hUvyBidgIIwCRzUMg2gkoG3n5scYz6VTegluVJXlG8EEOPmYDPGR/jipljjFlGQyFCmAFUA9evp+NQ3jlShSMlwvQvtySMYzVi8XZGqYO9j8oJ3YAHIJqFq2aPoLEGwPMkYuM/ewBx0FOGVyCCPoQaajMwDnr3z057U5VUjdjO7nO3rTM2ULBw0cgiVFOAXjHUkfxCo/s/wBsG8II5SSCob+Wap2ltJNHcSEyidD/AAfMBx374qBdRmWRWdPMdcY345Ge9Qp6LmOxU22+Vl5bQG0lA87zQfuAYGe3tmvL/iV4clurM3unIV1Gy5cKMcd1PvjmvUJNUgVfMyI1Y4lBbgt7fnWTdxC4a6BjjAmGD83UY4NDa6G+HnOnK7PANE1UGXMoAmB5Vhgg9/wr2jwhqVveQx21/hrdx5bJnhdx6/yzXlnxG8PSreTX9uJTcJtywwQygYPvxxz6daxPDXi+WxcRz4AzyccGkk1qj1qqjXjyt2fRn1DbaejaLf21hKj2ql1SJCRImWIxuznoBg/SvMr4/wDCPvHEzSCZQySeco4weOc4Jx1rO0zxtOUWWzLRjI3+W2MjsCO4rq/Dus6dBMbm7WK5MpLNGsKnyTyQY88Z9sVTnGVuhyQo1MPzOXvJnMxW8OuXA8yd4bYcSTON0cY9T/hWVHo2tWUptF0+5bkmNlQtvQkgMpHGD2Nema1q8bWxudN1KNYQUWSEwJHKgBO3CgYYDJ57A1hReIZrmCcT3c8jOD+9jkKuueMZHp6dKzktdzop4io1dR07f0keeSeFvENybiV9PnSKEMWllwinb1AJ6nntVvSNClt71k1TSbi6TYSYFbyzx6kdvpXWapMl8tsl5PPKIEw583qAuFG08BRVrw5b7kkUfvnERKqpxjB6n/gO6o5ddzd4mag3L+vmctY6Ml5c2Ns4KNuVCGHTc3UA8Hg8E8cV6NpdneaFPqUV86zcJBBIqqXjj3EBuPl3Y6j2HNZ3iDVS1lbW+o27PFEuYJBHtzxjlsc4Hoe1ZV1qt2iwxzWs0enS/NAJYigY9yp7/wAu9WmorQ56jqV0r6L+tn+hY0/w1aWsss1qkkE9u4e2vIw+6QbuCR029frzUuvabNqmryS6a1gsTKT58kxjDEDkFDyOatSeL1W1t0UnZDwsRORkDjP+HeqcPjG2m01rLVbO3uVBzCQmGAJyee3tSSj3IX1i/Pb+v6+RkvodxE6i6vbNUQBmAfJA9jirekaekurLqGkSI93GpaOynjaQMw4K7sADIycnpVdrzw+Y991JeLIh4iQBty+m/HBP0xVHUfFFhbRhbS3eGGMnaWkIZx6Pjgn6YpXOl+0mra/doaNno97YqlyLuG3ScMWEcoV1GcMu48Z56CuL1/WraScQ2a7xENibvmwM9Pc0l1qB1y9jgt7SR94VBaws0kkrepPOMn0xV2DwTrItbKeKO1Auy3lwI/zptPO84wD7Amlyt7GqtB3qPU51tfuRGYltQTuyeDxUkOq65E6yxxuinO1nTIGOo59K6tdG1ePTZmXS1aOLHmSIV46YBPU9aSPwtrOoxR3F1KyRMSZXO4omMckgYJ+npzRyop1IdWjirm71C/nInlMp77fX6Vpab4Z1SeaOKCBZZZOkckiru9wTgYrobjT7eC5ENjbu1pE5QXEI3mR/75zzg9hUkgvktdkGmzXKvJ5IdBs2uDyo9CcjNCSQOenumIuiPcXGJ7iKEDgrjceOwx19KrXPh64jukt3tHTnll6H2z0rc/sKS2uGeKC6nnT5C+3CpLjLYx+Qz6ZrofDtr4hlEkFpY3Pzr5PzMoRsAZGW4x3p8pMq3Kua6+ehkad4HiaI/aJwuIg+WjxtPcH1Ga0ksbXT2i+1wCZXT/VpJwhPdvQ1dh03X7y0ubjzLSOOCQRiNtztcYPJHovoTWmvgXWtRHm3V/FBK7M8ixQ/LCpGeM9W9vbrTs3sjlniIr+JNWMH+3tOt4orZLGzLq2WRotxkIP8Tf0rIutQtLadryUxRMWL+WnRD6KO1dj/AMIJoKWEsQa5uLvzDsnd9pbsMn9eK3NG8C2Wk2cwtkhleWMGZ5IldmJONqFhwvQ5xk0KLkZvF0KaurnmkbatrtnHdabbRx6bGzeYDJtL8HO72xV2x8Iz6nKFMk5s4okmklijIeHPSLHce/416bPpqmRNPs4EhlU+ZOdigr1/u9c1tWtmbO2mtYwy5O6WRSCZCfw7DH5U1C7MKmYcq9xW/rcw9E8MW32e2Mssn2KybzLSJVA3NnJdhjJOe9bEkKy24uJ3MSxx7jHj5SBzg9+TjJ6mrrsglCb22Rrnd6Vm3N4l9PLaxllt4SHdtu4u3Tb/AF9q0k4xVkeZzzqyu/6/4cr6OIVtheyDcZywIKkbRnAUHqTVq2ghnhuHBVFBIjXGA2Oef0/KpbmOQ2hUsYzwqlG5OeufrT3tUW1SB9+FPAzwT3NZpPbpYJTT1uSxRyKFLDy02g7VxxnrUwKr+7bKgpk7RxgdBTY4/wB55Sgjyxh8Y69qkVUDPndlRmtkjBsSKNY4go4HVs9vamJta5yM7VHC49aep3An5snqM4JqNSQ7K4J4zkd/88U29rC7jxgvuyScEg+n+FROwUM2c8YJ74z/ADpQGIU4+8B7H6U2WRWQgKSTx8uDz/jSb0GlqOL+YGaNQIgQAx9OpJFMnkKRq/Lqv8WBiq4KJGNzyZG7kHp9fSq11deVJwpZgu9ue3GOKlzsi1C70FWYs02XwsTAq2e4747jnmroGZFYj90ASCeCMnrVO3hke3J2IScsdnBOcZ/LjjrVyIrLIiugOwFWI74PH41EL/eOduhMS+9lwT5fGQM/jTILhUTDqQSSR3zTkYIG3KztkcjsKqzQOGG2UYIz83BrSUmtUZpJ6MwFjWKRGEpWRunO3J9Pfpmor2N25A3ruGfmxk1aTqOB69KqXUjrE5V2zuIBz0rlT0PRje5AkyXF026JUVR39PWrFwwEoRC5GCcMuMU+NQsC47jJzzmpZPleNRwpXdj3yKvVFOSuZ91ZCaFUhOCOQR8pB+teGfEDwo1tqLz2sb+ZKxJTAwWzyB/Ovo9kU5yo6Y4GK4zxRBF5Eh2DcBkHuDg1abi9DbD1OZ8rPnLydQsEE3l3MUWcb9p28dRnpWnpnia6hOJXyh/iUdPwr1VLaKOwup4k8uZFG1kJXGdoPT1rznWLSCSOG5aMedMHLsCRkjocDirbUldo74Np2TNKLxNYvsW6aTeVwChwBnueKHvr6R1WwlgmDNhUVtrN/T9a5QW0RgLFeeO5qNWa3D+SxTnsaz5V0OhSO7a41m0tzJfaTeLHCf3kyrvjUHG35hmtHRvGMVrtLyneDuVk/hJPr3rkNC1O9jXdHcyoQARtOOat6vawGyiufLUTyIXZhxk5Pp9KhrsVyqa949ys/HtheaeqXrwCYkMUlAaM+4HUGm6hrWh6vezC/DSxIdyPG6qVAHPXtz6V83xEsrsSdwPXNb2lQxyWLSOgZz3bnvTc57NnIsvpp3jdHqupz+A47hZjBM4CtuCXJ3Ox4HTpWDJo1hrF3DaeGtJ1G1u5490Uk158hAGS53DkYB4Bq7BpVhZQ6VPbWsSTS797bc5w5A6+1a0bvBeW7xOysSBkE8DPQeg9hSu+or+zXutt+bf5GJb/AAw1G4lR7rWYRbP8xlhAIPqM54wPX1rqdM8BaPBPJBFYx3tvIF23Ms48/aByRnhBxySOhqxJfXMWtytFJsJUJhQAMEDt0rSuJ5G1W0jJBR5EDjaPmGOh9R7U+aK6HLUrV5by6FrTvC1rZxmW1tRA+75BGNmIx/dwM49T1Oe1aGpxQCKGKEPNMoH2WzhIIHqxxwBj+XesPVby5j1CeNJ5FjLbdoOMDPQegq5pNvH9ssotp2PHlvmOT179a1Uk9EjjlGb9+crk9zEtxp4hV7dzKpIgiyVVj3djwWHr7cCq0OnLPZbJpXeNTgogI8zAGM810kFtBFcSRRxKsUceVUDgZB/wplooa3gBAwcZqvZ66mKr2WhUOmQiCW2VI44HwzohwXPuar29n9l+x2yM0ccJICg4AJz8+R3rVKj7uPlERb8c4qK7Y/ZHOTkBSD79KJR6ohVJPRlYaRCk6xxShLb/AFmxDgdMEknr/WozbxzhraHzIdNjG1vLGGZc8gHsD3p95I76iIGP7kITsHA6VdhAb5G5WNQFHpUJpuyG5SSTb/r/ADI49NSVMxAQhQvlJnhVHIz/AJ9KnffLGwcuI2GJG53MAecelLZMZpm835sY61LuL3EgY5ATgVqkmjGUnezIfLS5jMSxxrADtQBOmOmP8ankkVV2KVLMNoXHIIqYIo3IB8qH5R6cZrItJXN7cEtkp93PalN8lvMUVzX8ieGAxRSNcL+9Zi+8Hlvx9Ksys67SC4UYI3DkE05APsyuQC7AEnFSxsWndW5XZnGKaj0QnK7uzK1mQW0IitVL7v4c/wAXY1NYQumnRQzgq5O52GOT3P1ptkoLyAgEbe/4Vah/49Gk/jXIB9OayguZuTLk7R5SC6jCzJ5WQijaBnJz60GAvMxzIsoAJOevpTYnZpACeN2KtdYyMnH1qoWkribcdBI055O1xznP9KU5JXruAyMEcHFOHzO2fQimryhY9cDmrsQOyAqkAhNuAAOpqoGaVyFbcvGcjp/+up7w+X5YTgE9PwNRafGn2eRto3YY5pO8pco1ZRuJLKYo2YcnJAB71EXSK1c8gEh+nC59qk1IBbIMOpKjNUtckdZHRWIVWyoHbC1E3y3ZcFzWRFqE3nF0gZ92AWC8Bj7k1BeWzCyn3FPMdRgrjOc8flVqFRLDaCQbvm28+m3NQty0gPIUhRnsNmf51m0373c2i7aLoTQyxxWUPmgsRGJTIoyCd201eg2JPksSkg4JHOR29e9Y7nfFIGAwkSgADHBGT+tSaoPsV6BakxhVLDBPBwKOflXNbREOHM7dzYDZhyuWAXAxxkVnX5jjmCyvIDtHVQ3FWbOV/J+8eV5qUEnJPJ96uS9orJmSfIz/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Severe thickening, and a scaly and indurated appearance is typical of atopic keratoconjunctivitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_15_14579=[""].join("\n");
var outline_f14_15_14579=null;
var title_f14_15_14580="Multiple sclerosis child PI";
var content_f14_15_14580=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F83278&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F83278&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 502px\">",
"   <div class=\"ttl\">",
"    Multiple sclerosis in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 482px; height: 620px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In multiple sclerosis, the immune system attacks nerve cells in the brain and spinal cord. These nerve cells work kind of like electrical wires. They carry electrical signals and are wrapped in insulation that helps the electrical signal move quickly down the nerve. This \"insulation\" is made of a material called myelin. Multiple sclerosis damages this myelin, so the nerve cells cannot carry signals very well.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_15_14580=[""].join("\n");
var outline_f14_15_14580=null;
var title_f14_15_14581="Montgomery-Asberg Depression Rating Scale - page 1";
var content_f14_15_14581=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F62945&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F62945&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 631px\">",
"   <div class=\"ttl\">",
"    Montgomery-Asberg Depression Rating Scale, page 1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 611px; height: 791px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Montgomery, SA. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_15_14581=[""].join("\n");
var outline_f14_15_14581=null;
var title_f14_15_14582="Patient selection for the nonsurgical treatment of gallstone disease";
var content_f14_15_14582=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Patient selection for the nonsurgical treatment of gallstone disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/15/14582/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/15/14582/contributors\">",
"     David Nunes, MD, FRCPI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/15/14582/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/15/14582/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/15/14582/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/15/14582/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/15/14582/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of medical management of gallstone disease has decreased in recent years, particularly since the introduction of laparoscopic cholecystectomy. Cholecystectomy is preferred because of its reduced cost, definitive nature, and safety [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14582/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The laparoscopic approach has been associated with a significant increase in the number of cholecystectomies being performed in the United States each year, indicative of both its acceptability to patients and popularity with surgeons.",
"   </p>",
"   <p>",
"    Nevertheless, medical management may be an alternative to cholecystectomy in selected patients with symptomatic gallstone disease. Historically, three non-surgical approaches have been described:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Oral bile salt therapy (primarily",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"       ursodeoxycholic acid",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Contact dissolution",
"     </li>",
"     <li>",
"      Extracorporeal shockwave lithotripsy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of these, only oral dissolution therapy remains a practical clinical approach for a small subset of patients with cholesterol gallstone disease who are not surgical candidates. Contact dissolution therapy is no longer used due to concerns about the safety of methyl tert butyl ether (MTBE), the primary dissolution agent used, as well as the invasiveness of this procedure. Extracorporeal shock-wave lithotripsy has also fallen out of favor but may be used in association with oral dissolution therapy.",
"   </p>",
"   <p>",
"    This topic will review the selection of patients for nonsurgical treatment of gallstone disease. The methods used for the nonsurgical treatment of gallstones as well as the surgical approaches to patients with gallstones are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/16/6408?source=see_link\">",
"     \"Dissolution therapy for the treatment of gallstones\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36489?source=see_link\">",
"     \"Open cholecystectomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11338?source=see_link\">",
"     \"Laparoscopic cholecystectomy: Techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION FOR NONSURGICAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The selection of patients for nonsurgical treatment of gallstone disease depends upon patient characteristics, gallbladder function, and a detailed understanding of the size, number, and composition of the stones. Dissolution therapy for gallstones should be considered as an alternative to surgery in carefully selected patients, and may also be useful as prophylaxis in patients at high risk for developing symptomatic gallstone disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Symptomatic gallstone disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe medical problems who are at high risk for or refuse surgery and who have mildly to moderately symptomatic gallstone disease should be considered for medical therapy. The definition of mild to moderate symptoms includes episodic biliary pain that occurs fewer than two to three times a month and can be controlled with the use of oral analgesics, and the absence of complications such as cholecystitis, cholangitis, pancreatitis, or obstructive jaundice.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"     Ursodeoxycholic acid",
"    </a>",
"    can reduce gallstone related symptoms and the risk of recurrent pancreatitis in individuals with microlithiasis or biliary sludge [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14582/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Patients with complicated gallstone disease who cannot undergo surgery are better treated by percutaneous stone removal, gallbladder drainage, or endoscopic retrograde cholangiopancreatography (ERCP).",
"   </p>",
"   <p>",
"    Characteristics of the gallstones also need to be considered before instituting medical therapy. This can usually be achieved by computed tomography (CT) combined with ultrasonography or cholescintigraphy (HIDA scan) of the gallbladder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=see_link&amp;anchor=H19#H19\">",
"     \"Pathogenesis, clinical features, and diagnosis of acute cholecystitis\", section on 'Cholescintigraphy (HIDA scan)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CT of the gallbladder permits assessment of stone density and the pattern of calcification. Stones of high density (&gt;100 Hounsfield units) dissolve poorly [",
"      <a class=\"abstract\" href=\"UTD.htm?14/15/14582/abstract/5\">",
"       5",
"      </a>",
"      ]; however, the pattern of calcification and morphologic appearance on CT imaging are equally important and formal density measurements are probably not necessary [",
"      <a class=\"abstract\" href=\"UTD.htm?14/15/14582/abstract/6\">",
"       6",
"      </a>",
"      ]. Highly calcified stones and stones with dense surface calcification are unlikely to dissolve and are more resistant to lithotripsy. Unfortunately, 15 to 20 percent of lucent gallstones are not cholesterol rich and respond poorly to dissolution therapy despite having favorable radiologic features.",
"     </li>",
"     <li>",
"      A functioning gallbladder is necessary to ensure that gallbladder debris is expelled and to minimize stone recurrence. Gallbladder function can be assessed by ultrasonography or a HIDA scan with measurement of ejection fraction. Oral cholecystography (which is now seldom used) can also demonstrate stone buoyancy and assess gallbladder function by its ability to concentrate and contract in response to a fatty meal. Buoyant stones tend to be cholesterol rich and suitable for dissolution.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Prophylaxis in patients at high risk for developing symptomatic gallstone disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevention of gallstone disease can be divided into primary, secondary, and tertiary. Primary prophylaxis refers to preventing the development of gallstones in high-risk patients; secondary to the prevention of symptoms in patients with gallstones; and tertiary to the prevention of recurrent gallstones in patients who have previously received medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14582/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Primary prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients at highest risk of developing symptomatic gallstones are those with known biliary sludge, pregnant women, patients undergoing rapid weight loss, patients on long-term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    , and those receiving long-term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    (TPN).",
"   </p>",
"   <p>",
"    Biliary sludge, which is often detected incidentally during imaging testing performed for other reasons, frequently occurs during pregnancy, following prolonged fasting (eg, after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    ), and in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    . Pregnancy is associated with both a qualitative change in bile and delayed gallbladder emptying, both of which promote stone formation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14582/abstract/8\">",
"     8",
"    </a>",
"    ]. Ceftriaxone, which is excreted in bile, can bind calcium and precipitate in bile [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14582/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4489?source=see_link\">",
"     \"Epidemiology of and risk factors for gallstones\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with biliary sludge who are consuming an oral diet should be encouraged to eat three meals daily, with each meal containing sufficient fat or protein to ensure good gallbladder contraction. In addition, their diet should be high in fiber and calcium, and low in saturated fats. They should also be encouraged to maintain a low body weight through regular exercise (which may itself prevent gallstone formation) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14582/abstract/10\">",
"     10",
"    </a>",
"    ] and calorie restriction. However, care should be taken to maintain nutritional requirements, especially in pregnancy.",
"   </p>",
"   <p>",
"    Biliary sludge and gallstones may resolve following pregnancy or when a normal diet is reinstituted in patients treated with TPN [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14582/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Prophylaxis in such cases is usually not necessary. However, in addition to dietary recommendations, we have used bile acid therapy in patients who develop pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cholestasis that was thought to be secondary to biliary sludge, and who had no evidence of acalculous cholecystitis or serious complications. These patients have been followed with serial ultrasonography to confirm clearance of the sludge.",
"   </p>",
"   <p>",
"    Patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    (TPN) should be periodically assessed for possible enteral feeding. A number of modalities have been used in an attempt to minimize the risk of gallstone disease in these patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study suggested that, in patients who require prolonged TPN, daily injections of cholecystokinin may promote gallbladder emptying and clearance of sludge [",
"      <a class=\"abstract\" href=\"UTD.htm?14/15/14582/abstract/14\">",
"       14",
"      </a>",
"      ]. However, subsequent data did not support this initial observation [",
"      <a class=\"abstract\" href=\"UTD.htm?14/15/14582/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      High doses of crystalline amino acids may produce the same effect by inducing secretion of endogenous cholecystokinin [",
"      <a class=\"abstract\" href=\"UTD.htm?14/15/14582/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Screening of patients on long-term TPN for the development of biliary sludge has not been established to be beneficial. However, some patients in whom sludge is documented (either because of clinical symptoms or when found incidentally) may benefit from prophylactic bile acid therapy. Such patients have a significant rate of subsequent gallstone formation, although most remain asymptomatic. We consider using prophylactic treatment in patients who would tolerate symptomatic gallstone disease or complications related to gallstones poorly.",
"   </p>",
"   <p>",
"    The use of prophylactic bile acid therapy in individuals following surgery for weight reduction has received increased interest in recent years. The risk of developing gallstones is greatest during the period of rapid weight reduction and falls once the patient's weight has stabilized [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14582/abstract/17\">",
"     17",
"    </a>",
"    ]. Several studies have suggested that the risk of gallstone formation is as high as 35 to 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14582/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. As a result, cholecystectomy is now performed in many patients undergoing bariatric surgery.",
"   </p>",
"   <p>",
"    Some studies have shown a striking benefit from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"     ursodeoxycholic acid",
"    </a>",
"    in patients undergoing rapid weight reduction without a prophylactic cholecystectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14582/abstract/17\">",
"     17",
"    </a>",
"    ]. On the other hand, treatment with ursodeoxycholic acid is not always successful, possibly because of poor compliance [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14582/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Secondary prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary prevention refers to the prevention of symptoms in patients who have gallstones but are asymptomatic. These patients are usually identified by ultrasonography performed for some other reason. While dietary maneuvers and bile acid therapy may result in gallstone dissolution and prevent further progression of gallstone disease, there are few data suggesting that drug therapy is cost-effective or should be used in this setting. At the present time, medical therapy of asymptomatic stones is",
"    <strong>",
"     not",
"    </strong>",
"    indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10374?source=see_link\">",
"     \"Approach to the patient with incidental gallstones\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Tertiary prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic gallstone recurrence following successful medical therapy remains a major concern because the gallbladder is left in place and patients currently selected for medical management are frequently poor surgical candidates. Without treatment, approximately 60 percent of patients who have undergone extracorporeal shockwave lithotripsy (ESWL) or medical dissolution have recurrent gallstone disease. In such cases, retreatment may be effective. Recurrent gallstones are often not \"true to type.\" Even in the case of previous calcified gallstones, recurrent gallstones are usually lucent on CT, rich in cholesterol, and likely to be suitable for bile acid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14582/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prevention of recurrence may be a more effective strategy than retreatment. Methods for the prevention of gallstone recurrence include dietary and other lifestyle modifications (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Primary prevention'",
"    </a>",
"    above) and continued bile acid therapy. Long-term bile acid therapy is likely to prevent further gallstone recurrence and the development of symptoms, but is expensive [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14582/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    and other nonsteroidal antiinflammatory drugs have also been assessed [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14582/abstract/24\">",
"     24",
"    </a>",
"    ]. These agents are thought to work through the inhibition of mucin secretion and the alteration in gallbladder mucosal function. Their efficacy is not well established in humans and therefore cannot be recommended at the present time.",
"   </p>",
"   <p>",
"    We use long-term bile salt therapy in patients whose medical condition precludes cholecystectomy, or in whom the risk of gallstone recurrence remains high because of lack of reversible predisposing features. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/16/6408?source=see_link\">",
"     \"Dissolution therapy for the treatment of gallstones\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/29/8658?source=see_link\">",
"       \"Patient information: Gallstones (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/56/1923?source=see_link\">",
"       \"Patient information: Gallbladder removal (cholecystectomy) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/21/7507?source=see_link\">",
"       \"Patient information: Gallstones (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medical management may be an alternative to cholecystectomy in selected patients with symptomatic gallstone disease. At present, two methods used alone or in combination are available for the nonsurgical management of patients with gallstone disease (see",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Oral bile salt therapy (primarily",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"       ursodeoxycholic acid",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Extracorporeal shockwave lithotripsy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with complicated gallstone disease who cannot undergo surgery are better treated by percutaneous stone removal, gallbladder drainage, or endoscopic retrograde cholangiopancreatography (ERCP).",
"     </li>",
"     <li>",
"      Characteristics of the gallstones need to be considered before instituting medical therapy. This can usually be achieved by computed tomography (CT) combined with ultrasonography or cholescintigraphy (HIDA scan) of the gallbladder. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Symptomatic gallstone disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest medical therapy for gallstones in patients with severe medical problems who are at high risk for or refuse surgery and who have mild to moderately symptomatic gallstone disease (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Treatment should be continued until ultrasonography demonstrates clearance of the gallstones. This usually requires six months or longer and is effective in less than 40 percent of patients. In successfully treated patients, long-term therapy should be considered to minimize stone recurrence. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/16/6408?source=see_link&amp;anchor=H3#H3\">",
"       \"Dissolution therapy for the treatment of gallstones\", section on 'Medical gallstone dissolution'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest",
"      <strong>",
"       not",
"      </strong>",
"      treating asymptomatic patients with incidentally found gallstones. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10374?source=see_link\">",
"       \"Approach to the patient with incidental gallstones\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients who develop pain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cholestasis thought to be due to biliary sludge, we suggest dietary changes and bile acid therapy, provided that they have no evidence of acalculous cholecystitis or serious complications (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Patients are followed with serial ultrasonography to confirm clearance of the sludge. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Primary prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who have undergone nonsurgical treatment (such as extracorporeal shockwave lithotripsy) whose gallbladder is not removed, we suggest long-term bile acid therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Tertiary prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14582/abstract/1\">",
"      Darzi A, Geraghty JG, Williams NN, et al. The pros and cons of laparoscopic cholecystectomy and extracorporeal shock wave lithotripsy in the management of gallstone disease. Ann R Coll Surg Engl 1994; 76:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14582/abstract/2\">",
"      Portincasa P, van de Meeberg P, van Erpecum KJ, et al. An update on the pathogenesis and treatment of cholesterol gallstones. Scand J Gastroenterol Suppl 1997; 223:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14582/abstract/3\">",
"      Tomida S, Abei M, Yamaguchi T, et al. Long-term ursodeoxycholic acid therapy is associated with reduced risk of biliary pain and acute cholecystitis in patients with gallbladder stones: a cohort analysis. Hepatology 1999; 30:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14582/abstract/4\">",
"      Testoni PA, Caporuscio S, Bagnolo F, Lella F. Idiopathic recurrent pancreatitis: long-term results after ERCP, endoscopic sphincterotomy, or ursodeoxycholic acid treatment. Am J Gastroenterol 2000; 95:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14582/abstract/5\">",
"      Caroli A, Del Favero G, Di Mario F, et al. Computed tomography in predicting gall stone solubility: a prospective trial. Gut 1992; 33:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14582/abstract/6\">",
"      Petroni ML, Jazrawi RP, Grundy A, et al. Prospective, multicenter study on value of computerized tomography (CT) in gallstone disease in predicting response to bile acid therapy. Dig Dis Sci 1995; 40:1956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14582/abstract/7\">",
"      Hofmann AF. Primary and secondary prevention of gallstone disease: implications for patient management and research priorities. Am J Surg 1993; 165:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14582/abstract/8\">",
"      Maringhini A, Ciambra M, Baccelliere P, et al. Biliary sludge and gallstones in pregnancy: incidence, risk factors, and natural history. Ann Intern Med 1993; 119:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14582/abstract/9\">",
"      Shiffman ML, Keith FB, Moore EW. Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility. Gastroenterology 1990; 99:1772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14582/abstract/10\">",
"      Leitzmann MF, Giovannucci EL, Rimm EB, et al. The relation of physical activity to risk for symptomatic gallstone disease in men. Ann Intern Med 1998; 128:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14582/abstract/11\">",
"      Valdivieso V, Covarrubias C, Siegel F, Cruz F. Pregnancy and cholelithiasis: pathogenesis and natural course of gallstones diagnosed in early puerperium. Hepatology 1993; 17:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14582/abstract/12\">",
"      Quigley EM, Marsh MN, Shaffer JL, Markin RS. Hepatobiliary complications of total parenteral nutrition. Gastroenterology 1993; 104:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14582/abstract/13\">",
"      Marks JW, Stein T, Schoenfield LJ. Natural history and treatment with ursodiol of gallstones formed during rapid loss of weight in man. Dig Dis Sci 1994; 39:1981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14582/abstract/14\">",
"      Sitzmann JV, Pitt HA, Steinborn PA, et al. Cholecystokinin prevents parenteral nutrition induced biliary sludge in humans. Surg Gynecol Obstet 1990; 170:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14582/abstract/15\">",
"      Dawes LG, Muldoon JP, Greiner MA, Bertolotti M. Cholecystokinin increases bile acid synthesis with total parenteral nutrition but does not prevent stone formation. J Surg Res 1997; 67:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14582/abstract/16\">",
"      Zoli G, Ballinger A, Healy J, et al. Promotion of gallbladder emptying by intravenous aminoacids. Lancet 1993; 341:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14582/abstract/17\">",
"      Sugerman HJ, Brewer WH, Shiffman ML, et al. A multicenter, placebo-controlled, randomized, double-blind, prospective trial of prophylactic ursodiol for the prevention of gallstone formation following gastric-bypass-induced rapid weight loss. Am J Surg 1995; 169:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14582/abstract/18\">",
"      Shiffman ML, Sugerman HJ, Kellum JM, et al. Gallstone formation after rapid weight loss: a prospective study in patients undergoing gastric bypass surgery for treatment of morbid obesity. Am J Gastroenterol 1991; 86:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14582/abstract/19\">",
"      Wudel LJ Jr, Wright JK, Debelak JP, et al. Prevention of gallstone formation in morbidly obese patients undergoing rapid weight loss: results of a randomized controlled pilot study. J Surg Res 2002; 102:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14582/abstract/20\">",
"      Pereira SP, Hussaini SH, Kennedy C, Dowling RH. Gallbladder stone recurrence after medical treatment. Do gallstones recur true to type? Dig Dis Sci 1995; 40:2568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14582/abstract/21\">",
"      Tudyka J, Wechsler JG, Kratzer W, et al. Gallstone recurrence after successful dissolution therapy. Dig Dis Sci 1996; 41:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14582/abstract/22\">",
"      Rubin RA, Kowalski TE, Khandelwal M, Malet PF. Ursodiol for hepatobiliary disorders. Ann Intern Med 1994; 121:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14582/abstract/23\">",
"      Tsumita R, Sugiura N, Abe A, et al. Long-term evaluation of extracorporeal shock-wave lithotripsy for cholesterol gallstones. J Gastroenterol Hepatol 2001; 16:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14582/abstract/24\">",
"      Adamek HE, Buttmann A, Weber J, Riemann JF. Can aspirin prevent gallstone recurrence after successful extracorporeal shockwave lithotripsy? Scand J Gastroenterol 1994; 29:355.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 665 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-B987512CC0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_15_14582=[""].join("\n");
var outline_f14_15_14582=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATIENT SELECTION FOR NONSURGICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Symptomatic gallstone disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Prophylaxis in patients at high risk for developing symptomatic gallstone disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Primary prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Secondary prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Tertiary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10374?source=related_link\">",
"      Approach to the patient with incidental gallstones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/16/6408?source=related_link\">",
"      Dissolution therapy for the treatment of gallstones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4489?source=related_link\">",
"      Epidemiology of and risk factors for gallstones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11338?source=related_link\">",
"      Laparoscopic cholecystectomy: Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36489?source=related_link\">",
"      Open cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of acute cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/56/1923?source=related_link\">",
"      Patient information: Gallbladder removal (cholecystectomy) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/21/7507?source=related_link\">",
"      Patient information: Gallstones (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/29/8658?source=related_link\">",
"      Patient information: Gallstones (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_15_14583="Xerocytosis";
var content_f14_15_14583=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Xerocytosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/15/14583/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/15/14583/contributors\">",
"     Carlo Brugnara, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/15/14583/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/15/14583/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/15/14583/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/15/14583/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/15/14583/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Xerocytosis (also called dessicocytosis) is defined by the presence in the peripheral smear of hyperchromic erythrocytes (",
"    <a class=\"graphic graphic_picture graphicRef62761 \" href=\"UTD.htm?3/30/3559\">",
"     picture 1",
"    </a>",
"    ). The hyperchromia (and elevated mean cell hemoglobin concentration) are indicative of marked dehydration of the red cells [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most of these syndromes are rare hereditary disorders, which involve unidentified abnormalities in the mechanisms controlling cell water and cation content [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/2\">",
"     2",
"    </a>",
"    ]. However, a variable percentage of dehydrated cells may be present in several other hematologic disorders, such as sickle cell disease and hemoglobin C disease. These will be described here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the red cell is freely permeable to water, dehydrated cells require the loss of cell solutes, which then induce osmotic water loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37224?source=see_link\">",
"     \"Control of red blood cell hydration\"",
"    </a>",
"    .) Xerocytosis is characterized by a reduction of cell content of potassium, the main intracellular cation. This may be associated with a slight increase in cell sodium content, but the total cation content of the red cell is significantly lower than in normal controls.",
"   </p>",
"   <p>",
"    The dehydrated cells are more resistant to lysis when incubated in hypotonic solutions. This decrease in osmotic fragility is due to the small baseline cell size. On the other hand, xerocytes exhibit a characteristic increase in cell rigidity and reduction in cell deformability. These changes are thought to play an important role in the hemolysis resulting from premature destruction of xerocytes. In vitro, these membrane deformability changes can be reversed by rehydrating xerocytes and decreasing the mean cell hemoglobin concentration (MCHC) to normal values [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Syndromes with hereditary xerocytosis cannot readily be distinguished from hereditary stomatocytosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42200?source=see_link\">",
"     \"Stomatocytosis\"",
"    </a>",
"    .) Several intermediate forms of disease exist between the classic overhydrated stomatocytosis (hydrocytosis) and classic xerocytosis.",
"   </p>",
"   <p>",
"    There are three major forms of xerocytosis that may not represent different disorders: classic hereditary xerocytosis, stomatocytic xerocytosis, and hereditary xerocytosis with hyperphosphatidylcholine hemolytic anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLASSIC HEREDITARY XEROCYTOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classic hereditary xerocytosis is usually inherited as an autosomal dominant trait. Affected patients present with hemolytic anemia, which may be severe enough in the neonatal period to require exchange transfusion. Perinatal cases with severe intrauterine ascites or hydrops fetalis have also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical course is characterized by a chronic hemolytic anemia, which may be exacerbated by concomitant viral infections and sometimes transient aplastic crises. Iron overload is frequently present. However, milder forms of this disease have been described. These patients have a normal hemoglobin concentration or only mild anemia, reticulocytosis, reduced erythrocyte 2,3-diphosphoglycerate (DPG) content, and a shortened red cell life span [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One such patient with was a competitive freestyle swimmer who had normal hemoglobin levels at rest but developed intravascular hemolysis and xerocytosis following exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/9\">",
"     9",
"    </a>",
"    ]. Since xerocytes are more sensitive to shear stress, the increase in hemolysis with exercise may have resulted from a shift of blood flow to vessels in exercising muscle, which have smaller diameters and higher shear rates.",
"   </p>",
"   <p>",
"    Since a reduction of red cell survival due to hemolysis produces abnormally low levels of hemoglobin A1C, an abnormally low glycohemoglobin level in a patient with suspected hypoglycemia resulted in the diagnosis of a previously undetected hereditary xerocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reduction in 2,3-DPG in patients with milder disease is thought to be a consequence of the increased number of Na-K-ATPase pumps in the red cells, resulting in an abnormally low",
"    <span class=\"nowrap\">",
"     ATP/ADP",
"    </span>",
"    ratio (3.8 versus 9.7 in normals). The increased availability of ADP shifts the metabolism of 1,3-DPG to 3-PG rather than 2,3-DPG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary xerocytosis was first described in 1974. [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/11\">",
"     11",
"    </a>",
"    ]. Subsequent studies have demonstrated that the increased potassium permeability of these cells is due to a hyperactive chloride-dependent transport system, most likely K-Cl cotransport. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37224?source=see_link\">",
"     \"Control of red blood cell hydration\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Indirect evidence in support of the role of increased K-Cl cotransport is the observation that this transporter is markedly stimulated by N-ethylmaleimide (NEM, a thiol group reagent) in normal cells but not in xerocytic cells [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A genome-wide search of patients with hereditary xerocytosis has mapped this disorder to a locus on chromosome 16q24.2-16qter [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Familial pseudohyperkalemia, a disorder in which red cells show a temperature-dependent leakage of potassium in collected blood, maps to the same locus [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/15\">",
"     15",
"    </a>",
"    ]. It has been suggested that about one-third of hereditary xerocytosis kindreds demonstrate pseudohyperkalemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42200?source=see_link&amp;anchor=H8#H8\">",
"     \"Stomatocytosis\", section on 'Familial pseudohyperkalemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Copy number analyses, linkage studies, and exome sequencing identified novel mutations affecting PIEZO1, encoded by the FAM38A gene in 2 multigenerational kindreds with hereditary xerocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/16\">",
"     16",
"    </a>",
"    ]. PIEZO proteins are the pore-forming subunits of channels that are capable of generating electrical currents in response to mechanical (eg, tension) stimuli, suggesting that these proteins play an important role in maintaining red cell volume homeostasis.",
"   </p>",
"   <p>",
"    As mentioned above, an increase in cell rigidity and reduction in cell deformability are thought to be responsible for the hemolysis in xerocytosis. Xerocytes also appear to be more susceptible to shear stress. In one study, this abnormality was reversed with cell hydration and could be induced in normal erythrocytes by cell dehydration (by exposure to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/53/32592?source=see_link\">",
"     nystatin",
"    </a>",
"    in a low potassium buffer) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of xerocytosis is made by the association of a chronic hemolytic anemia with xerocytes (",
"    <a class=\"graphic graphic_picture graphicRef62761 \" href=\"UTD.htm?3/30/3559\">",
"     picture 1",
"    </a>",
"    ), target cells, schistocytes, eccentrocytes, elevated mean corpuscular hemoglobin concentration (MCHC), decreased osmotic fragility, and red cells with markedly reduced potassium content [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/14\">",
"     14",
"    </a>",
"    ]. Xerocytes are also more stable than normal red cells when exposed to high temperatures (46&deg; and 49&deg;C for 15 to 60 minutes) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/17\">",
"     17",
"    </a>",
"    ]. It is not clear if this abnormality has the same diagnostic value as a reduced cell potassium content.",
"   </p>",
"   <p>",
"    Routine red cell indices may be misleading:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean corpuscular volume may actually be increased due to the presence of reticulocytes and other young cells (",
"      <a class=\"graphic graphic_figure graphicRef75542 \" href=\"UTD.htm?28/47/29438\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Although the xerocytes have an elevated MCHC, the impedance method used by Coulter instruments underestimates the MCHC of dehydrated cells, [",
"      <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/18\">",
"       18",
"      </a>",
"      ]. As a result, the diagnosis of xerocytosis may be missed unless instruments that directly measure MCHC or manual methods are used.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     STOMATOCYTIC XEROCYTOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several families have been described with hemolysis accompanied by the presence of stomatocytes and dehydrated cells in the peripheral smear. This disorder has been called stomatocytic xerocytosis or dehydrated hereditary stomatocytosis, and is also variably associated with pseudohyperkalemia and perinatal edema [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/19\">",
"     19",
"    </a>",
"    ]. In a study of 10 families, the defect has been mapped to 16q23-q24 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/13,15,20\">",
"     13,15,20",
"    </a>",
"    ]. Studies in a large Canadian kindred have further refined the locus of interest to 16q24.2-16qter, an area containing at least 51 known or predicted genes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/14\">",
"     14",
"    </a>",
"    ]. Linkage analysis of the genetic loci for the cytoskeletal proteins stomatin, alpha-, and beta-adducin, and for the red cell calcium-gated potassium channel (Gardos channel) excluded these as candidate genes for the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Unpublished data suggest that dehydrated stomatocytosis is not associated with mutations in the anion exchange protein AE1 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Membrane permeability studies show increased permeability to sodium, decreased total cation and potassium content, and moderately increased cell sodium content [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. The molecular defects underlying these syndromes have not yet been clarified. They probably involve a transporter in the cell membrane or one of its regulators. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37224?source=see_link\">",
"     \"Control of red blood cell hydration\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of stomatocytic xerocytosis is based upon the blood morphology, which shows both stomatocytes (",
"    <a class=\"graphic graphic_picture graphicRef75535 \" href=\"UTD.htm?8/51/9015\">",
"     picture 2",
"    </a>",
"    ) and dehydrated, target cells. Osmotic fragility is reduced, in contrast to the increase in fragility in hyperhydrated stomatocytosis. Red cells in affected patients tend to have increases in mean corpuscular volume and mean corpuscular hemoglobin concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/20\">",
"     20",
"    </a>",
"    ]. Reticulocyte percentage is increased along with relatively normal hemoglobin concentrations, indicating the presence of a compensated hemolytic process. Osmotic gradient ektacytometry is consistent with the presence of normal red cell deformability, cellular dehydration, and an increase in the erythrocyte",
"    <span class=\"nowrap\">",
"     surface/volume",
"    </span>",
"    ratio.",
"   </p>",
"   <p>",
"    The clinical severity of stomatocytic xerocytosis is variable. Perinatal ascites and sub-lethal hydrops have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Several patients splenectomized as treatment for their hemolysis all developed thromboembolic complications, indicating that splenectomy is hazardous in this condition [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/20,28,29\">",
"     20,28,29",
"    </a>",
"    ]. Iron overload may develop later in life [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/13,30\">",
"     13,30",
"    </a>",
"    ], and can be a late presentation of this underlying, previously undiagnosed hematologic condition [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/30\">",
"     30",
"    </a>",
"    ]. No particular differences in clinical severity have been identified between this form and overhydrated stomatocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42200?source=see_link\">",
"     \"Stomatocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Stomatocytic xerocytosis should be considered as a possible diagnosis in anemic women whose pregnancies are complicated by severe fetal hydrops [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     HEREDITARY XEROCYTOSIS WITH HYPERPHOSPHATIDYLCHOLINE HEMOLYTIC ANEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary xerocytosis with hyperphosphatidylcholine hemolytic anemia is also associated with stomatocytes on the peripheral smear. The red cells in this disorder are characterized by reduced cell potassium and sodium content with cellular dehydration (rather than increased cation content and overhydration, as in the classic form of hereditary stomatocytosis), and a relative increase of membrane phosphatidylcholine [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/4,31-34\">",
"     4,31-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This syndrome is characterized by a significant increase in membrane permeability to potassium. However, the distinction between this disorder and classic hereditary xerocytosis has been questioned [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     OTHER HEMATOLOGIC DISORDERS WITH DEHYDRATED CELLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the above inherited conditions, a number of other hematologic disorders are associated with dehydrated red cells. These include sickle cell disease and hemoglobin C disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Sickle cell disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cell dehydration is a characteristic feature of sickle cell disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. These dense, dehydrated erythrocytes (",
"    <a class=\"graphic graphic_picture graphicRef64449 \" href=\"UTD.htm?1/42/1703\">",
"     picture 3",
"    </a>",
"    ) play an important role in pathogenesis of the vasoocclusive manifestations of the disease. Although the percentage of circulating dense cells does not predict disease severity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/37\">",
"     37",
"    </a>",
"    ], an inverse correlation has been demonstrated between the percent of irreversibly sickled cells (ISC) and erythrocyte survival [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dense ISC play an important role in the trapping of erythrocytes in postcapillary venules [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/39\">",
"     39",
"    </a>",
"    ] and in the associated microvascular obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/40\">",
"     40",
"    </a>",
"    ]. The number of dense cells increases prior to or in the very first phase of painful crises and then falls [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. On the other hand, alpha thalassemia and an increased cellular content of Hb F, which reduce the severity of sickle cell disease, are associated with a reduction in the number of circulating dense cells [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. When isolated on a density gradient, labeled, and reinfused, these dense cells have a reduced in vivo survival, especially those with the lowest content of Hb F [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14330?source=see_link&amp;anchor=H10#H10\">",
"     \"Vasoocclusion in sickle cell disease\", section on 'Dense irreversibly sickled cells'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Red cell dehydration in sickle cell disease is due to K loss via K-Cl cotransport",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the Gardos channel [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. It is believed that every time sickle erythrocytes are exposed to an environment that has high urea concentrations",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    low pH, they lose potassium, chloride, and water. Sickle erythrocytes exhibit a marked increase in K-Cl cotransport, an effect that is most likely due to interaction of Hb S with the cell membrane or the regulatory machinery of the transporter [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/48\">",
"     48",
"    </a>",
"    ]. K-Cl cotransport in normal erythrocytes is inhibited by low oxygen tension and is refractory to stimulation by low pH or urea; in contrast, the activity of the transporter in sickle erythrocytes is independent of oxygen tension and retains the ability to be activated by low pH and urea [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37224?source=see_link\">",
"     \"Control of red blood cell hydration\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These observations suggest that prevention of cell dehydration is a possible therapeutic target for sickle cell disease. Oral administration of magnesium (a K-Cl cotransport blocker) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/18/33056?source=see_link\">",
"     clotrimazole",
"    </a>",
"    (a Gardos channel blocker) reduces sickle cell dehydration in vivo. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/33/34330?source=see_link\">",
"     \"Specific therapies for sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hemoglobin C disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cell dehydration with target cells is a characteristic feature of homozygous hemoglobin C (HbCC) disease (",
"    <a class=\"graphic graphic_picture graphicRef61082 \" href=\"UTD.htm?5/48/5892\">",
"     picture 4",
"    </a>",
"    ). This disease is in most cases characterized by a mild, compensated hemolysis with no significant anemia. Dehydration is due to abnormal cell potassium loss via the K-Cl cotransport pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37224?source=see_link\">",
"     \"Control of red blood cell hydration\"",
"    </a>",
"    .) The cellular dehydration of HbCC disease may result from a still undefined interaction between the abnormally positively charged hemoglobin variant and the cell membrane, resulting in increased K-Cl cotransport activity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/48,50,51\">",
"     48,50,51",
"    </a>",
"    ]. In support of this, transgenic mice expressing exclusively human HbC have been shown to exhibit an abnormally elevated K-Cl cotransport [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/52\">",
"     52",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Infantile pyknocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A study has identified infantile pyknocytosis as an unusual cause of anemia in 14 of 149 neonates referred for unexplained hemolytic anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14583/abstract/53\">",
"     53",
"    </a>",
"    ]. In the affected children, early jaundice without splenomegaly was associated with transient hemolytic anemia, peaking at three to four weeks of age and resolving by four to six months of age. The etiology of this condition is unknown.",
"   </p>",
"   <p>",
"    In this study, pyknocytes were defined by the presence of distorted, irregular, densely stained erythrocytes, presenting with several to many projections. The percent of these hyperdense, dehydrated erythrocytes (MCHC &gt;41",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    in this series ranged from 3 to 16 percent.",
"   </p>",
"   <p>",
"    Infantile pyknocytosis may also be seen in subjects with hereditary elliptocytosis, in whom the elliptocytes may not appear until later in life. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/60/43977?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of hemolytic anemias in children\", section on 'Hereditary elliptocytosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H799747\">",
"    <span class=\"h1\">",
"     RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following two",
"    <span class=\"nowrap\">",
"     laboratories/experts",
"    </span>",
"    serve as reference laboratories for the diagnosis of rare anemias:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       United States",
"      </strong>",
"      &mdash; Blood Disease Reference Laboratory, Department of Pathology",
"      <br/>",
"      310 Cedar Street, CB 541a",
"      <br/>",
"      New Haven, CT 06520",
"      <br/>",
"      Tel: 203-737-1349",
"      <br/>",
"      <br/>",
"      Medical Director: Patrick G Gallagher MD, Department of Pediatrics, Yale University",
"      <br/>",
"      333 Cedar Street, LCI 402",
"      <br/>",
"      New Haven, CT 06520-8084",
"      <br/>",
"      Tel: 203-785-4652",
"      <br/>",
"      Fax: 203-785-6974",
"      <br/>",
"      patrick.gallagher@yale.edu",
"     </li>",
"     <li>",
"      <strong>",
"       Europe",
"      </strong>",
"      &mdash; CEINGE- Advanced Biotechnologies",
"      <br/>",
"      Via Gaetano Salvatore 486",
"      <br/>",
"      80145 Naples, Italy",
"      <br/>",
"      Tel:&nbsp;+39 081 37 37 897",
"      <br/>",
"      Lab:&nbsp;+39 081 37 37 898",
"      <br/>",
"      Fax:&nbsp;+39 081 37 37 804",
"      <br/>",
"      <a class=\"external\" href=\"file://www.ceinge.unina.it/\">",
"       www.ceinge.unina.it",
"      </a>",
"      <br/>",
"      <br/>",
"      Medical Director: Dr. Achille Iolascon, MD, PhD. Department of Molecular Medicine and Medical&nbsp;Biotechnologies",
"      <br/>",
"      University Federico II of Naples",
"      <br/>",
"      achille.iolascon@unina.it",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13067736\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Xerocytosis (dessicocytosis) is defined by the presence in the peripheral smear of hyperchromic red cells (",
"    <a class=\"graphic graphic_picture graphicRef62761 \" href=\"UTD.htm?3/30/3559\">",
"     picture 1",
"    </a>",
"    ) with an elevated mean cell hemoglobin concentration (MCHC), indicative of marked red cell dehydration. Dehydrated cells have suffered the loss of cell solutes, specifically potassium, which then induces osmotic water loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37224?source=see_link\">",
"     \"Control of red blood cell hydration\"",
"    </a>",
"    .) They are more resistant to lysis when incubated in hypotonic solutions and exhibit a characteristic increase in cell rigidity and reduction in cell deformability. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Pathophysiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Classic hereditary xerocytosis",
"      </strong>",
"      &mdash; This autosomal dominant trait is associated with chronic hemolytic anemia, which may be exacerbated by concomitant viral infections. Increased potassium permeability of these cells is due to a hyperactive chloride-dependent transport system. The diagnosis is made by the association of a chronic hemolytic anemia with xerocytes, target cells, decreased osmotic fragility, and red cells with markedly reduced potassium content. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Classic hereditary xerocytosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Stomatocytic xerocytosis",
"      </strong>",
"      &mdash; Several families have been described with hemolysis accompanied by the presence of stomatocytes and dehydrated cells in the peripheral smear. The diagnosis is based upon blood morphology, which shows both stomatocytes (",
"      <a class=\"graphic graphic_picture graphicRef75535 \" href=\"UTD.htm?8/51/9015\">",
"       picture 2",
"      </a>",
"      ) and dehydrated, target cells. The molecular defect underlying this syndrome has not yet been clarified. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Stomatocytic xerocytosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Hereditary xerocytosis with hyperphosphatidyl choline hemolytic anemia",
"      </strong>",
"      &mdash; This condition is associated with stomatocytes having reduced cell potassium and sodium content with cellular dehydration, and a relative increase of membrane phosphatidylcholine.",
"     </li>",
"     <li>",
"      <strong>",
"       Other causes of dehydrated red cells",
"      </strong>",
"      &mdash; A number of hematologic disorders are associated with the presence of dehydrated red cells. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Other hematologic disorders with dehydrated cells'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Sickle cell disease &mdash; Red cell dehydration is a characteristic feature of sickle cell disease due to potassium loss via K-Cl cotransport",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the Gardos channel.",
"     </li>",
"     <li>",
"      Hemoglobin C disease &mdash; Red cell dehydration with target cells is a characteristic feature of homozygous hemoglobin C (HbCC) disease (",
"      <a class=\"graphic graphic_picture graphicRef61082 \" href=\"UTD.htm?5/48/5892\">",
"       picture 4",
"      </a>",
"      ). Dehydration is due to abnormal cell potassium loss via the K-Cl cotransport pathway.",
"     </li>",
"     <li>",
"      Infantile pyknocytosis &mdash; Pyknocytes are distorted, irregular, hyperdense (MCHC &gt;41",
"      <span class=\"nowrap\">",
"       g/dL)",
"      </span>",
"      dehydrated erythrocytes, with several to many projections.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Gallagher PG, Forget BG, Lux SE. Disorders of the erythrocyte membrane. In: Hematology of Infancy and Childhood, Nathan DG, Orkin SH, Ginsburg D, Look TA (Eds), WB Saunders, Philadelphia 2003. p.560.",
"    </li>",
"    <li>",
"     Stewart GW. The hereditary stomatocytosis and allied conditions: inherited disorders Na and K transport. In: Red cell membrane transport in health and disease, Bernhardt I, Ellory JC (Eds), Springer Verlag, Berlin 2003. p.511.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/3\">",
"      Clark MR, Mohandas N, Caggiano V, Shohet SB. Effects of abnormal cation transport on deformability of desiccytes. J Supramol Struct 1978; 8:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/4\">",
"      Clark MR, Shohet SB, Gottfried EL. Hereditary hemolytic disease with increased red blood cell phosphatidylcholine and dehydration: one, two, or many disorders? Am J Hematol 1993; 42:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/5\">",
"      Entezami M, Becker R, Menssen HD, et al. Xerocytosis with concomitant intrauterine ascites: first description and therapeutic approach. Blood 1996; 87:5392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/6\">",
"      Vicente-Guti&eacute;rrez MP, Castell&oacute;-Almaz&aacute;n I, Salv&iacute;a-Roiges MD, et al. Nonimmune hydrops fetalis due to congenital xerocytosis. J Perinatol 2005; 25:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/7\">",
"      Ogburn PL Jr, Ramin KD, Danilenko-Dixon D, et al. In utero erythrocyte transfusion for fetal xerocytosis associated with severe anemia and non-immune hydrops fetalis. Am J Obstet Gynecol 2001; 185:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/8\">",
"      Wiley JS. Inherited red cell dehydration: a hemolytic syndrome in search of a name. Pathology 1984; 16:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/9\">",
"      Platt OS, Lux SE, Nathan DG. Exercise-induced hemolysis in xerocytosis. Erythrocyte dehydration and shear sensitivity. J Clin Invest 1981; 68:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/10\">",
"      Jokinen CH, Swaim WR, Nuttall FQ. A case of hereditary xerocytosis diagnosed as a result of suspected hypoglycemia and observed low glycohemoglobin. J Lab Clin Med 2004; 144:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/11\">",
"      Glader BE, Fortier N, Albala MM, Nathan DG. Congenital hemolytic anemia associated with dehydrated erythrocytes and increased potassium loss. N Engl J Med 1974; 291:491.",
"     </a>",
"    </li>",
"    <li>",
"     Fairbanks G, Dino JE, Snyder LM. Passive cation transport in hereditary xerocytosis. In: Erythrocyte Membranes 3: Recent clinical and experimental advances, Alan R Liss, New York 1984. p.205.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/13\">",
"      Carella M, Stewart G, Ajetunmobi JF, et al. Genomewide search for dehydrated hereditary stomatocytosis (hereditary xerocytosis): mapping of locus to chromosome 16 (16q23-qter). Am J Hum Genet 1998; 63:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/14\">",
"      Houston BL, Zelinski T, Israels SJ, et al. Refinement of the hereditary xerocytosis locus on chromosome 16q in a large Canadian kindred. Blood Cells Mol Dis 2011; 47:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/15\">",
"      Iolascon A, Stewart GW, Ajetunmobi JF, et al. Familial pseudohyperkalemia maps to the same locus as dehydrated hereditary stomatocytosis (hereditary xerocytosis). Blood 1999; 93:3120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/16\">",
"      Zarychanski R, Schulz VP, Houston BL, et al. Mutations in the mechanotransduction protein PIEZO1 are associated with hereditary xerocytosis. Blood 2012; 120:1908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/17\">",
"      Vives Corrons JL, Besson I, Aymerich M, et al. Hereditary xerocytosis: a report of six unrelated Spanish families with leaky red cell syndrome and increased heat stability of the erythrocyte membrane. Br J Haematol 1995; 90:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/18\">",
"      Paterakis GS, Laoutaris NP, Alexia SV, et al. The effect of red cell shape on the measurement of red cell volume. A proposed method for the comparative assessment of this effect among various haematology analysers. Clin Lab Haematol 1994; 16:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/19\">",
"      Grootenboer S, Schischmanoff PO, Cynober T, et al. A genetic syndrome associating dehydrated hereditary stomatocytosis, pseudohyperkalaemia and perinatal oedema. Br J Haematol 1998; 103:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/20\">",
"      Grootenboer S, Schischmanoff PO, Laurendeau I, et al. Pleiotropic syndrome of dehydrated hereditary stomatocytosis, pseudohyperkalemia, and perinatal edema maps to 16q23-q24. Blood 2000; 96:2599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/21\">",
"      Innes DS, Sinard JH, Gilligan DM, et al. Exclusion of the stomatin, alpha-adducin and beta-adducin loci in a large kindred with dehydrated hereditary stomatocytosis. Am J Hematol 1999; 60:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/22\">",
"      Gallagher PG, Smith BD. Dehydrated hereditary stomatocytosis is not linked to the hlK1 locus, a Gardos channel candidate, on chromosome 19q13.2. Blood 1999; 93:2134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/23\">",
"      Bruce LJ. Hereditary stomatocytosis and cation-leaky red cells--recent developments. Blood Cells Mol Dis 2009; 42:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/24\">",
"      Miller DR, Rickles FR, Lichtman MA, et al. A new variant of hereditary hemolytic anemia with stomatocytosis and erythrocyte cation abnormality. Blood 1971; 38:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/25\">",
"      Chailley B, Feo C, Garay R, et al. Evidence for imbalanced furosemide-sensitive Na+, K+ cotransport in hereditary stomatocytosis. Scand J Haematol 1981; 27:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/26\">",
"      Basu AP, Carey P, Cynober T, et al. Dehydrated hereditary stomatocytosis with transient perinatal ascites. Arch Dis Child Fetal Neonatal Ed 2003; 88:F438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/27\">",
"      Grootenboer-Mignot S, Cr&eacute;tien A, Laurendeau I, et al. Sub-lethal hydrops as a manifestation of dehydrated hereditary stomatocytosis in two consecutive pregnancies. Prenat Diagn 2003; 23:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/28\">",
"      Stewart GW, Amess JA, Eber SW, et al. Thrombo-embolic disease after splenectomy for hereditary stomatocytosis. Br J Haematol 1996; 93:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/29\">",
"      Ja&iuml;s X, Till SJ, Cynober T, et al. An extreme consequence of splenectomy in dehydrated hereditary stomatocytosis: gradual thrombo-embolic pulmonary hypertension and lung-heart transplantation. Hemoglobin 2003; 27:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/30\">",
"      Syfuss PY, Ciupea A, Brahimi S, et al. Mild dehydrated hereditary stomatocytosis revealed by marked hepatosiderosis. Clin Lab Haematol 2006; 28:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/31\">",
"      Jaff&eacute; ER, Gottfried EL. Hereditary nonspherocytic hemolytic disease associated with an altered phospholipid composition of the erythrocytes. J Clin Invest 1968; 47:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/32\">",
"      Wiley JS, Ellory JC, Shuman MA, et al. Characteristics of the membrane defect in the hereditary stomatocytosis syndrome. Blood 1975; 46:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/33\">",
"      Shohet SB, Nathan DG, Livermore BM, et al. Hereditary hemolytic anemia associated with abnormal membrane lipid. II. Ion permeability and transport abnormalities. Blood 1973; 42:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/34\">",
"      Shojania AM, Godin DV, Frohlich J. Hereditary high phosphatidylcholine hemolytic anemia: report of a new family and review of the literature. Clin Invest Med 1990; 13:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/35\">",
"      Clark MR, Morrison CE, Shohet SB. Monovalent cation transport in irreversibly sickled cells. J Clin Invest 1978; 62:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/36\">",
"      Bertles JF, Milner PF. Irreversibly sickled erythrocytes: a consequence of the heterogeneous distribution of hemoglobin types in sickle-cell anemia. J Clin Invest 1968; 47:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/37\">",
"      Billett HH, Kim K, Fabry ME, Nagel RL. The percentage of dense red cells does not predict incidence of sickle cell painful crisis. Blood 1986; 68:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/38\">",
"      Serjeant GR, Serjeant BE, Milner PF. The irreversibly sickled cell; a determinant of haemolysis in sickle cell anaemia. Br J Haematol 1969; 17:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/39\">",
"      Kaul DK, Chen D, Zhan J. Adhesion of sickle cells to vascular endothelium is critically dependent on changes in density and shape of the cells. Blood 1994; 83:3006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/40\">",
"      Kaul DK, Fabry ME, Nagel RL. Vaso-occlusion by sickle cells: evidence for selective trapping of dense red cells. Blood 1986; 68:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/41\">",
"      Ballas SK, Smith ED. Red blood cell changes during the evolution of the sickle cell painful crisis. Blood 1992; 79:2154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/42\">",
"      Lawrence C, Fabry ME, Nagel RL. Red cell distribution width parallels dense red cell disappearance during painful crises in sickle cell anemia. J Lab Clin Med 1985; 105:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/43\">",
"      Fabry ME, Mears JG, Patel P, et al. Dense cells in sickle cell anemia: the effects of gene interaction. Blood 1984; 64:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/44\">",
"      Horiuchi K, Stephens MJ, Adachi K, et al. Image analysis studies of the degree of irreversible deformation of sickle cells in relation to cell density and Hb F level. Br J Haematol 1993; 85:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/45\">",
"      Franco RS, Yasin Z, Lohmann JM, et al. The survival characteristics of dense sickle cells. Blood 2000; 96:3610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/46\">",
"      Gibson JS, Speake PF, Ellory JC. Differential oxygen sensitivity of the K+-Cl- cotransporter in normal and sickle human red blood cells. J Physiol 1998; 511 ( Pt 1):225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/47\">",
"      Brugnara C, de Franceschi L, Alper SL. Inhibition of Ca(2+)-dependent K+ transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives. J Clin Invest 1993; 92:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/48\">",
"      Olivieri O, Vitoux D, Galacteros F, et al. Hemoglobin variants and activity of the (K+Cl-) cotransport system in human erythrocytes. Blood 1992; 79:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/49\">",
"      Brugnara C, Kopin AS, Bunn HF, Tosteson DC. Regulation of cation content and cell volume in hemoglobin erythrocytes from patients with homozygous hemoglobin C disease. J Clin Invest 1985; 75:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/50\">",
"      Brugnara C. Characteristics of the volume- and chloride-dependent K transport in human erythrocytes homozygous for hemoglobin C. J Membr Biol 1989; 111:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/51\">",
"      Fabry ME, Romero JR, Suzuka SM, et al. Hemoglobin C in transgenic mice with full mouse globin knockouts [abstract]. Blood 1998; 92:330a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/52\">",
"      Romero JR, Suzuka SM, Nagel RL, Fabry ME. Expression of HbC and HbS, but not HbA, results in activation of K-Cl cotransport activity in transgenic mouse red cells. Blood 2004; 103:2384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14583/abstract/53\">",
"      Eyssette-Guerreau S, Bader-Meunier B, Garcon L, et al. Infantile pyknocytosis: a cause of haemolytic anaemia of the newborn. Br J Haematol 2006; 133:439.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7074 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-221.179.173.170-189A616C48-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_15_14583=[""].join("\n");
var outline_f14_15_14583=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13067736\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLASSIC HEREDITARY XEROCYTOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      STOMATOCYTIC XEROCYTOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      HEREDITARY XEROCYTOSIS WITH HYPERPHOSPHATIDYLCHOLINE HEMOLYTIC ANEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      OTHER HEMATOLOGIC DISORDERS WITH DEHYDRATED CELLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hemoglobin C disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Infantile pyknocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H799747\">",
"      RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13067736\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7074\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7074|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/47/29438\" title=\"figure 1\">",
"      Xerocytosis flow cytometry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7074|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/30/3559\" title=\"picture 1\">",
"      Xerocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/51/9015\" title=\"picture 2\">",
"      Stomatocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/42/1703\" title=\"picture 3\">",
"      Sickle cell anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/48/5892\" title=\"picture 4\">",
"      Hemoglobin C disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37224?source=related_link\">",
"      Control of red blood cell hydration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/60/43977?source=related_link\">",
"      Overview of hemolytic anemias in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/33/34330?source=related_link\">",
"      Specific therapies for sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42200?source=related_link\">",
"      Stomatocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14330?source=related_link\">",
"      Vasoocclusion in sickle cell disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_15_14584="Causes and diagnosis of bilateral diaphragmatic paralysis";
var content_f14_15_14584=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Causes and diagnosis of bilateral diaphragmatic paralysis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/15/14584/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/15/14584/contributors\">",
"     Bartolome R Celli, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/15/14584/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/15/14584/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/15/14584/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/15/14584/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/15/14584/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventilation depends upon the ability of the respiratory pump to move air in and out of the gas exchanging portion of the lungs. The dome-shaped diaphragm is the chief muscle of inspiration and the most powerful of the respiratory muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14584/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The other main muscles of inspiration are the scalenes, external intercostals, and sternomastoids. The muscles of expiration are the internal intercostals and the muscles of the abdominal wall (including the rectus abdominus, internal and external obliques, and transversus abdominus).",
"   </p>",
"   <p>",
"    In addition to its role in the respiratory pump, the diaphragm also serves as a mechanical barrier between the abdominal and thoracic cavities and maintains the pressure gradient between the cavities.",
"   </p>",
"   <p>",
"    The causes and diagnostic evaluation of bilateral diaphragmatic paralysis in adults will be reviewed here. The clinical manifestations and evaluation of respiratory muscle weakness due to neuromuscular disease, the disorders of control of ventilation, the evaluation of unilateral diaphragmatic paralysis, the evaluation and management of diaphragm paralysis in the newborn, and the management of diaphragmatic paralysis in adults are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35142?source=see_link\">",
"     \"Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22520?source=see_link\">",
"     \"Disorders of ventilatory control\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36951?source=see_link\">",
"     \"Diaphragmatic paralysis in the newborn\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/27/44469?source=see_link\">",
"     \"Treatment of diaphragmatic paralysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12247?source=see_link\">",
"     \"Causes and diagnosis of unilateral diaphragmatic paralysis and eventration\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NORMAL DIAPHRAGM FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diaphragm has two components: the non-contractile central tendon that separates the right and left sides and extends to the dome of each hemidiaphragm and the contracting muscle fibers [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14584/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The diaphragmatic muscle fibers radiate centrifugally and insert peripherally onto the inner surface of the lower six ribs laterally, the costal cartilages and sternum anteriorly, and the arcuate ligaments that extend from the upper lumbar vertebrae to the 12",
"    <sup>",
"     th",
"    </sup>",
"    ribs posteriorly [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14584/abstract/4\">",
"     4",
"    </a>",
"    ]. The crura are posterior muscle bundles that run from the medial central tendon to the upper lumbar vertebral bodies posteriorly (L1 to L3 on the right, and L1 to L2 on the left).",
"   </p>",
"   <p>",
"    The left and right sides of diaphragm are innervated by the ipsilateral phrenic nerves, which derive from cervical nerve roots three, four, and five [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14584/abstract/4\">",
"     4",
"    </a>",
"    ]. Each nerve divides into four trunks that innervate the anterolateral, posterolateral, sternal, and crural portions of the diaphragm on that side.",
"   </p>",
"   <p>",
"    Contraction of the diaphragm has the following effects that promote air movement into the lungs [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14584/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Decrease in intrapleural pressure",
"     </li>",
"     <li>",
"      Elevation of the rib cage, using the abdomen as a fulcrum",
"     </li>",
"     <li>",
"      Expansion of the rib cage by generating positive intraabdominal pressure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the diaphragm performs most of the work of breathing, normal ventilation also requires the simultaneous contraction of some of the accessory muscles of respiration (eg, scalene and the parasternal portions of the internal and external intercostal muscles). These muscles elevate and expand the upper ribcage during inspiration and pull the ribcage down and in during expiration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ALTERED FUNCTION WITH DIAPHRAGMATIC PARALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diaphragmatic paralysis can involve either the whole diaphragm (bilateral) or only one leaflet (unilateral) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14584/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. Depending upon the degree of diaphragmatic compromise, the other hemidiaphragm or the accessory muscles of respiration assume some or all the work of breathing. This compensation is achieved by more intense contraction of the accessory muscles and by the progressive recruitment of other, less important accessory inspiratory muscles (sternomastoid, trapezius, latissimus dorsi, and pectoralis minor and major). Patients may also recruit abdominal muscles to augment exhalation, which forces the respiratory system to a low volume (below functional residual capacity) at end-exhalation. The low volume increases the elastic recoil energy in the chest wall, assisting the next inspiration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     BILATERAL DIAPHRAGMATIC PARALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilateral diaphragmatic paralysis is a severe form of respiratory muscle weakness and needs prompt evaluation and management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/27/44469?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of diaphragmatic paralysis\", section on 'Bilateral diaphragmatic paralysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilateral diaphragmatic paralysis is usually seen in the context of severe generalized muscle weakness. In some cases, however, the diaphragm is the initial or only muscle involved. The most common causes of bilateral diaphragmatic paralysis are the motor neuron and the generalized muscle diseases, although some cases are idiopathic (",
"    <a class=\"graphic graphic_table graphicRef74792 \" href=\"UTD.htm?28/18/28972\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14584/abstract/9-12\">",
"     9-12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17479766\">",
"    <span class=\"h3\">",
"     Spinal cord disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Permanent diaphragmatic paralysis occurs in patients with destructive processes involving the cervical spine, such as large tumors and spinal cord transection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/49/23321?source=see_link&amp;anchor=H12087678#H12087678\">",
"     \"Respiratory physiologic changes following spinal cord injury\", section on 'Injury at C3 through C5'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17479619\">",
"    <span class=\"h3\">",
"     Motor neuron disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree of diaphragmatic paralysis or paresis with motor neuron disease is generally in proportion to the degree of generalized muscle weakness (eg, amyotrophic lateral sclerosis) (",
"    <a class=\"graphic graphic_table graphicRef64932 \" href=\"UTD.htm?14/17/14621\">",
"     table 2",
"    </a>",
"    ). However, some patients with motor neuron disease have diaphragmatic involvement that precedes or is greater than involvement of peripheral muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14584/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40280?source=see_link\">",
"     \"Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16938?source=see_link\">",
"     \"Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease\"",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17479697\">",
"    <span class=\"h3\">",
"     Neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of neuropathies are associated with bilateral diaphragmatic paralysis, including post-polio syndrome, Guillain-Barre, post-viral neuropathy, and thyroid and autoimmune diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14584/abstract/15\">",
"     15",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    Some patients with peripheral nerve disease have primary involvement of the diaphragm. Examples include patients who develop reversible diaphragmatic paralysis after cardiac surgery and patients with post-polio syndrome. Post-polio syndrome occurs in some patients who experienced respiratory insufficiency and bulbar polio during the epidemic of the 1950s and then developed new respiratory symptoms later in life. Severe decompensation due to post-polio syndrome is unusual. It is unclear whether such progression is due to motor neuron damage or reflects an axonal process. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/45/5849?source=see_link\">",
"     \"Post-polio syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with Guillain-Barr&eacute; syndrome, the consequences of diaphragmatic paralysis are often magnified by the rapidity of onset and coexistent weakness of other ventilatory muscles. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/22/5481?source=see_link\">",
"     \"Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Post-viral neuropathy can cause potentially reversible diaphragm paralysis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14584/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Thyroid disease appears to cause reversible respiratory muscle weakness through both neuropathy and myopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23701?source=see_link&amp;anchor=H4#H4\">",
"     \"Respiratory function in thyroid disease\", section on 'Respiratory muscle weakness'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some patients with systemic lupus erythematosus, the radiographic appearance of an elevated diaphragm, called the &ldquo;shrinking lung syndrome,&rdquo; may be due to phrenic nerve involvement, although the precise etiology of this clinical disorder remains unknown and may be multifactorial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/60/11210?source=see_link&amp;anchor=H26#H26\">",
"     \"Pulmonary manifestations of systemic lupus erythematosus in adults\", section on 'Shrinking lung syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17480032\">",
"    <span class=\"h3\">",
"     Neuromuscular junction disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory failure due to diaphragmatic weakness in myasthenia gravis is a rare but serious occurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14584/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Eaton Lambert Syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14584/abstract/19\">",
"     19",
"    </a>",
"    ] and systemic botulism are presynaptic neuromuscular junction disorders which can also cause severe weakness or paralysis of the diaphragm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17206?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical manifestations of myasthenia gravis\", section on 'Respiratory muscles'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/9/35992?source=see_link\">",
"     \"Clinical features and diagnosis of Lambert-Eaton myasthenic syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/36/37448?source=see_link&amp;anchor=H10#H10\">",
"     \"Botulism\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17479626\">",
"    <span class=\"h3\">",
"     Muscle disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of myopathies are associated with bilateral diaphragm paralysis, including the following:",
"   </p>",
"   <p>",
"    Polymyositis, dermatomyositis, and inclusion body myopathy comprise the inflammatory myopathies, which can all be associated with diaphragmatic muscle weakness, generally in proportion to the degree of skeletal muscle weakness. However, occasionally the diaphragm is disproportionately affected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35142?source=see_link\">",
"     \"Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11560?source=see_link\">",
"     \"Tests of respiratory muscle strength\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Certain forms of muscular dystrophy, particularly limb-girdle muscular dystrophy, can cause diaphragmatic weakness as part of the progressive muscle disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/32/15881?source=see_link\">",
"     \"Limb-girdle muscular dystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adult patients with acid maltase deficiency typically present with progressive proximal muscle weakness in a limb girdle distribution with associated diaphragmatic involvement leading to respiratory insufficiency. The diagnosis is made by characteristic electromyogram changes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17736?source=see_link&amp;anchor=H7#H7\">",
"     \"Lysosomal acid maltase deficiency (glycogen storage disease II, Pompe disease)\", section on 'Juvenile and adult forms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypothyroidism and hyperthyroidism can impair diaphragmatic function as part of a generalized myopathy. Function reverts to normal in both cases following treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23701?source=see_link\">",
"     \"Respiratory function in thyroid disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Malnutrition, generally affects all muscle groups, but can predominantly affect the diaphragm [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14584/abstract/20\">",
"     20",
"    </a>",
"    ]. This dysfunction is reversible with refeeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Often, bilateral diaphragmatic paralysis occurs as an anticipated consequence of a known neuromuscular disease. Patients with bilateral diaphragmatic paralysis as the primary manifestation of their disease typically present with dyspnea that worsens in the supine position [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14584/abstract/11,21\">",
"     11,21",
"    </a>",
"    ]. This symptom is frequently misinterpreted as a sign of heart failure, but the evaluation for cardiac disease is negative. These processes can be differentiated in most patients as the onset of orthopnea from bilateral diaphragmatic paralysis is dramatic, occurring within minutes of recumbency, and associated with tachypnea and rapid shallow breathing. In contrast, orthopnea due to heart failure usually develops more gradually over the course of the night. Patients with bilateral diaphragm paralysis also complain of daytime fatigue, probably due to poor sleep and increased work of breathing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16553?source=see_link\">",
"     \"Approach to the patient with dyspnea\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Close observation of the breathing pattern reveals tachypnea and paradoxical abdominal wall retraction (instead of normal protrusion) during inspiration due to elevation of the anterior rib cage by accessory muscles, best appreciated when the patient is supine. Care must be taken in assessing abdominal wall motion in patients who are actively exhaling. In these individuals, contraction of the lateral oblique abdominal muscles during expiration and subsequent relaxation of these muscles as an assistance to inspiration may give the appearance of outward motion of the anterior abdominal wall during inspiration. Additional insight regarding diaphragm function may be obtained by palpating under the costal margins to feel for the descending hemidiaphragms during inspiration, manifest by caudad motion of the upper quadrant organs.",
"   </p>",
"   <p>",
"    Hypoxemia is a common finding in bilateral diaphragmatic paralysis, due primarily to the atelectasis that results from the inability to fully expand the lungs. Atelectasis causes ventilation-perfusion mismatching and hypoxemia, which worsens with sleep when the patient is in the recumbent position.",
"   </p>",
"   <p>",
"    Disease progression is associated with progressive hypercapnia and hypoxemia, which are most evident during sleep and most commonly occur in patients with an underlying systemic neuromuscular disease. Morning headaches, confusion, and signs of cor pulmonale can occur in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14584/abstract/22\">",
"     22",
"    </a>",
"    ]. Frank ventilatory failure, severe pulmonary hypertension, and secondary erythrocytosis may dominate the clinical picture in the most severe cases (",
"    <a class=\"graphic graphic_algorithm graphicRef57872 \" href=\"UTD.htm?8/49/8991\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35142?source=see_link\">",
"     \"Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Evaluation and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;When bilateral diaphragmatic paralysis is suspected clinically on the basis of dyspnea and orthopnea, a chest radiograph and pulmonary function tests are typically obtained to exclude other causes of dyspnea and to assess the severity of impairment. Neither study is completely diagnostic for diaphragmatic paralysis. The need for further testing varies with the clinical setting. Clinical observation, sitting and supine spirometry, and measurement of maximal inspiratory and expiratory pressures may be sufficient to establish the diagnosis of bilateral diaphragmatic paralysis in patients with generalized neuromuscular disease. In comparison, measurement of transdiaphragmatic pressures or performance of a diaphragmatic electromyography, with or without phrenic nerve stimulation, may be necessary in those cases in which the diagnosis is in question or the patient is being considered for diaphragmatic pacing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3303894\">",
"    <span class=\"h3\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory tests (eg, creatine&nbsp;kinase [CK], aldolase, aspartate aminotransferase [AST], alanine aminotransferase [ALT], antinuclear antibody, cerebrospinal fluid examination) are chosen based on whether generalized muscle weakness is present and whether the etiology is known. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26694?source=see_link&amp;anchor=H13#H13\">",
"     \"Approach to the patient with muscle weakness\", section on 'Clinical investigations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26028691\">",
"    <span class=\"h3\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;An upright, inspiratory chest radiograph is obtained to assess the position and contour of the diaphragm and to exclude parenchymal lung processes that might be causing the patient&rsquo;s dyspnea. Normally, the dome of the right hemidiaphragm projects anteriorly over the fifth or sixth rib and posteriorly over the tenth rib, and the dome of the left hemidiaphragm is up to one interspace lower than the right. With bilateral diaphragmatic paralysis, bilateral, smooth elevation of the hemidiaphragms and small lung volumes are usually seen, and the costophrenic and costovertebral sulci are deep and narrow. The lateral view confirms a smooth contour and elevated diaphragmatic position. Plate-like atelectasis may also be present, usually at the lung base.",
"   </p>",
"   <p>",
"    The differential diagnosis of bilateral diaphragmatic elevation on the plain chest radiograph includes subpulmonic effusions, pleural adhesions, obesity with decreased chest wall and abdominal compliance, and subdiaphragmatic processes such as ascites, organomegaly, and ileus.",
"   </p>",
"   <p>",
"    Fluoroscopy can be misleading in bilateral diaphragm paralysis because the cephalad movement of the ribs as the accessory muscles contract may give the false appearance of caudad displacement of the diaphragm. This limitation is",
"    <strong>",
"     not",
"    </strong>",
"    seen in unilateral diaphragmatic paralysis, where the sniff fluoroscopy test is positive in over 90 percent of cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12247?source=see_link&amp;anchor=H17481178#H17481178\">",
"     \"Causes and diagnosis of unilateral diaphragmatic paralysis and eventration\", section on 'Imaging'",
"    </a>",
"    .) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14584/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Computed tomographic (CT) scanning of the thorax is rarely helpful in the evaluation of bilateral diaphragm paralysis. When pleural effusion or thickening is suspected, and not diagnosed by simpler methods, CT scanning might be useful. CT scan of the abdomen can help to exclude subdiaphragmatic causes of diaphragm elevation.",
"   </p>",
"   <p>",
"    Measurement of diaphragmatic thickness by ultrasonography has been used in a small series to confirm diaphragmatic paralysis and to assess recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14584/abstract/24\">",
"     24",
"    </a>",
"    ]. However, the small field of view and obscuration of the diaphragm by intervening lung or bowel air make assessment of diaphragm function difficult. This technique requires operator expertise and its role in the assessment of diaphragmatic paralysis is unclear.",
"   </p>",
"   <p>",
"    Dynamic magnetic resonance imaging of the thorax, in which sequentially obtained still pictures are arranged in a way that reveals dynamic changes, may eventually prove to be more useful than still MRI in the evaluation of diaphragmatic paralysis, but is not part of the routine evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14584/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26028698\">",
"    <span class=\"h3\">",
"     Pulmonary function tests and arterial blood gases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important pulmonary function test in the patient with bilateral diaphragmatic paralysis is measurement of the vital capacity (VC) in the upright and supine positions. Normal recumbency results in up to a 10 percent decrease in the VC compared to the upright value. In contrast, patients with bilateral diaphragmatic paralysis show a 50 percent decrease in the VC when they are supine [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14584/abstract/26\">",
"     26",
"    </a>",
"    ]. This is due to a cephalad displacement of abdominal contents without the normal concomitant increase in diaphragmatic tone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=see_link\">",
"     \"Overview of pulmonary function testing in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11560?source=see_link\">",
"     \"Tests of respiratory muscle strength\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Maximal inspiratory and expiratory pressures (MIP, MEP) are measured to confirm respiratory muscle weakness. The maximal inspiratory pressure (MIP) reflects the strength of the diaphragm. Patients with diaphragmatic dysfunction or paralysis have decreased MIPs. This is especially true in those with systemic or generalized neuromuscular disease. The MIP in patients with bilateral diaphragm paralysis is lower (less negative) than -60 cm H2O. Rarely, the MIP is normal in patients with isolated diaphragmatic paralysis because of preserved strength of the accessory muscles. The MEP is usually normal, but may be mildly reduced, as it is measured at full inspiration and patients with diaphragmatic paralysis are unable to achieve full inspiration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11560?source=see_link&amp;anchor=H2#H2\">",
"     \"Tests of respiratory muscle strength\", section on 'Technique'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We obtain arterial blood gases in patients with bilateral diaphragmatic paralysis to assess for elevation in the partial pressure of carbon dioxide (PaCO",
"    <sub>",
"     2",
"    </sub>",
"    ) due to alveolar hypoventilation. Hypoxemia may also be present, reflecting the alteration in ventilation-perfusion matching due to poor ventilation of the lung bases.",
"   </p>",
"   <p>",
"    Magnetometers or inductance plethysmographic coils placed around the abdomen and chest may also provide diagnostic insight by revealing paradoxical chest wall motion during the respiratory cycle, although this technology is rarely used outside a research setting (",
"    <a class=\"graphic graphic_waveform graphicRef80120 \" href=\"UTD.htm?9/48/9987\">",
"     waveform 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26028764\">",
"    <span class=\"h3\">",
"     Diaphragmatic electromyography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diaphragmatic electromyography (EMG) is usually obtained as part of the evaluation for potential phrenic nerve pacing, but is not usually part of the routine evaluation of diaphragmatic paralysis as it is more invasive and only performed in specialized centers. The diaphragmatic EMG is recorded with either esophageal or surface electrodes and may show either a neuropathic or a myopathic pattern, depending on the etiology of the paralysis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14584/abstract/11,27\">",
"     11,27",
"    </a>",
"    ]. In some cases, absence of an EMG signal may indicate complete transection of the phrenic nerves. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/43/10934?source=see_link&amp;anchor=H4#H4\">",
"     \"Diaphragmatic pacing\", section on 'Assessment of phrenic nerve function'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    EMG may be complemented by phrenic nerve stimulation at the neck [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14584/abstract/28\">",
"     28",
"    </a>",
"    ]. Prolongation of nerve conduction time helps differentiate neuropathy from myopathy. However, this test requires a certain degree of expertise in its performance and interpretation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/31/2554?source=see_link\">",
"     \"Overview of nerve conduction studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26028725\">",
"    <span class=\"h3\">",
"     Measurement of transdiaphragmatic pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gold standard for the diagnosis of diaphragmatic paralysis is the objective measurement of transdiaphragmatic pressure (Pdi). This test is performed via the transnasal placement of two thin-walled balloon-tipped catheters (",
"    <a class=\"graphic graphic_waveform graphicRef80120 \" href=\"UTD.htm?9/48/9987\">",
"     waveform 1",
"    </a>",
"    ). One is placed in the lower third of the esophagus above the diaphragm to assess changing pleural pressure (Ppl); the location is adjusted to avoid cardiac contraction signals that can modify the tracing [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14584/abstract/29\">",
"     29",
"    </a>",
"    ]. The second balloon is placed in the stomach, to reflect changing abdominal or gastric pressure (Pga) (",
"    <a class=\"graphic graphic_waveform graphicRef80120 \" href=\"UTD.htm?9/48/9987\">",
"     waveform 1",
"    </a>",
"    ). In adults, the distance between the nostril and the tip of the balloon is 35 to 40 cm for the esophageal balloon and 50 to 60 cm for the gastric balloon [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14584/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Pdi is the difference between Ppl and Pga (Pdi = Ppl &ndash; Pga). The Pdi can be measured at rest, during tidal breathing (Pdi) at end inspiration or end expiration, with voluntary maneuvers such as a deep breath [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14584/abstract/30\">",
"     30",
"    </a>",
"    ], a sniff (sniff Pdi) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14584/abstract/31,32\">",
"     31,32",
"    </a>",
"    ], or a maximal inspiratory force maneuver with airflow limited by a partially closed shutter (Pdi-max) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14584/abstract/10,33\">",
"     10,33",
"    </a>",
"    ]. At peak tidal volume inspiration, the value for Pdi is negative in diaphragm paralysis, but positive if the diaphragm is working normally (",
"    <a class=\"graphic graphic_waveform graphicRef80120 \" href=\"UTD.htm?9/48/9987\">",
"     waveform 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The normal value for Pdi depends upon the method used to obtain it. Reliability is also an issue since there is great variation even in the same individual. In an attempt to avert this problem, Pdi may be measured independent of the patient's effort. This is done by electrically stimulating the phrenic nerve and measuring the twitch Pdi [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14584/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with EMG, expertise is needed in the performance and interpretation of these tests. In experienced hands, measurement of the Pdi can be extremely useful in differentiating diaphragmatic paralysis from other causes of respiratory failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3303909\">",
"    <span class=\"h3\">",
"     Polysomnography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with bilateral diaphragmatic paralysis often report dyspnea with recumbency and disturbed sleep. As patients with ventilatory disorders may have a coexistent sleep related disorder of breathing that would require an alternate therapeutic approach, we typically obtain overnight polysomnography prior to or at the same time as initiating noninvasive positive pressure ventilation (",
"    <a class=\"graphic graphic_table graphicRef79606 \" href=\"UTD.htm?20/44/21195\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/22/1382?source=see_link\">",
"     \"Evaluation of sleep-disordered breathing in patients with neuromuscular and chest wall disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/27/44469?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of diaphragmatic paralysis\", section on 'Ventilatory support'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Overnight pulse oximetry is generally not adequate testing for sleep-disordered breathing in these patients, as it underestimates the degree of hypoventilation and sleep disturbance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10603971\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diaphragm is the chief muscle of inspiration and the most powerful of the respiratory muscles. Diaphragmatic paralysis can involve either the whole diaphragm (bilateral) or only one leaflet (unilateral). The causes and diagnosis of unilateral diaphragm paralysis are discussed separately. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Normal diaphragm function'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12247?source=see_link\">",
"       \"Causes and diagnosis of unilateral diaphragmatic paralysis and eventration\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with bilateral diaphragmatic paralysis typically present with dyspnea that worsens in the supine position. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      On physical examination, close observation of the breathing pattern reveals tachypnea and paradoxical abdominal wall retraction (instead of normal protrusion) during inspiration, best appreciated when the patient is supine. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The preferred diagnostic approach to the patient with suspected bilateral diaphragm paralysis varies with the clinical setting. Clinical observation, sitting and supine spirometry, and measurement of maximal inspiratory and expiratory pressures may be sufficient to establish the diagnosis of bilateral diaphragmatic paralysis in patients with generalized neuromuscular disease. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      On an upright, inspiratory chest radiograph, bilateral, smooth elevation of the hemidiaphragms and small lung volumes are usually seen, and the costophrenic and costovertebral sulci are deep and narrow. The lateral view confirms a smooth contour and elevated diaphragmatic position. (See",
"      <a class=\"local\" href=\"#H26028691\">",
"       'Imaging studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fluoroscopy can be misleading in bilateral diaphragm paralysis because the cephalad movement of the ribs as the accessory muscles contract may give the false appearance of caudad displacement of the diaphragm. (See",
"      <a class=\"local\" href=\"#H26028691\">",
"       'Imaging studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Measurement of the vital capacity (VC) in the upright and supine positions is useful in recognition of bilateral diaphragmatic paralysis. Normal recumbency results in up to a 10 percent decrease in the VC compared to the upright value. In contrast, recumbency in patients with bilateral diaphragmatic paralysis results in a 50 percent decrease in the VC. (See",
"      <a class=\"local\" href=\"#H26028698\">",
"       'Pulmonary function tests and arterial blood gases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The gold standard for the diagnosis of diaphragmatic paralysis is the objective measurement of transdiaphragmatic pressure (Pdi). However, this testing is not usually necessary unless the diagnosis of diaphragmatic paralysis is in question. (See",
"      <a class=\"local\" href=\"#H26028725\">",
"       'Measurement of transdiaphragmatic pressure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We typically obtain overnight polysomnography prior to or at the same time as initiating nocturnal noninvasive positive pressure ventilation (NPPV), as patients with ventilatory disorders may have a coexistent sleep disturbances that require an alternate therapeutic approach (",
"      <a class=\"graphic graphic_table graphicRef79606 \" href=\"UTD.htm?20/44/21195\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3303909\">",
"       'Polysomnography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of patients with bilateral diaphragmatic paralysis is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/27/44469?source=see_link&amp;anchor=H4#H4\">",
"       \"Treatment of diaphragmatic paralysis\", section on 'Bilateral diaphragmatic paralysis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14584/abstract/1\">",
"      Roussos C, Macklem PT. The respiratory muscles. N Engl J Med 1982; 307:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14584/abstract/2\">",
"      Fell SC. Surgical anatomy of the diaphragm and the phrenic nerve. Chest Surg Clin N Am 1998; 8:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14584/abstract/3\">",
"      Rochester DF. The diaphragm: contractile properties and fatigue. J Clin Invest 1985; 75:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14584/abstract/4\">",
"      Maish MS. The diaphragm. Surg Clin North Am 2010; 90:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14584/abstract/5\">",
"      Davis J, Goldman M, Loh L, Casson M. Diaphragm function and alveolar hypoventilation. Q J Med 1976; 45:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14584/abstract/6\">",
"      Gibson GJ. Diaphragmatic paresis: pathophysiology, clinical features, and investigation. Thorax 1989; 44:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14584/abstract/7\">",
"      Laroche CM, Carroll N, Moxham J, Green M. Clinical significance of severe isolated diaphragm weakness. Am Rev Respir Dis 1988; 138:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14584/abstract/8\">",
"      Lisboa C, Par&eacute; PD, Pertuz&eacute; J, et al. Inspiratory muscle function in unilateral diaphragmatic paralysis. Am Rev Respir Dis 1986; 134:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14584/abstract/9\">",
"      Piehler JM, Pairolero PC, Gracey DR, Bernatz PE. Unexplained diaphragmatic paralysis: a harbinger of malignant disease? J Thorac Cardiovasc Surg 1982; 84:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14584/abstract/10\">",
"      Celli BR, Rassulo J, Corral R. Ventilatory muscle dysfunction in patients with bilateral idiopathic diaphragmatic paralysis: reversal by intermittent external negative pressure ventilation. Am Rev Respir Dis 1987; 136:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14584/abstract/11\">",
"      Kumar N, Folger WN, Bolton CF. Dyspnea as the predominant manifestation of bilateral phrenic neuropathy. Mayo Clin Proc 2004; 79:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14584/abstract/12\">",
"      Stojkovic T, Latour P, Viet G, et al. Vocal cord and diaphragm paralysis, as clinical features of a French family with autosomal recessive Charcot-Marie-Tooth disease, associated with a new mutation in the GDAP1 gene. Neuromuscul Disord 2004; 14:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14584/abstract/13\">",
"      Chen R, Grand'Maison F, Strong MJ, et al. Motor neuron disease presenting as acute respiratory failure: a clinical and pathological study. J Neurol Neurosurg Psychiatry 1996; 60:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14584/abstract/14\">",
"      de Carvalho M, Matias T, Coelho F, et al. Motor neuron disease presenting with respiratory failure. J Neurol Sci 1996; 139 Suppl:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14584/abstract/15\">",
"      Betensley AD, Jaffery SH, Collins H, et al. Bilateral diaphragmatic paralysis and related respiratory complications in a patient with West Nile virus infection. Thorax 2004; 59:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14584/abstract/16\">",
"      Crausman RS, Summerhill EM, McCool FD. Idiopathic diaphragmatic paralysis: Bell's palsy of the diaphragm? Lung 2009; 187:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14584/abstract/17\">",
"      Maher J, Grand'Maison F, Nicolle MW, et al. Diagnostic difficulties in myasthenia gravis. Muscle Nerve 1998; 21:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14584/abstract/18\">",
"      Valadas A, de Carvalho M. Myasthenia gravis and respiratory failure related to phrenic nerve lesion. Muscle Nerve 2008; 38:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14584/abstract/19\">",
"      Nicolle MW, Stewart DJ, Remtulla H, et al. Lambert-Eaton myasthenic syndrome presenting with severe respiratory failure. Muscle Nerve 1996; 19:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14584/abstract/20\">",
"      Murciano D, Rigaud D, Pingleton S, et al. Diaphragmatic function in severely malnourished patients with anorexia nervosa. Effects of renutrition. Am J Respir Crit Care Med 1994; 150:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14584/abstract/21\">",
"      Sandham JD, Shaw DT, Guenter CA. Acute supine respiratory failure due to bilateral diaphragmatic paralysis. Chest 1977; 72:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14584/abstract/22\">",
"      Qureshi A. Diaphragm paralysis. Semin Respir Crit Care Med 2009; 30:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14584/abstract/23\">",
"      Alexander C. Diaphragm movements and the diagnosis of diaphragmatic paralysis. Clin Radiol 1966; 17:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14584/abstract/24\">",
"      Summerhill EM, El-Sameed YA, Glidden TJ, McCool FD. Monitoring recovery from diaphragm paralysis with ultrasound. Chest 2008; 133:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14584/abstract/25\">",
"      Gierada DS, Slone RM, Fleishman MJ. Imaging evaluation of the diaphragm. Chest Surg Clin N Am 1998; 8:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14584/abstract/26\">",
"      Mier-Jedrzejowicz A, Brophy C, Moxham J, Green M. Assessment of diaphragm weakness. Am Rev Respir Dis 1988; 137:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14584/abstract/27\">",
"      Davis JN. Phrenic nerve conduction in man. J Neurol Neurosurg Psychiatry 1967; 30:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14584/abstract/28\">",
"      Bellemare F, Bigland-Ritchie B. Assessment of human diaphragm strength and activation using phrenic nerve stimulation. Respir Physiol 1984; 58:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14584/abstract/29\">",
"      American Thoracic Society/European Respiratory Society. ATS/ERS Statement on respiratory muscle testing. Am J Respir Crit Care Med 2002; 166:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14584/abstract/30\">",
"      Laporta D, Grassino A. Assessment of transdiaphragmatic pressure in humans. J Appl Physiol 1985; 58:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14584/abstract/31\">",
"      Miller JM, Moxham J, Green M. The maximal sniff in the assessment of diaphragm function in man. Clin Sci (Lond) 1985; 69:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14584/abstract/32\">",
"      Steier J, Kaul S, Seymour J, et al. The value of multiple tests of respiratory muscle strength. Thorax 2007; 62:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14584/abstract/33\">",
"      Aubier M, Murciano D, Lecocguic Y, et al. Bilateral phrenic stimulation: a simple technique to assess diaphragmatic fatigue in humans. J Appl Physiol 1985; 58:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14584/abstract/34\">",
"      Ciccolella DE, Daly BD, Celli BR. Improved diaphragmatic function after surgical plication for unilateral diaphragmatic paralysis. Am Rev Respir Dis 1992; 146:797.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5115 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-8E53C3882F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_15_14584=[""].join("\n");
var outline_f14_15_14584=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10603971\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NORMAL DIAPHRAGM FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ALTERED FUNCTION WITH DIAPHRAGMATIC PARALYSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      BILATERAL DIAPHRAGMATIC PARALYSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Etiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17479766\">",
"      - Spinal cord disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17479619\">",
"      - Motor neuron disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17479697\">",
"      - Neuropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17480032\">",
"      - Neuromuscular junction disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17479626\">",
"      - Muscle disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Evaluation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3303894\">",
"      - Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26028691\">",
"      - Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26028698\">",
"      - Pulmonary function tests and arterial blood gases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26028764\">",
"      - Diaphragmatic electromyography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26028725\">",
"      - Measurement of transdiaphragmatic pressure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3303909\">",
"      - Polysomnography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10603971\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/5115\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/5115|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?8/49/8991\" title=\"algorithm 1\">",
"      Neuromuscular respir failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/5115|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/18/28972\" title=\"table 1\">",
"      Causes diaphragmatic paralysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/17/14621\" title=\"table 2\">",
"      Differential diagnosis of ALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/44/21195\" title=\"table 3\">",
"      Sleep study indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/5115|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?9/48/9987\" title=\"waveform 1\">",
"      Transdiaphragmatic pressure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16553?source=related_link\">",
"      Approach to the patient with dyspnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26694?source=related_link\">",
"      Approach to the patient with muscle weakness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/36/37448?source=related_link\">",
"      Botulism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12247?source=related_link\">",
"      Causes and diagnosis of unilateral diaphragmatic paralysis and eventration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/22/5481?source=related_link\">",
"      Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/9/35992?source=related_link\">",
"      Clinical features and diagnosis of Lambert-Eaton myasthenic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40280?source=related_link\">",
"      Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17206?source=related_link\">",
"      Clinical manifestations of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16938?source=related_link\">",
"      Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/43/10934?source=related_link\">",
"      Diaphragmatic pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36951?source=related_link\">",
"      Diaphragmatic paralysis in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22520?source=related_link\">",
"      Disorders of ventilatory control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/22/1382?source=related_link\">",
"      Evaluation of sleep-disordered breathing in patients with neuromuscular and chest wall disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/32/15881?source=related_link\">",
"      Limb-girdle muscular dystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17736?source=related_link\">",
"      Lysosomal acid maltase deficiency (glycogen storage disease II, Pompe disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/31/2554?source=related_link\">",
"      Overview of nerve conduction studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=related_link\">",
"      Overview of pulmonary function testing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/45/5849?source=related_link\">",
"      Post-polio syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/60/11210?source=related_link\">",
"      Pulmonary manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23701?source=related_link\">",
"      Respiratory function in thyroid disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35142?source=related_link\">",
"      Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/49/23321?source=related_link\">",
"      Respiratory physiologic changes following spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11560?source=related_link\">",
"      Tests of respiratory muscle strength",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/27/44469?source=related_link\">",
"      Treatment of diaphragmatic paralysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_15_14585="Epidemiology, pathogenesis, and pathology of neuroblastoma";
var content_f14_15_14585=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, pathogenesis, and pathology of neuroblastoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/15/14585/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/15/14585/contributors\">",
"     Heidi V Russell, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/15/14585/contributors\">",
"     Jason M Shohet, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/15/14585/contributors\">",
"     Jed G Nuchtern, MD, FACS, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/15/14585/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/15/14585/contributors\">",
"     Julie R Park, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/15/14585/contributors\">",
"     Patrick Y Wen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/15/14585/contributors\">",
"     Jay S Loeffler, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/15/14585/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/15/14585/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/15/14585/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term neuroblastoma is commonly used to refer to a spectrum of neuroblastic tumors (including neuroblastomas, ganglioneuroblastomas, and ganglioneuromas) that arise from primitive sympathetic ganglion cells. The neuroectodermal cells that comprise neuroblastic tumors originate from the neural crest during fetal development, and are destined for the adrenal medulla and sympathetic nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/1\">",
"     1",
"    </a>",
"    ]. By contrast, pheochromocytomas and paragangliomas arise from a different type of cell, the chromaffin cell, that also migrates from the neural crest to the adrenal gland (",
"    <a class=\"graphic graphic_figure graphicRef53140 \" href=\"UTD.htm?15/42/16046\">",
"     figure 1",
"    </a>",
"    ). Together, both types of cells make up the adrenal medulla, a component of the sympathetic nervous system. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/14/38121?source=see_link\">",
"     \"Pheochromocytoma in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7815?source=see_link\">",
"     \"Chordoma and chondrosarcoma of the skull base\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neuroblastomas, which account for 97 percent of all neuroblastic tumors, are heterogeneous, varying in terms of location, histopathologic appearance, and biologic characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/2\">",
"     2",
"    </a>",
"    ]. They are most remarkable for their broad spectrum of clinical behavior, which can range from spontaneous regression, to maturation to a benign ganglioneuroma, or aggressive disease with metastatic dissemination leading to death [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/3\">",
"     3",
"    </a>",
"    ]. Clinical diversity correlates closely with numerous clinical and biological factors (including patient age, tumor stage and histology, and genetic and chromosomal abnormalities), although its molecular basis remains largely unknown. For example, most infants with disseminated disease have a favorable outcome following treatment with chemotherapy and surgery, while the majority of children over the age of one with advanced-stage disease die from progressive disease despite intensive multimodality therapy.",
"   </p>",
"   <p>",
"    The epidemiology, embryogenesis, molecular pathogenesis, and pathology of neuroblastoma will be presented here. The clinical presentation, diagnosis, evaluation, treatment, and prognosis of neuroblastoma are presented separately, as is a discussion of neuroblastomas arising in the olfactory epithelium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/15/15609?source=see_link\">",
"     \"Clinical presentation, diagnosis, and staging evaluation of neuroblastoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/9/18586?source=see_link\">",
"     \"Treatment and prognosis of neuroblastoma\"",
"    </a>",
"    .) Olfactory neuroblastoma, a malignancy of the olfactory epithelium, which has a different cell of origin, presentation, and treatment than neuroblastoma, also is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/46/12008?source=see_link\">",
"     \"Olfactory neuroblastoma (esthesioneuroblastoma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroblastoma is almost exclusively a disease of children. It is the third most common childhood cancer, after leukemia and brain tumors, and is the most common solid extracranial tumor in children. More than 600 cases are diagnosed in the United States each year [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/2\">",
"     2",
"    </a>",
"    ], and neuroblastoma accounts for approximately 15 percent of all pediatric cancer fatalities.",
"   </p>",
"   <p>",
"    Incidence rates are age-dependent (",
"    <a class=\"graphic graphic_figure graphicRef72658 \" href=\"UTD.htm?18/54/19310\">",
"     figure 2",
"    </a>",
"    ). The median age at diagnosis is 17.3 months, and 40 percent of patients are diagnosed before one year of age [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Neuroblastomas are the most common extracranial solid malignant tumor diagnosed during the first two years of life, and the most common cancer among infants younger than 12 months, in whom the incidence rate is almost twice that of leukemia (58 versus 37 per one million infants) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/4\">",
"     4",
"    </a>",
"    ]. The incidence of neuroblastoma is greater among white than black infants (ratio of 1.7 and 1.9 to 1 for males and females, respectively), but little if any racial difference is apparent among older children [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/2\">",
"     2",
"    </a>",
"    ]. Neuroblastoma is slightly more common among boys compared to girls [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Little is known about the etiology of sympathetic nervous system tumors. The early age of onset suggests that preconceptual or gestational environmental events (eg, exposure to drugs, hormones, toxins, or viruses) may play a role.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Maternal factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have suggested a number of maternal factors that may be associated with the subsequent development of neuroblastoma. These include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Opiate consumption &mdash; At least one case control study has linked maternal consumption of opiates (particularly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"       codeine",
"      </a>",
"      , odds ratio 3.4) while pregnant or nursing with an increased risk of neuroblastoma in children [",
"      <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Folate deficiency &mdash; Maternal folate consumption has been associated with a decreased risk of neuroblastoma. In a population-based study investigating the effect of fortification of flour with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      to prevent neural tube defects, the incidence of neuroblastoma declined from 1.6 to 0.6 cases per 10,000 births before and after fortification, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/6\">",
"       6",
"      </a>",
"      ]. This finding was consistent with an earlier association between maternal vitamin use and decreased risk of neuroblastoma [",
"      <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Toxic exposures &mdash; Epidemiologic studies provide little convincing evidence for toxic or infectious environmental exposure as an etiologic factor for the development of neuroblastoma [",
"      <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/2,8-18\">",
"       2,8-18",
"      </a>",
"      ]. However, given the identification of maternal folate deficiency as a risk factor, it is possible that case control studies in a folate deficient population might uncover an environmental factor.",
"     </li>",
"     <li>",
"      Congenital abnormalities &mdash; An association between the presence of major congenital abnormalities and the subsequent development of neuroblastoma has been reported in some [",
"      <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/19-23\">",
"       19-23",
"      </a>",
"      ], but not all [",
"      <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/13,24-26\">",
"       13,24-26",
"      </a>",
"      ], studies.",
"     </li>",
"     <li>",
"      Gestational diabetes mellitus &mdash; A case control study of 240 children with neuroblastoma showed a correlation with the presence of maternal gestational diabetes mellitus [",
"      <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/22\">",
"       22",
"      </a>",
"      ]. The effect was greatest in those children diagnosed prior to one year of age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of neuroblastomas are sporadic and not correlated with any specific constitutional germline chromosomal abnormality (see below), inherited predisposition, or associated congenital anomalies. However, there are at least some exceptions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A higher incidence of neuroblastoma has been suggested in girls with Turner syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/27\">",
"       27",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hirschsprung's disease, central hypoventilation, and neurofibromatosis type 1 (NF1) have all been described in association with neuroblastoma, suggesting the existence of a global disorder of neural crest derived cells (ie, neurocristopathy) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/28-31\">",
"       28-31",
"      </a>",
"      ]. There are scattered reports of germline NF1 gene mutations in neuroblastomas [",
"      <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/32,33\">",
"       32,33",
"      </a>",
"      ]; however, the available epidemiologic evidence does not support an etiologic role in most familial or sporadic cases [",
"      <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/31\">",
"       31",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22520?source=see_link&amp;anchor=H5#H5\">",
"       \"Disorders of ventilatory control\", section on 'Congenital central hypoventilation syndrome'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41848?source=see_link\">",
"       \"Congenital aganglionic megacolon (Hirschsprung disease)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=see_link\">",
"       \"Neurofibromatosis type 1 (von Recklinghausen's disease)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Familial neuroblastoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the majority of neuroblastomas are sporadic, in 1 to 2 percent of cases, there is a family history of neuroblastoma [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. These cases appear to be inherited in an autosomal dominant pattern with incomplete penetrance and a broad spectrum of clinical behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/37\">",
"     37",
"    </a>",
"    ]. Inherited cases usually present at an earlier age than sporadic cases (mean age 9 versus 17 months), and a large proportion have bilateral adrenal or multifocal disease. Some reports suggest that familial predisposition may be conferred through disruption of a locus at 16p12-13 (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Implications for siblings and future offspring",
"    </span>",
"    &nbsp;&mdash;&nbsp;In families without a history of multiple affected individuals, it is unlikely that a sibling of a patient with neuroblastoma will also be affected. The risk for children of survivors of neuroblastoma is difficult to determine because of the small number of cases and treatment-related infertility. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7977?source=see_link\">",
"     \"Overview of fertility and pregnancy in cancer survivors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Much remains to be learned about the molecular pathogenesis of neuroblastoma, although considerable progress has been made in the last decade. The identification of specific transformation-linked genetic changes has contributed greatly to our understanding of treatment responsiveness and prognosis, although their role in tumorigenesis remains unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Embryogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenal neuroblastomas are thought to develop from residual microscopic neuroblastic nodules, which can be detected in fetuses, most often between the 15th and 20th weeks of gestation, and regress by the time of birth or shortly thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/3,40,41\">",
"     3,40,41",
"    </a>",
"    ]. The subsequent malignant transformation of these cells may result, at least in part, from a failure to respond fully to the normal signals that stimulate morphologic differentiation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/1\">",
"     1",
"    </a>",
"    ]. The origin of extraadrenal neuroblastomas is unknown, but presumably reflects persistent rests of primitive ganglion cells in other locations as well.",
"   </p>",
"   <p>",
"    These data have been interpreted by some as supporting the view that neuroblastomas develop more often than are detected clinically and that tumors can regress spontaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/15/15609?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical presentation, diagnosis, and staging evaluation of neuroblastoma\", section on 'Screening for neuroblastoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Molecular pathogenesis and implications for prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various molecular and cytogenetic factors have been implicated in the pathogenesis of neuroblastoma, some of which have proven useful in predicting clinical behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. Some of these factors have been incorporated into the Children's Oncology Group Neuroblastoma Risk Stratification System for the selection of treatment (",
"    <a class=\"graphic graphic_table graphicRef53708 \" href=\"UTD.htm?9/21/9565\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/9/18586?source=see_link\">",
"     \"Treatment and prognosis of neuroblastoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    What follows is a brief synopsis of the major cytogenetic and molecular abnormalities that characterize neuroblastomas, with an emphasis on their prognostic value. An extensive discussion of this topic is beyond the scope of this review.",
"   </p>",
"   <p>",
"    Chromosomal deletions (loss of heterozygosity, LOH) are found in approximately 50 percent of neuroblastomas, and are consistently localized to chromosomes 1p, 11q, and 14q [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/1,47-50\">",
"     1,47-50",
"    </a>",
"    ]. Deletion of a part of chromosome 1p is one of the most common chromosomal changes observed in neuroblastoma and is associated with a poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. For example, in a study of cytogenetic factors in 89 neuroblastomas, multivariate analysis indicated that loss of chromosome 1p was a strong prognostic factor. Among patients with stage 1, 2, or 4S disease, mean three-year event-free survival was greater among those without than with allelic loss of chromosome 1p (100 versus 34 percent for those with stage 1, 2, or 4S disease and 53 versus 0 percent for those with stage 3 or 4 disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/54\">",
"     54",
"    </a>",
"    ]. The staging of neuroblastoma (",
"    <a class=\"graphic graphic_table graphicRef73974 \" href=\"UTD.htm?36/45/37595\">",
"     table 2",
"    </a>",
"    ) is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/9/18586?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment and prognosis of neuroblastoma\", section on 'Tumor stage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Deletions of 1p are highly associated with amplification (increased copy number) and overexpression of the oncogene MYCN (also called N-myc), a close relative of the oncogene c-myc that resides on chromosome 2p24-25 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/51,55\">",
"     51,55",
"    </a>",
"    ]. Gene overexpression results in persistently high levels of the MYCN protein, a DNA binding transcription factor known to cause malignant transformation in both in vitro and in vivo tumor models [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. A 50- to 400-fold amplification of MYCN is found in approximately 25 percent of neuroblastomas and is an indicator of poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/58-63\">",
"     58-63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognostic significance of MYCN amplification was illustrated by a study of 2660 patients with stage 1 or stage 2 neuroblastoma from the International Neuroblastoma Risk Group (INRB) database (",
"    <a class=\"graphic graphic_table graphicRef73974 \" href=\"UTD.htm?36/45/37595\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/63\">",
"     63",
"    </a>",
"    ]. Patients with MYCN-amplified tumors had significantly worse event-free and overall survival (53 versus 90 and 72 versus 98 percent, respectively) compared to those without MYCN amplification. A similar impact of MYCN amplification was observed in a study of 110 infants with stage 4S neuroblastoma, in whom survival was significantly worse for those with MYCN amplification compared to those without amplification (&lt;50 versus &gt;90 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among children with stage 4 neuroblastoma and without amplification of MYCN, prognosis is depends upon age [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/64\">",
"     64",
"    </a>",
"    ]. In a study from the Children's Cancer Group, the six-year event-free survival rates for those under 12 months, 12 to 18 months, 18 to 24 months, and over 24 months was 92, 74, 31, and 23 percent, respectively.",
"   </p>",
"   <p>",
"    The absence of MYCN amplification and the absence of other structural abnormalities, such as in 11q or 17q, can define low-risk tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/65\">",
"     65",
"    </a>",
"    ]. Deletions of 11q",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    14q are detected in 25 to 50 percent of neuroblastomas [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/49,50,65\">",
"     49,50,65",
"    </a>",
"    ]. Neuroblastomas that are characterized by these changes generally lack 1p deletions and MYCN amplification, and they appear to represent a distinct tumor subtype (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Genetic model of neuroblastoma development'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A gain of chromosome 17q material (trisomy 17q) occurs in over one-half of neuroblastoma and appears to be associated with a particularly aggressive phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. As an example, in one report, overall survival was significantly worse in children with trisomy 17q compared to those whose tumors had a normal 17q number (31 versus 86 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/67\">",
"     67",
"    </a>",
"    ]. In contrast, in another report, whole chromosome 17 gain was associated with increased survival [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In additional to structural chromosomal changes, alterations in total DNA content, which presumably result from mitotic dysfunction, are an important indicator of both outcome and response to therapy. Neuroblastomas with a higher DNA content (hyperdiploid, with a DNA index [DI] &gt;1) are associated with lower tumor stage, better response to initial therapy, and an overall better prognosis than diploid tumors (ie, DI = 1), particularly if they lack MYCN amplification [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/69-76\">",
"     69-76",
"    </a>",
"    ]. As an example, in one study, the two-year disease free-survival rate was 94 percent for patients with near-triploid neuroblastoma compared to 45 percent for patients with diploid tumors without MYCN amplification, and 11 percent for patients with diploid or near-diploid tumors and MYCN amplification [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/73\">",
"     73",
"    </a>",
"    ]. The influence of ploidy on outcome of neuroblastoma seems to be lost in children over the age of two, possibly because hyperdiploid tumors in older children typically have a number of structural rearrangements as well.",
"   </p>",
"   <p>",
"    Other factors that have not been incorporated into the Neuroblastoma Risk Stratification System (",
"    <a class=\"graphic graphic_table graphicRef53708 \" href=\"UTD.htm?9/21/9565\">",
"     table 1",
"    </a>",
"    ) but may affect prognosis include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Expression of neurotrophic factors, such as nerve growth factor (NGF) and brain derived neurotrophic factor (BDNF) along with their receptors (tyrosine kinases that are encoded by three TRK genes, TRK A, B and C) has been implicated in the pathogenesis of neuroblastoma, although their precise role is unclear [",
"      <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/77\">",
"       77",
"      </a>",
"      ]. Expression of TRKA is inversely correlated with MYCN amplification, and high TRKA expression appears to identify a biologically favorable subgroup of neuroblastomas, while expression of TRK B or C is prognostically unfavorable [",
"      <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/78-81\">",
"       78-81",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Variations in the anaplastic lymphoma kinase (ALK) gene have been identified in several studies as being an important contributor to the development of familial and sporadic neuroblastoma [",
"      <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/82-86\">",
"       82-86",
"      </a>",
"      ]. Somatic mutations in the tyrosine kinase region of this gene appear to have a significant role in subsequent tumor development, and ALK inhibitors are being studied as a possible therapeutic intervention.",
"     </li>",
"     <li>",
"      Telomeres are repeated nucleotide sequences that stabilize chromosomes, thereby preventing cell senescence. Telomerase is the enzyme that compensates for telomere shortening during cell division by synthesizing telomeric DNA, thereby maintaining telomere length. Preserved length of telomeres has been identified as a possible independent poor prognostic sign in children with neuroblastoma [",
"      <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/87\">",
"       87",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Gene expression profiling (GEP) may offer additional information to distinguish between patients with favorable and unfavorable prognoses [",
"      <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/88-90\">",
"       88-90",
"      </a>",
"      ]. This was illustrated by a study in which a 59 gene microarray expression was developed in a series of 579 patients and then validated in an independent cohort of 236 cases [",
"      <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/88\">",
"       88",
"      </a>",
"      ]. When clinical outcomes in the validation cohort were compared with prognosis using standard classification systems, the gene signature was an independent risk predictor, identifying patients with an increased risk of poor outcome in the current clinical-risk groups. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39674?source=see_link\">",
"       \"Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Genetic model of neuroblastoma development",
"    </span>",
"    &nbsp;&mdash;&nbsp;The molecular and cytogenetic characterization of neuroblastomas is a routine part of the clinical evaluation because of the influence of these findings on clinical outcome.",
"   </p>",
"   <p>",
"    There is increasing evidence for two or three genetic subsets of neuroblastoma that are highly predictive of clinical behavior. One classification scheme takes into account abnormalities of 1p, MYCN copy number, and assessment of DNA content to define three subtypes of disease (",
"    <a class=\"graphic graphic_figure graphicRef67284 \" href=\"UTD.htm?25/54/26469\">",
"     figure 3",
"    </a>",
"    ), which have different clinical and biologic features. This model also provides a possible explanation for the propensity of some neuroblastomas to spontaneously regress or differentiate. At least in vitro, neuroblastoma cells that have a high level of TRKA expression are prone to differentiate in the presence of NGF, while they undergo apoptosis in its absence [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The selection of treatment based upon molecular and genetic factors (ie, risk-adapted therapy) is described in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/9/18586?source=see_link\">",
"     \"Treatment and prognosis of neuroblastoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumors of neuroblastic origin are classified according to the balance between neural-type cells (primitive neuroblasts, maturing neuroblasts, and ganglion cells) and Schwann-type cells (Schwannian-blasts and mature Schwann cells) into one of three types: neuroblastoma, ganglioneuroblastoma, or ganglioneuroma. Neuroblastomas are the most undifferentiated-appearing and aggressive of this family of tumors, and they in turn may be classified as undifferentiated, poorly differentiated, or differentiating [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The degree of differentiation and stromal component of neuroblastoma tumors can be predictive of outcome and is used in the determination of Children's Oncology Group (COG) risk category for treatment. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/9/18586?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment and prognosis of neuroblastoma\", section on 'Pathologic risk classification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Neuroblastoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most undifferentiated neuroblastomas are composed almost entirely of neuroblasts, with very few Schwannian (or stromal) cells. Because of the lack of Schwannian cells, these tumors are called \"stroma-poor\" [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/1\">",
"     1",
"    </a>",
"    ]. Under light microscopy, they appear as a monotonous collection of small, round, blue cells. Morphologically, the appearance is similar to that of other small round blue cell tumors involving bone and soft tissue, including lymphoma, small cell osteosarcoma, mesenchymal chondrosarcoma, the Ewing sarcoma family of tumors, primitive neuroectodermal tumors (PNETs), and undifferentiated soft tissue sarcomas such as rhabdomyosarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/91\">",
"     91",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/37/7770?source=see_link\">",
"     \"Epidemiology, pathology, and molecular genetics of the Ewing sarcoma family of tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of their morphologic similarity, these tumors are difficult to distinguish on the basis of light microscopic findings. Electron microscopy or panels of tissue specific monoclonal antibodies can be used to help with the differentiation. Neuroblastomas typically react with antibodies that distinguish neural tissue (eg, neuron-specific enolase [NSE], synaptophysin, chromogranin, and S100). While NSE may be positive in other tumors (eg, rhabdomyosarcoma), the staining pattern is characteristically diffuse and strongly positive in neuroblastomas.",
"   </p>",
"   <p>",
"    In contrast to the undifferentiated neuroblastomas, some evidence of neural differentiation (eg, primitive neuroblasts) can be seen in the poorly differentiated and differentiating types of neuroblastoma. These cells are approximately 7 to 10 micronsin diameter, have hyperchromatic nuclei and scanty cytoplasm, and may form Homer-Wright rosettes (",
"    <a class=\"graphic graphic_picture graphicRef73187 \" href=\"UTD.htm?41/49/42768\">",
"     picture 1",
"    </a>",
"    ). The density of the neuroblasts, rate of mitosis or mitosis-karyorrhexis index (MKI), and neuroblastic differentiation can vary between neuroblastomas and even within the tumor itself.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Ganglioneuroblastoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ganglioneuroblastoma is called an \"intermixed stroma-rich\" or \"stroma-rich\" tumor because of the increased proportion of Schwannian cells. The neuroblasts, which generally have a more mature appearance, are clustered together in foci or nests surrounded by the Schwannian cells (",
"    <a class=\"graphic graphic_picture graphicRef63408 \" href=\"UTD.htm?5/38/5734\">",
"     picture 2",
"    </a>",
"    ). These tumors generally have intermediate malignant potential, between that of neuroblastomas and ganglioneuromas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Ganglioneuroma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ganglioneuroma (Schwannian cell dominant) is predominantly composed of Schwannian cells studded with maturing or fully mature ganglion cells (",
"    <a class=\"graphic graphic_picture graphicRef76244 \" href=\"UTD.htm?0/36/581\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/32,92,93\">",
"     32,92,93",
"    </a>",
"    ]. These tumors tend to occur in older children (five to seven years of age) rather than the more aggressive neuroblastomas. They are considered to be benign [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/94,95\">",
"     94,95",
"    </a>",
"    ], although they can metastasize [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/96\">",
"     96",
"    </a>",
"    ]. Nevertheless, the prognosis is excellent, even when complete tumor removal is not possible [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14585/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neuroblastomas are neuroblastic tumors of children, with a median age at diagnosis of about 17 months. The causative factors are not well defined, although various genetic disorders occasionally associated with the development of neuroblastomas. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The molecular pathogenesis of neuroblastomas has been extensively studied, and information about specific abnormalities is an important component of the definition of prognostic risk groups (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Molecular pathogenesis and implications for prognosis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Chromosomal deletions, particularly of chromosome 1p, are associated with a poor prognosis.",
"     </li>",
"     <li>",
"      Deletions of chromosome 1p are associated with amplification of the MYCN oncogene, which is associated with poor prognosis.",
"     </li>",
"     <li>",
"      The presence or absence of chromosomal abnormalities and the amplification of MYCN have been incorporated into the Children's Oncology Group Neuroblastoma Risk Stratification System (",
"      <a class=\"graphic graphic_table graphicRef53708 \" href=\"UTD.htm?9/21/9565\">",
"       table 1",
"      </a>",
"      ), which is important in determining the appropriate therapy for newly diagnosed patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/9/18586?source=see_link\">",
"       \"Treatment and prognosis of neuroblastoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Schwab, M, Shimada, H, Joshi, V, Brodeur, GM. Neuroblastic tumours of adrenal gland and sympathetic nervous system. In: Pathology and Genetics of Tumours of the Nervous System, Kleihues, P, Cavenee, WK (Eds), World Health Organization, IARC, Lyon, France 2000. p.153.",
"    </li>",
"    <li>",
"     Goodman MT, Gurney JG, Smith MA, Olshan AF. Sympathetic nervous system tumors. In: Cancer Incidence and Survival among Children and Adolescents: United States SEER Program, 1975-1995, Ries, LA, Smith, MA, Gurney, JG, et al (Eds), National Cancer Institute, Bethesda, MD 1999. p.35.",
"    </li>",
"    <li>",
"     Brodeur GM, Hogarty MD, Mosse YP, Maris JM. Neuroblastoma. In: Principles and Practice of Pediatric Oncology, Pizzo PA, Poplack DG (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. p.886.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/4\">",
"      Gurney JG, Ross JA, Wall DA, et al. Infant cancer in the U.S.: histology-specific incidence and trends, 1973 to 1992. J Pediatr Hematol Oncol 1997; 19:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/5\">",
"      Cook MN, Olshan AF, Guess HA, et al. Maternal medication use and neuroblastoma in offspring. Am J Epidemiol 2004; 159:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/6\">",
"      French AE, Grant R, Weitzman S, et al. Folic acid food fortification is associated with a decline in neuroblastoma. Clin Pharmacol Ther 2003; 74:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/7\">",
"      Olshan AF, Smith JC, Bondy ML, et al. Maternal vitamin use and reduced risk of neuroblastoma. Epidemiology 2002; 13:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/8\">",
"      Kramer S, Ward E, Meadows AT, Malone KE. Medical and drug risk factors associated with neuroblastoma: a case-control study. J Natl Cancer Inst 1987; 78:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/9\">",
"      Schwartzbaum JA. Influence of the mother's prenatal drug consumption on risk of neuroblastoma in the child. Am J Epidemiol 1992; 135:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/10\">",
"      Michalek AM, Buck GM, Nasca PC, et al. Gravid health status, medication use, and risk of neuroblastoma. Am J Epidemiol 1996; 143:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/11\">",
"      Satg&eacute; D, Sasco AJ, Little J. Antenatal therapeutic drug exposure and fetal/neonatal tumours: review of 89 cases. Paediatr Perinat Epidemiol 1998; 12:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/12\">",
"      Johnson CC, Spitz MR. Neuroblastoma: case-control analysis of birth characteristics. J Natl Cancer Inst 1985; 74:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/13\">",
"      Neglia JP, Smithson WA, Gunderson P, et al. Prenatal and perinatal risk factors for neuroblastoma. A case-control study. Cancer 1988; 61:2202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/14\">",
"      Bunin GR, Ward E, Kramer S, et al. Neuroblastoma and parental occupation. Am J Epidemiol 1990; 131:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/15\">",
"      Spitz MR, Johnson CC. Neuroblastoma and paternal occupation. A case-control analysis. Am J Epidemiol 1985; 121:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/16\">",
"      Wilkins JR 3rd, Hundley VD. Paternal occupational exposure to electromagnetic fields and neuroblastoma in offspring. Am J Epidemiol 1990; 131:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/17\">",
"      Flaegstad T, Andresen PA, Johnsen JI, et al. A possible contributory role of BK virus infection in neuroblastoma development. Cancer Res 1999; 59:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/18\">",
"      Menegaux F, Olshan AF, Neglia JP, et al. Day care, childhood infections, and risk of neuroblastoma. Am J Epidemiol 2004; 159:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/19\">",
"      Mili F, Khoury MJ, Flanders WD, Greenberg RS. Risk of childhood cancer for infants with birth defects. I. A record-linkage study, Atlanta, Georgia, 1968-1988. Am J Epidemiol 1993; 137:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/20\">",
"      Foulkes WD, Buu PN, Filiatrault D, et al. Excess of congenital abnormalities in French-Canadian children with neuroblastoma: a case series study from Montr&eacute;al. Med Pediatr Oncol 1997; 29:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/21\">",
"      Menegaux F, Olshan AF, Reitnauer PJ, et al. Positive association between congenital anomalies and risk of neuroblastoma. Pediatr Blood Cancer 2005; 45:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/22\">",
"      Chow EJ, Friedman DL, Mueller BA. Maternal and perinatal characteristics in relation to neuroblastoma. Cancer 2007; 109:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/23\">",
"      Munzer C, Menegaux F, Lacour B, et al. Birth-related characteristics, congenital malformation, maternal reproductive history and neuroblastoma: the ESCALE study (SFCE). Int J Cancer 2008; 122:2315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/24\">",
"      Buck GM, Michalek AM, Chen CJ, et al. Perinatal factors and risk of neuroblastoma. Paediatr Perinat Epidemiol 2001; 15:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/25\">",
"      Windham GC, Bjerkedal T, Langmark F. A population-based study of cancer incidence in twins and in children with congenital malformations or low birth weight, Norway, 1967-1980. Am J Epidemiol 1985; 121:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/26\">",
"      Mili F, Lynch CF, Khoury MJ, et al. Risk of childhood cancer for infants with birth defects. II. A record-linkage study, Iowa, 1983-1989. Am J Epidemiol 1993; 137:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/27\">",
"      Blatt J, Olshan AF, Lee PA, Ross JL. Neuroblastoma and related tumors in Turner's syndrome. J Pediatr 1997; 131:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/28\">",
"      Shahar E, Shinawi M. Neurocristopathies presenting with neurologic abnormalities associated with Hirschsprung's disease. Pediatr Neurol 2003; 28:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/29\">",
"      Nemecek ER, Sawin RW, Park J. Treatment of neuroblastoma in patients with neurocristopathy syndromes. J Pediatr Hematol Oncol 2003; 25:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/30\">",
"      Stovroff M, Dykes F, Teague WG. The complete spectrum of neurocristopathy in an infant with congenital hypoventilation, Hirschsprung's disease, and neuroblastoma. J Pediatr Surg 1995; 30:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/31\">",
"      Kushner BH, Hajdu SI, Helson L. Synchronous neuroblastoma and von Recklinghausen's disease: a review of the literature. J Clin Oncol 1985; 3:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/32\">",
"      Origone P, Defferrari R, Mazzocco K, et al. Homozygous inactivation of NF1 gene in a patient with familial NF1 and disseminated neuroblastoma. Am J Med Genet A 2003; 118A:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/33\">",
"      The I, Murthy AE, Hannigan GE, et al. Neurofibromatosis type 1 gene mutations in neuroblastoma. Nat Genet 1993; 3:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/34\">",
"      Arenson EB Jr, Hutter JJ Jr, Restuccia RD, Holton CP. Neuroblastoma in father and son. JAMA 1976; 235:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/35\">",
"      Maris JM, Chatten J, Meadows AT, et al. Familial neuroblastoma: a three-generation pedigree and a further association with Hirschsprung disease. Med Pediatr Oncol 1997; 28:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/36\">",
"      Kushner BH, Gilbert F, Helson L. Familial neuroblastoma. Case reports, literature review, and etiologic considerations. Cancer 1986; 57:1887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/37\">",
"      Perri P, Longo L, McConville C, et al. Linkage analysis in families with recurrent neuroblastoma. Ann N Y Acad Sci 2002; 963:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/38\">",
"      Maris JM, Weiss MJ, Mosse Y, et al. Evidence for a hereditary neuroblastoma predisposition locus at chromosome 16p12-13. Cancer Res 2002; 62:6651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/39\">",
"      Weiss MJ, Guo C, Shusterman S, et al. Localization of a hereditary neuroblastoma predisposition gene to 16p12-p13. Med Pediatr Oncol 2000; 35:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/40\">",
"      Turkel SB, Itabashi HH. The natural history of neuroblastic cells in the fetal adrenal gland. Am J Pathol 1974; 76:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/41\">",
"      Ikeda Y, Lister J, Bouton JM, Buyukpamukcu M. Congenital neuroblastoma, neuroblastoma in situ, and the normal fetal development of the adrenal. J Pediatr Surg 1981; 16:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/42\">",
"      Woods WG, Gao RN, Shuster JJ, et al. Screening of infants and mortality due to neuroblastoma. N Engl J Med 2002; 346:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/43\">",
"      Bessho F. Comparison of the incidences of neuroblastoma for screened and unscreened cohorts. Acta Paediatr 1999; 88:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/44\">",
"      Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003; 3:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/45\">",
"      Perez CA, Matthay KK, Atkinson JB, et al. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study. J Clin Oncol 2000; 18:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/46\">",
"      Riley RD, Heney D, Jones DR, et al. A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res 2004; 10:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/47\">",
"      Westermann F, Schwab M. Genetic parameters of neuroblastomas. Cancer Lett 2002; 184:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/48\">",
"      Guo C, White PS, Hogarty MD, et al. Deletion of 11q23 is a frequent event in the evolution of MYCN single-copy high-risk neuroblastomas. Med Pediatr Oncol 2000; 35:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/49\">",
"      Srivatsan ES, Ying KL, Seeger RC. Deletion of chromosome 11 and of 14q sequences in neuroblastoma. Genes Chromosomes Cancer 1993; 7:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/50\">",
"      Attiyeh EF, London WB, Moss&eacute; YP, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005; 353:2243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/51\">",
"      Maris JM, Weiss MJ, Guo C, et al. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study. J Clin Oncol 2000; 18:1888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/52\">",
"      Krona C, Ejesk&auml;r K, Abel F, et al. Screening for gene mutations in a 500 kb neuroblastoma tumor suppressor candidate region in chromosome 1p; mutation and stage-specific expression in UBE4B/UFD2. Oncogene 2003; 22:2343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/53\">",
"      Roberts T, Chernova O, Cowell JK. NB4S, a member of the TBC1 domain family of genes, is truncated as a result of a constitutional t(1;10)(p22;q21) chromosome translocation in a patient with stage 4S neuroblastoma. Hum Mol Genet 1998; 7:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/54\">",
"      Caron H, van Sluis P, de Kraker J, et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 1996; 334:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/55\">",
"      Komuro H, Valentine MB, Rowe ST, et al. Fluorescence in situ hybridization analysis of chromosome 1p36 deletions in human MYCN amplified neuroblastoma. J Pediatr Surg 1998; 33:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/56\">",
"      Cole MD, McMahon SB. The Myc oncoprotein: a critical evaluation of transactivation and target gene regulation. Oncogene 1999; 18:2916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/57\">",
"      Lutz W, St&ouml;hr M, Sch&uuml;rmann J, et al. Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene 1996; 13:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/58\">",
"      Schwab M. Oncogene amplification in solid tumors. Semin Cancer Biol 1999; 9:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/59\">",
"      Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999; 341:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/60\">",
"      Brodeur GM, Seeger RC, Schwab M, et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984; 224:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/61\">",
"      Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985; 313:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/62\">",
"      Katzenstein HM, Bowman LC, Brodeur GM, et al. Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience--a pediatric oncology group study. J Clin Oncol 1998; 16:2007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/63\">",
"      Bagatell R, Beck-Popovic M, London WB, et al. Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database. J Clin Oncol 2009; 27:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/64\">",
"      Schmidt ML, Lal A, Seeger RC, et al. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study. J Clin Oncol 2005; 23:6474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/65\">",
"      Cohn SL, Pearson AD, London WB, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009; 27:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/66\">",
"      Stallings RL, Howard J, Dunlop A, et al. Are gains of chromosomal regions 7q and 11p important abnormalities in neuroblastoma? Cancer Genet Cytogenet 2003; 140:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/67\">",
"      Bown N, Cotterill S, Lastowska M, et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 1999; 340:1954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/68\">",
"      Vandesompele J, Baudis M, De Preter K, et al. Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J Clin Oncol 2005; 23:2280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/69\">",
"      Look AT, Hayes FA, Shuster JJ, et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 1991; 9:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/70\">",
"      Look AT, Hayes FA, Nitschke R, et al. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 1984; 311:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/71\">",
"      Christiansen H, Lampert F. Tumour karyotype discriminates between good and bad prognostic outcome in neuroblastoma. Br J Cancer 1988; 57:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/72\">",
"      Kaneko Y, Kanda N, Maseki N, et al. Different karyotypic patterns in early and advanced stage neuroblastomas. Cancer Res 1987; 47:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/73\">",
"      Bourhis J, De Vathaire F, Wilson GD, et al. Combined analysis of DNA ploidy index and N-myc genomic content in neuroblastoma. Cancer Res 1991; 51:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/74\">",
"      Oppedal BR, Storm-Mathisen I, Lie SO, Brandtzaeg P. Prognostic factors in neuroblastoma. Clinical, histopathologic, and immunohistochemical features and DNA ploidy in relation to prognosis. Cancer 1988; 62:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/75\">",
"      Cohn SL, Rademaker AW, Salwen HR, et al. Analysis of DNA ploidy and proliferative activity in relation to histology and N-myc amplification in neuroblastoma. Am J Pathol 1990; 136:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/76\">",
"      Mora J, Cheung NK, Chen L, et al. Survival analysis of clinical, pathologic, and genetic features in neuroblastoma presenting as locoregional disease. Cancer 2001; 91:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/77\">",
"      Brodeur GM, Nakagawara A, Yamashiro DJ, et al. Expression of TrkA, TrkB and TrkC in human neuroblastomas. J Neurooncol 1997; 31:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/78\">",
"      Eggert A, Grotzer MA, Ikegaki N, et al. Expression of neurotrophin receptor TrkA inhibits angiogenesis in neuroblastoma. Med Pediatr Oncol 2000; 35:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/79\">",
"      Nakagawara A, Arima M, Azar CG, et al. Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Res 1992; 52:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/80\">",
"      Nakagawara A, Arima-Nakagawara M, Scavarda NJ, et al. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 1993; 328:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/81\">",
"      Suzuki T, Bogenmann E, Shimada H, et al. Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas. J Natl Cancer Inst 1993; 85:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/82\">",
"      Chen Y, Takita J, Choi YL, et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008; 455:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/83\">",
"      Janoueix-Lerosey I, Lequin D, Brugi&egrave;res L, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008; 455:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/84\">",
"      Moss&eacute; YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008; 455:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/85\">",
"      George RE, Sanda T, Hanna M, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008; 455:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/86\">",
"      Cazes A, Louis-Brennetot C, Mazot P, et al. Characterization of rearrangements involving the ALK gene reveals a novel truncated form associated with tumor aggressiveness in neuroblastoma. Cancer Res 2013; 73:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/87\">",
"      Ohali A, Avigad S, Ash S, et al. Telomere length is a prognostic factor in neuroblastoma. Cancer 2006; 107:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/88\">",
"      Vermeulen J, De Preter K, Naranjo A, et al. Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol 2009; 10:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/89\">",
"      Oberthuer A, Berthold F, Warnat P, et al. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol 2006; 24:5070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/90\">",
"      Fischer M, Oberthuer A, Brors B, et al. Differential expression of neuronal genes defines subtypes of disseminated neuroblastoma with favorable and unfavorable outcome. Clin Cancer Res 2006; 12:5118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/91\">",
"      Golden CB, Feusner JH. Malignant abdominal masses in children: quick guide to evaluation and diagnosis. Pediatr Clin North Am 2002; 49:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/92\">",
"      Shimada H, Chatten J, Newton WA Jr, et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 1984; 73:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/93\">",
"      Shimada H, Ambros IM, Dehner LP, et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999; 86:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/94\">",
"      Koch CA, Brouwers FM, Rosenblatt K, et al. Adrenal ganglioneuroma in a patient presenting with severe hypertension and diarrhea. Endocr Relat Cancer 2003; 10:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/95\">",
"      Meyer S, Reinhard H, Ziegler K, et al. Ganglianeuroma: radiological and metabolic features in 4 children. Pediatr Hematol Oncol 2002; 19:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/96\">",
"      Geoerger B, Hero B, Harms D, et al. Metabolic activity and clinical features of primary ganglioneuromas. Cancer 2001; 91:1905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14585/abstract/97\">",
"      De Bernardi B, Gambini C, Haupt R, et al. Retrospective study of childhood ganglioneuroma. J Clin Oncol 2008; 26:1710.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5204 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.117.136.88-C2C11C53A9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_15_14585=[""].join("\n");
var outline_f14_15_14585=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Maternal factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Familial neuroblastoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Implications for siblings and future offspring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Embryogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Molecular pathogenesis and implications for prognosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Genetic model of neuroblastoma development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Neuroblastoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Ganglioneuroblastoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Ganglioneuroma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/5204\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5204|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/42/16046\" title=\"figure 1\">",
"      Neural crest and embryogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/54/19310\" title=\"figure 2\">",
"      Neuroblastoma incidence by age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/54/26469\" title=\"figure 3\">",
"      Genetic model neuroblast",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5204|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/49/42768\" title=\"picture 1\">",
"      Neuroblastoma in marrow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/38/5734\" title=\"picture 2\">",
"      Ganglioneuroblastoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/36/581\" title=\"picture 3\">",
"      Ganglioneuroma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5204|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/21/9565\" title=\"table 1\">",
"      Neuroblastoma risk categories",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/45/37595\" title=\"table 2\">",
"      International neuroblastoma staging system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7815?source=related_link\">",
"      Chordoma and chondrosarcoma of the skull base",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=related_link\">",
"      Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/15/15609?source=related_link\">",
"      Clinical presentation, diagnosis, and staging evaluation of neuroblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41848?source=related_link\">",
"      Congenital aganglionic megacolon (Hirschsprung disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22520?source=related_link\">",
"      Disorders of ventilatory control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/37/7770?source=related_link\">",
"      Epidemiology, pathology, and molecular genetics of the Ewing sarcoma family of tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=related_link\">",
"      Neurofibromatosis type 1 (von Recklinghausen's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/46/12008?source=related_link\">",
"      Olfactory neuroblastoma (esthesioneuroblastoma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7977?source=related_link\">",
"      Overview of fertility and pregnancy in cancer survivors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39674?source=related_link\">",
"      Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/14/38121?source=related_link\">",
"      Pheochromocytoma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/9/18586?source=related_link\">",
"      Treatment and prognosis of neuroblastoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_15_14586="Initial treatment of fibromyalgia in adults";
var content_f14_15_14586=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial treatment of fibromyalgia in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/15/14586/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/15/14586/contributors\">",
"     Don L Goldenberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/15/14586/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/15/14586/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/15/14586/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/15/14586/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/15/14586/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibromyalgia is a chronic pain disorder that is challenging to treat. Effective interventions include a number of nonpharmacologic and pharmacologic therapies that are often provided in combination. Patients with fibromyalgia generally respond best to a multidisciplinary, individualized treatment program that incorporates both physician and non-physician providers, including physical medicine, rehabilitation, and mental health specialists [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial steps in the treatment of fibromyalgia in adults will be reviewed here. The treatment of fibromyalgia in adults who do not respond to initial therapies; the pathogenesis, clinical manifestations, diagnosis, and differential diagnosis of fibromyalgia; and fibromyalgia in children and adolescents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5786?source=see_link\">",
"     \"Treatment of fibromyalgia in adults not responsive to initial therapies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31031?source=see_link\">",
"     \"Pathogenesis of fibromyalgia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8056?source=see_link\">",
"     \"Clinical manifestations and diagnosis of fibromyalgia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35608?source=see_link\">",
"     \"Differential diagnosis of fibromyalgia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7896?source=see_link\">",
"     \"Clinical manifestations and diagnosis of fibromyalgia in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7185818\">",
"    <span class=\"h1\">",
"     OVERVIEW OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of fibromyalgia is directed at reducing the major symptoms of this disorder, including chronic widespread pain, fatigue, insomnia, and cognitive dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. A variety of modalities are employed, using a stepwise approach (",
"    <a class=\"graphic graphic_table graphicRef60515 \" href=\"UTD.htm?23/54/24427\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8056?source=see_link\">",
"     \"Clinical manifestations and diagnosis of fibromyalgia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Our initial approach to all patients with fibromyalgia includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient education regarding the disease, the treatment approaches, good sleep hygiene, and the importance of treating comorbidities that may contribute to symptoms, including mood or sleep disorders (see",
"      <a class=\"local\" href=\"#H352170621\">",
"       'Patient education'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      An exercise program, including aerobic conditioning, stretching, and strengthening (see",
"      <a class=\"local\" href=\"#H352172117\">",
"       'Exercise'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Drug monotherapy (eg, with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"       amitriptyline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"       duloxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"       pregabalin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/32/36358?source=see_link\">",
"       milnacipran",
"      </a>",
"      ) for treatment of symptoms not relieved by nonpharmacologic measures (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Medications'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Interventions that we use in patients who do not respond adequately to initial therapies are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5786?source=see_link\">",
"     \"Treatment of fibromyalgia in adults not responsive to initial therapies\"",
"    </a>",
"    .) Briefly, these include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Combinations of drugs (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5786?source=see_link&amp;anchor=H22299532#H22299532\">",
"       \"Treatment of fibromyalgia in adults not responsive to initial therapies\", section on 'Combination drug therapy'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Referral for a supervised physical therapy evaluation and treatment program (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5786?source=see_link&amp;anchor=H351009661#H351009661\">",
"       \"Treatment of fibromyalgia in adults not responsive to initial therapies\", section on 'Exercise and physical therapy'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Referral for psychological interventions for pain management, including cognitive behavioral therapy and other interventions (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5786?source=see_link&amp;anchor=H22299539#H22299539\">",
"       \"Treatment of fibromyalgia in adults not responsive to initial therapies\", section on 'Psychological therapies'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Consultation with one or more specialists, such as a rheumatologist, physiatrist, psychiatrist, psychologist, or pain management specialist, depending upon the specific expertise needed (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5786?source=see_link&amp;anchor=H351008147#H351008147\">",
"       \"Treatment of fibromyalgia in adults not responsive to initial therapies\", section on 'Consultation and referral'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Assessment and care in a specialized multidisciplinary program, particularly for patients with disease refractory to other interventions or for those on chronic opioids (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5786?source=see_link&amp;anchor=H281624293#H281624293\">",
"       \"Treatment of fibromyalgia in adults not responsive to initial therapies\", section on 'Multidisciplinary treatment programs'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Other treatments, including medications for which there is more limited evidence, and complementary and alternative measures, including &ldquo;mind-body&rdquo; therapies such as tai chi and yoga (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5786?source=see_link&amp;anchor=H22300507#H22300507\">",
"       \"Treatment of fibromyalgia in adults not responsive to initial therapies\", section on 'Analgesic and antiinflammatory drugs'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5786?source=see_link&amp;anchor=H22300584#H22300584\">",
"       \"Treatment of fibromyalgia in adults not responsive to initial therapies\", section on 'Complementary and alternative therapies'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5786?source=see_link&amp;anchor=H22300536#H22300536\">",
"       \"Treatment of fibromyalgia in adults not responsive to initial therapies\", section on 'Selective serotonin reuptake inhibitors'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nonpharmacologic interventions are important in the initial management of fibromyalgia and remain of benefit in patients with disease that does not respond to initial therapies. Some patients respond sufficiently well without drug therapy to avoid the need for medications; this is more common among those presenting in the primary care setting. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The benefits of nonpharmacologic interventions are supported by systematic reviews and a 2009 meta-analysis, which have found that cardiovascular exercise, cognitive behavioral therapy (CBT), other psychological therapies, patient education, and multidisciplinary interventions may provide benefit in patients with fibromyalgia, particularly short-term improvements in pain and health-related quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/2,3,6-8\">",
"     2,3,6-8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H352170621\">",
"    <span class=\"h1\">",
"     PATIENT EDUCATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with fibromyalgia need to understand their illness before any medications are prescribed [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]. It is important to educate the patient regarding the diagnosis and treatment of fibromyalgia, the uncertainty regarding pathogenesis, and the patient&rsquo;s role in their own treatment. This approach is supported by systematic reviews of observational studies and randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/2\">",
"     2",
"    </a>",
"    ]. When possible, such education should also include family members. (See",
"    <a class=\"local\" href=\"#H352170655\">",
"     'Effectiveness of patient education'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H352172356\">",
"     'Efficacy of exercise'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H9485848\">",
"     'Information for patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patient education should include the following elements:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reassurance that fibromyalgia is a real illness &mdash; The patient must be reassured that fibromyalgia is a real illness and is not imagined or &ldquo;in your head.&rdquo; The benign nature of the disorder should also be emphasized. As an example, patients must be told that this is not a deforming or deteriorating condition and that it is neither a life-threatening nor a cosmetic problem. The relationship of neurohormones to pain perception, fatigue, abnormal sleep, and mood disturbances should be discussed; this will help the patient to understand the rationale of therapy with medications such as tricyclic and other antidepressants and antiseizure medications.",
"     </li>",
"     <li>",
"      Lack of evidence of persistent infection &mdash; Patients should be assured that, although infections may be important precipitating factors, there is no evidence that these syndromes are related to persistent infection. Diagnostic criteria for the classification of chronic fatigue syndrome (CFS) are similar to those for fibromyalgia, and the majority of patients with CFS meet tender point criteria for fibromyalgia [",
"      <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/10\">",
"       10",
"      </a>",
"      ]. Similarly, approximately 70 percent of patients with fibromyalgia meet the criteria for CFS [",
"      <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/11\">",
"       11",
"      </a>",
"      ]. Some patients with fibromyalgia, particularly those who also meet the criteria for chronic fatigue syndrome, may believe that their illness is caused by an undiagnosed infection. In our experience, patients generally have a better response to treatment when they understand that they are not harboring some infectious agent over which they have no control. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30825?source=see_link\">",
"       \"Clinical features and diagnosis of chronic fatigue syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Role of stress and mood disorders &mdash; A review of the role of stress and mood disturbances in fibromyalgia will encourage the patient to learn simple relaxation techniques and to consider formal stress-reduction programs. Physical or emotional stress may precipitate or aggravate fibromyalgia. Additionally, approximately 30 percent of patients with fibromyalgia have major depression at the time of diagnosis. The lifetime prevalence of depression is 74 percent, and that of an anxiety disorder is 60 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/1,12,13\">",
"       1,12,13",
"      </a>",
"      ]. Patients with mood disorders should be strongly encouraged to obtain treatment for these conditions, which may be provided by primary care physicians or by experts in psychiatric care.",
"     </li>",
"     <li>",
"      Role of sleep disorders and sleep hygiene &mdash; Patients should be educated regarding good sleep hygiene and the potential benefit of correcting poor sleep habits and of recognizing and obtaining treatment for sleep disorders that may contribute to symptoms of fibromyalgia. Relatively common sleep disorders that may require intervention include obstructive sleep apnea and restless legs syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6359?source=see_link\">",
"       \"Overview of obstructive sleep apnea in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32554?source=see_link\">",
"       \"Restless legs syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Role of exercise &mdash; We counsel patients regarding the importance of exercise for reconditioning and for functional capacity and caution that a temporary increase in myalgias may occur upon initiating an exercise program. It has been suggested that blood flow to muscle and skin may be sluggish in fibromyalgia. In our experience, a discussion of the role of muscle &ldquo;spasm&rdquo; and deficient muscle blood flow is useful when prescribing exercise and physical therapy.",
"     </li>",
"     <li>",
"      Prognosis &mdash; Patients need to appreciate that their symptoms will wax and wane but that the pain and fatigue generally persist. Despite the presence of these chronic symptoms, it is reassuring to emphasize that the great majority of patients live normal and active lives.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H352170655\">",
"    <span class=\"h2\">",
"     Effectiveness of patient education",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient education, including making or confirming the diagnosis, and education regarding the nature of the disorder and the rationale for the treatment approach have a beneficial effect. Most patients have had fibromyalgia for years before the diagnosis is finally made. They often have undergone multiple diagnostic evaluations and have consulted with many different specialists. Some patients may feel rejected by the medical profession, while others may fear that a life-threatening illness will eventually be found.",
"   </p>",
"   <p>",
"    Evidence of benefit for patients and society from making the diagnosis includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study from the United Kingdom, which found that there were fewer referrals and less diagnostic testing after a fibromyalgia diagnosis was made [",
"      <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/14\">",
"       14",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Another study, in which, following a diagnosis of fibromyalgia, patients underwent less diagnostic testing and imaging and in which there were fewer specialty referrals, fewer primary care visits, and fewer drug prescriptions than prior to the diagnosis being made [",
"      <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/15\">",
"       15",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Evidence of benefit from education is illustrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The benefits of educational interventions are supported by a 2004 systematic review of treatment of fibromyalgia that assessed the effectiveness of educational interventions in patients receiving those interventions, compared with controls either waiting for care or receiving training in gentle stretching exercises [",
"      <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/2\">",
"       2",
"      </a>",
"      ]. The studies reviewed were typically unblinded. Small group sessions, printed materials, lectures, and demonstrations were used to inform patients of the nature of fibromyalgia. Numbers of sessions ranged from 6 to 17. Those receiving the educational intervention had significantly more improvement than the controls in one or more of several outcomes used, including pain, sleep, fatigue, self-efficacy, quality of life, and the six-minute walk, and beneficial effects lasted from 3 to 12 months after the sessions ended.",
"     </li>",
"     <li>",
"      A single intensive educational intervention may also be beneficial, as was the case in a study in which patients received education from a multidisciplinary team over 1.5 days [",
"      <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/16\">",
"       16",
"      </a>",
"      ]. One month later, there was significantly less pain, as well as more improvement in self-reported function, fatigue, stiffness, anxiety, and depressed mood, in those who received the educational intervention.",
"     </li>",
"     <li>",
"      Trials demonstrating the benefit of multidisciplinary nonpharmacologic treatment programs have frequently included a significant patient education component [",
"      <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]. Additionally, education focusing on self-management, combined with exercise, enhances the benefits of exercise in fibromyalgia [",
"      <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/19\">",
"       19",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H352172117\">",
"       'Exercise'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H352172356\">",
"       'Efficacy of exercise'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H352172117\">",
"    <span class=\"h1\">",
"     EXERCISE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise can be of significant benefit for pain and function, and we recommend cardiovascular fitness training for patients with fibromyalgia based upon the data from randomized trials and observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/6,20-24\">",
"     6,20-24",
"    </a>",
"    ]. In practice, it has been difficult to start and maintain fibromyalgia patients in a structured cardiovascular exercise program, because patients generally perceive that their pain and fatigue worsen as they begin to exercise. Thus, it is important to instruct patients in the principles and methods of gradual incremental cardiovascular fitness programs.",
"   </p>",
"   <p>",
"    Low-impact aerobic activities such as fast walking, biking, swimming, or water aerobics are most successful among the interventions that have been studied and in our experience [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/2,6,24,25\">",
"     2,6,24,25",
"    </a>",
"    ]. The type and intensity of the program should be individualized and should be based upon patient preference and the presence of any other cardiovascular, pulmonary, or musculoskeletal comorbidities. Physical therapists or exercise physiologists familiar with fibromyalgia can provide helpful instruction.",
"   </p>",
"   <p>",
"    Optimal cardiovascular fitness training generally requires a minimum of 30 minutes of aerobic exercise three times per week in a range near target heart rate. However, even with gradual increases in exercise, some patients may not achieve this goal, and patients should be encouraged to continue exercising regularly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28394?source=see_link&amp;anchor=H32#H32\">",
"     \"Overview of the benefits and risks of exercise\", section on 'Exercise prescription'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/28/14793?source=see_link&amp;anchor=H20#H20\">",
"     \"Exercise and fitness in the prevention of cardiovascular disease\", section on 'The exercise prescription'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional forms of exercise that have shown some benefit in fibromyalgia but which are not primarily directed at developing aerobic fitness include &ldquo;mind-body&rdquo; interventions such as tai chi and yoga. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5786?source=see_link&amp;anchor=H22300591#H22300591\">",
"     \"Treatment of fibromyalgia in adults not responsive to initial therapies\", section on 'Tai chi'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5786?source=see_link&amp;anchor=H22300598#H22300598\">",
"     \"Treatment of fibromyalgia in adults not responsive to initial therapies\", section on 'Yoga'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H352172356\">",
"    <span class=\"h2\">",
"     Efficacy of exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2008 systematic review of randomized trials of aerobic exercise for fibromyalgia, involving 2276 subjects across 34 studies, found beneficial effects on aerobic performance, pain, and pressure thresholds over tender points in those subjects who received aerobic exercise training [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/6\">",
"     6",
"    </a>",
"    ]. Improvement was seen in pain, global well-being, and physical function.",
"   </p>",
"   <p>",
"    Strength-training and flexibility exercises have not been extensively studied; however, there is some evidence of benefit from strength training. One report found comparable benefits for muscle strength training compared with an aerobic exercise program [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/20\">",
"     20",
"    </a>",
"    ]. Reports also suggest that water exercises may be an effective form of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A Canadian panel that reviewed the evidence for exercise in 2008 created a practice guideline that makes similar recommendations to ours for aerobic fitness exercises and strength training in the management of fibromyalgia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/21,26,27\">",
"     21,26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most patients, we recommend the use of medications for the treatment of the symptoms associated with fibromyalgia together with continued nonpharmacologic measures. However, some patients respond adequately to nonpharmacologic measures alone; such responses are more common among patients presenting initially to primary care physicians, compared with those initially seen by specialists or referred to specialty treatment centers. (See",
"    <a class=\"local\" href=\"#H352170621\">",
"     'Patient education'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H352172117\">",
"     'Exercise'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The medications that are the best studied and that have been most consistently effective in the treatment of fibromyalgia are certain antidepressants and selected anticonvulsants. The antidepressants include widely available tricyclic medications, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    , and several selective serotonin and norepinephrine reuptake inhibitors (SNRI), including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/32/36358?source=see_link\">",
"     milnacipran",
"    </a>",
"    . Another related tricyclic medication,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/60/13254?source=see_link\">",
"     cyclobenzaprine",
"    </a>",
"    , is also effective in patients with fibromyalgia, but it is not used to treat depression. The anticonvulsants that are beneficial include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The efficacy of these drugs compared with placebo has been demonstrated in randomized trials and meta-analyses, but there have been few direct comparisons of one with another, particularly with the older drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. We base the choice between these medications in an individual patient upon our clinical experience, patient preference, and symptoms. Factors we consider include the relative prominence of particular symptoms, including fatigue, insomnia, and depression; potential adverse effects; patient tolerance of individual medications; and patient cost and regulatory limitations on prescription choice [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We take a stepwise approach to treatment, most often initiating therapy with a tricyclic (",
"    <a class=\"graphic graphic_table graphicRef60515 \" href=\"UTD.htm?23/54/24427\">",
"     table 1",
"    </a>",
"    ). In patients with an inadequate response or with intolerance of a tricyclic, we use a SNRI (one of the dual reuptake inhibitors) or one of the anticonvulsants. An alternative initial therapy in patients with more severe fatigue or depression or with more severe sleep disturbance is a SNRI or an anticonvulsant, respectively. In general, drugs should be started at low doses and should be built up slowly. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Tricyclic antidepressants as initial drug therapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H95200155\">",
"     'Inadequate response to tricyclics'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Tricyclic antidepressants as initial drug therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tricyclic antidepressants and related agents are often effective as initial treatment for patients with fibromyalgia. We suggest initiating therapy with a low dose of a tricyclic medication (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    10 mg) at night time, especially since these drugs are effective, widely available, and far less costly for most patients than some of the newer agents. The dose may be limited by adverse side effects, especially in older adults. In patients with mild to moderate symptoms,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/60/13254?source=see_link\">",
"     cyclobenzaprine",
"    </a>",
"    is an alternative to amitriptyline.",
"   </p>",
"   <p>",
"    Individual randomized trials have demonstrated that clinically important improvement occurs in 25 to 45 percent of patients treated with these medications, compared with 0 to 20 percent of those treated with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/31-38\">",
"     31-38",
"    </a>",
"    ]. However, their use is limited by a lack of uniform effectiveness and by a relatively high frequency of side effects. In addition, the efficacy of the tricyclic drugs may decrease over time in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/35,39\">",
"     35,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    studied have been 25 to 50 mg, usually given as a single bedtime dose. These doses are usually lower than those required to treat depression. Nevertheless, even at low doses, dry mouth, constipation, fluid retention, weight gain, grogginess, and difficulty concentrating are common. Such side effects and possible cardiotoxicity limit use in older patients.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39144?source=see_link\">",
"     Desipramine",
"    </a>",
"    is a tricyclic antidepressant that has been less well-studied for fibromyalgia but that remains a possible alternative because it generally has fewer anticholinergic side effects.",
"   </p>",
"   <p>",
"    Regardless of the agent chosen, patients with fibromyalgia should be started on very low doses; a typical starting dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39144?source=see_link\">",
"     desipramine",
"    </a>",
"    is 5 to 10 mg one to three hours before bedtime. The dose may be increased by 5 mg at two-week intervals. The final dose should be set by the patient, based upon efficacy and side effects, always keeping the dose as low as possible. A dose of 20 to 30 mg is adequate in many patients, and we do not exceed a dose of 75 mg in most patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95201010\">",
"    <span class=\"h3\">",
"     Comparative efficacy of amitriptyline",
"    </span>",
"    &nbsp;&mdash;&nbsp;The comparative efficacy and side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    and the other available agents that are also used as antidepressants are illustrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 2010 systematic review and meta-analysis provided an indirect comparison that suggested greater efficacy of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"       amitriptyline",
"      </a>",
"      (AMT) compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"       duloxetine",
"      </a>",
"      (DLX) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/32/36358?source=see_link\">",
"       milnacipran",
"      </a>",
"      (MLN) in reducing pain, sleep disturbance, and fatigue, without differences in acceptability [",
"      <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/29\">",
"       29",
"      </a>",
"      ]. The strength of the conclusions was limited, to some degree, by the lower methodologic quality of the AMT trials.",
"     </li>",
"     <li>",
"      A 2009 meta-analysis comparing antidepressants for the treatment of fibromyalgia included 18 randomized trials of a variety of agents, finding evidence for efficacy of antidepressants for pain relief, fatigue, depressed mood, sleep disturbance, and improvement in health-related quality of life [",
"      <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/30\">",
"       30",
"      </a>",
"      ]. The effect sizes for tricyclic antidepressants were larger than those for selective serotonin reuptake inhibitors (SSRIs) (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      ) and for dual serotonin and norepinephrine reuptake inhibitors (SNRIs) (eg, DLX or MLN). However, the comparisons were largely indirect, and authors of the meta-analysis concluded that the data did not allow for &ldquo;a definitive conclusion regarding the superiority of one class of antidepressants over another.&rdquo; This meta-analysis did not include two additional placebo-controlled randomized trials also suggesting benefit with use of the SNRI, MLN, which were published subsequently [",
"      <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/40,41\">",
"       40,41",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H1979168\">",
"       'Milnacipran'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Cyclobenzaprine as alternative initial drug",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with mild to moderate symptoms,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/60/13254?source=see_link\">",
"     cyclobenzaprine",
"    </a>",
"    is an alternative to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    . The medications have a similar tricyclic structure and presumed mode of action in fibromyalgia, although cyclobenzaprine is thought to have minimal antidepressant effect [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/5,33\">",
"     5,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Various doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/60/13254?source=see_link\">",
"     cyclobenzaprine",
"    </a>",
"    have been used in placebo-controlled trials, including 10 mg in the morning and 20 mg at night [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/34\">",
"     34",
"    </a>",
"    ], 10 mg three times daily [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/42\">",
"     42",
"    </a>",
"    ], 10 mg in the morning and 30 mg in the evening [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/43\">",
"     43",
"    </a>",
"    ], and 10 to 40 mg daily as needed [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/33\">",
"     33",
"    </a>",
"    ]. We usually start with doses of 10 mg near bedtime and increase as tolerated to the larger doses. In patients who find an initial dose of 10 mg too sedating, we reduce the dose to 5 mg before bedtime.",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/60/13254?source=see_link\">",
"     cyclobenzaprine",
"    </a>",
"    is illustrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 2004 meta-analysis of five randomized trials included 312 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/35\">",
"       35",
"      </a>",
"      ]. Self-reported improvement (measured in three studies) was more likely in subjects receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/60/13254?source=see_link\">",
"       cyclobenzaprine",
"      </a>",
"      than placebo (odds ratio 3.0, 95% CI 1.6-5.6); the absolute difference in the rate of improvement was 21 percent, suggesting that approximately five patients would need to be treated with cyclobenzaprine for one to improve. The degree of benefit relative to placebo was similar to that observed with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"       amitriptyline",
"      </a>",
"      in trials comparing the latter drug with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/36,37\">",
"       36,37",
"      </a>",
"      ]. Pain decreased more in those who received cyclobenzaprine than placebo for four weeks, but the change in pain was not significantly different in active or placebo groups after 8 or 12 weeks. Changes in pain and in the number of tender points were not significantly different between the groups at any time.",
"     </li>",
"     <li>",
"      A randomized eight-week trial performed subsequent to the meta-analysis above and involving 36 patients found that use of very low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/60/13254?source=see_link\">",
"       cyclobenzaprine",
"      </a>",
"      (1 to 4 mg at bedtime) statistically significantly improved the symptoms of fibromyalgia, including pain, fatigue, and depression, compared with symptoms at baseline and with use of placebo, which did not result in significant improvement [",
"      <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/44\">",
"       44",
"      </a>",
"      ]. Significantly more patients who received the low-dose cyclobenzaprine had improved restorative sleep, based upon analysis of cyclic alternating pattern sleep by electroencephalography; the increase in nights with improved sleep by this measure correlated with improvements in fatigue and depression. The authors proposed that improvement in cyclic alternating sleep may be a biomarker for treatment efficacy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95200155\">",
"    <span class=\"h2\">",
"     Inadequate response to tricyclics",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who do not respond to trials of low-dose tricyclics or who have intolerable side effects, we advise a trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/32/36358?source=see_link\">",
"     milnacipran",
"    </a>",
"    , depending upon the patient&rsquo;s symptoms. These medications may also be used as an alternative to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    for initial therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients who have more severe problems due to fatigue, we use a dual uptake inhibitor (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"       duloxetine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/32/36358?source=see_link\">",
"       milnacipran",
"      </a>",
"      ) at breakfast. Duloxetine may be preferred in patients with depression requiring drug therapy, but, in such cases, care should be coordinated with a clinician with expertise in psychopharmacology of depression. In addition, regulatory factors may limit availability of one or the other agent (eg, there are differences between the US and Europe regarding which of these medications has regulatory approval for the treatment of mood disorders). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Dual reuptake inhibitors'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H1979157\">",
"       'Duloxetine'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H1979168\">",
"       'Milnacipran'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In those patients with more severe problems with sleep, we use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"       pregabalin",
"      </a>",
"      taken at bedtime.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       Gabapentin",
"      </a>",
"      is an acceptable alternative for patients for whom cost or regulatory constraints limit the availability of pregabalin. (See",
"      <a class=\"local\" href=\"#H352171895\">",
"       'Anticonvulsants (alpha2-ligands)'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H352171902\">",
"       'Pregabalin'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H352171909\">",
"       'Gabapentin'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Dual reuptake inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serotonin and norepinephrine reuptake inhibitors (SNRIs or dual reuptake inhibitors),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/32/36358?source=see_link\">",
"     milnacipran",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    , inhibit both norepinephrine and serotonin reuptake and have been evaluated in patients with fibromyalgia. Duloxetine and milnacipran, which are both available for the treatment of fibromyalgia in the United States, have shown benefit in multiple randomized trials, while venlafaxine has received more limited study [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/40,41,45-51\">",
"     40,41,45-51",
"    </a>",
"    ]. These drugs have been compared indirectly with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    and other agents. (See",
"    <a class=\"local\" href=\"#H95201010\">",
"     'Comparative efficacy of amitriptyline'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H95200969\">",
"     'Comparison of dual reuptake inhibitors and other agents'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1979157\">",
"    <span class=\"h4\">",
"     Duloxetine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients unresponsive to or intolerant of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    and in patients who have severe fatigue or who require concomitant drug therapy for depression in addition to pain, we suggest treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    in place of amitriptyline. It is also available in many countries for the treatment of depression and of diabetic neuropathy. Duloxetine should be used in the morning at breakfast. The usual starting dose in patients with fibromyalgia is 20 to 30",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    which is gradually increased to the recommended dose of 60",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"   </p>",
"   <p>",
"    The",
"    efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    in patients with fibromyalgia was initially demonstrated in two multicenter trials of 12 weeks&rsquo; duration [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. As an example, in one trial, pain was reduced by at least 30 percent in a significantly greater proportion of patients receiving duloxetine (60 mg once or twice daily) compared with those taking placebo (55 and 54 versus 33 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A longer term benefit was demonstrated in a subsequent six-month, multicenter, randomized, double-blind, placebo-controlled trial of 520 patients who were assigned to a single daily dose of either 60 mg or 120 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    or to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/47\">",
"     47",
"    </a>",
"    ]. Duloxetine statistically significantly reduced pain severity (measured on a 0 to 10 scale) in patients receiving duloxetine at three and six months (-2.0 and -2.3 versus -1.4 at both time points). Global assessments were also improved. The reductions in pain were seen in the first week of therapy and occurred in patients with and without major depression. Mental fatigue improved, but general fatigue did not. The most common side effects were nausea, headache, and dry mouth. They usually occurred within the first three months of therapy.",
"   </p>",
"   <p>",
"    In our experience, sustained responses are seen in most patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    who initially benefit from treatment, when such patients are followed for more than one year on continued therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1979168\">",
"    <span class=\"h4\">",
"     Milnacipran",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/32/36358?source=see_link\">",
"     Milnacipran",
"    </a>",
"    is an alternative to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    in patients with severe fatigue in addition to pain. We initiate therapy with 12.5 mg each morning, gradually titrating as tolerated to 50 mg twice daily. Some patients will require a higher dose; up to 100 mg twice daily may be needed.",
"   </p>",
"   <p>",
"    In randomized trials, it improved pain and global well-being more than placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/40,41,48-51\">",
"     40,41,48-51",
"    </a>",
"    ]. As an example, in one trial, 1196 patients were randomly assigned to treatment with one of two doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/32/36358?source=see_link\">",
"     milnacipran",
"    </a>",
"    or to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/40\">",
"     40",
"    </a>",
"    ]. Primary outcomes were improvement in a composite of pain, patient-reported global status, and self-reported physical function after 15 weeks of treatment. A greater than 30 percent improvement in the composite measure was significantly more likely among those receiving milnacipran at either dose (100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or 200",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    than among the placebo group (OR 1.79, 95% CI 1.14-2.8, and 1.75, 95% CI 1.11-2.75, respectively). Greater improvements in individual component scores (ie, pain, global status, and physical function) were also noted in the milnacipran-treated patients compared with the placebo group. As an example, patient-reported pain (on a 100 point scale) improved from baseline levels by a statistically greater degree in the patients receiving milnacipran than those receiving placebo (-15.7 and -17.4 versus -13).",
"   </p>",
"   <p>",
"    Adverse effects leading to discontinuation of study drug were more common in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/32/36358?source=see_link\">",
"     milnacipran",
"    </a>",
"    -treated subjects than in the placebo group (19 to 24 percent versus 9.5 percent, respectively). Commonly reported adverse effects were nausea, headache, and constipation.",
"   </p>",
"   <p>",
"    The other major trial randomly assigned 888 patients, followed similar efficacy measures, and also noted greater efficacy for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/32/36358?source=see_link\">",
"     milnacipran",
"    </a>",
"    than placebo for pain relief, improvement in global well-being, and physical function [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/41\">",
"     41",
"    </a>",
"    ]. Nausea and headache were the most frequent adverse effects.",
"   </p>",
"   <p>",
"    Responses to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/32/36358?source=see_link\">",
"     milnacipran",
"    </a>",
"    were sustained among patients responding initially in randomized trials during follow-up with continued treatment for periods of up to one year [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5084764\">",
"    <span class=\"h4\">",
"     Venlafaxine",
"    </span>",
"    &nbsp;&mdash;&nbsp;We generally do not use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    , although, as a selective serotonin and norepinephrine reuptake inhibitor (SNRI), it might be expected to provide similar benefit to that observed with other SNRIs. Additionally, it may be available to some patients at lower cost than the other SNRIs. However, there are more limited data regarding the efficacy of venlafaxine for fibromyalgia, compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/32/36358?source=see_link\">",
"     milnacipran",
"    </a>",
"    , and withdrawal symptoms may more readily occur because of the short half-life of this medication if a dose is missed. A small study using a flexible dose design in which the final mean dose of venlafaxine was 167 mg per day suggested that this agent may also be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95200969\">",
"    <span class=\"h4\">",
"     Comparison of dual reuptake inhibitors and other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dual reuptake inhibitors have been compared indirectly with each other and with other antidepressants and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    in several studies. The medications differed from one another in efficacy for particular symptoms and in their side effect profiles. A meta-analysis of the relative efficacy of DLX, pregabalin (PGB), and MLN, involving 7739 patients in 17 studies, found that all three were superior to placebo for pain relief, although DLX and PGB were superior to MLN [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/28\">",
"     28",
"    </a>",
"    ]. The drugs also differed in their effects on sleep disturbance and depression and in alleviating fatigue. Headaches and nausea were more likely with DLX and MLN; diarrhea was more likely with DLX and MLN; and cognitive defects and weight gain were more likely with PGB.",
"   </p>",
"   <p>",
"    The medications have also been compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    and other antidepressant agents. (See",
"    <a class=\"local\" href=\"#H95201010\">",
"     'Comparative efficacy of amitriptyline'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H352171895\">",
"    <span class=\"h3\">",
"     Anticonvulsants (alpha2-ligands)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The &alpha;",
"    <sub>",
"     2",
"    </sub>",
"    &delta; calcium channel modulators, also termed &alpha;",
"    <sub>",
"     2",
"    </sub>",
"    -ligands, including the anticonvulsants",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    , are beneficial for the treatment of fibromyalgia and other conditions causing chronic pain. Pregabalin and gabapentin have similar effects on cellular calcium channels and may exert their analgesic effects by blocking the release of various neurotransmitters.",
"   </p>",
"   <p>",
"    The efficacy of these agents was best described in a meta-analysis of five placebo-controlled randomized trials (four with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    and one with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    ) consisting of 2918 patients with fibromyalgia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/55\">",
"     55",
"    </a>",
"    ]. Compared with placebo, active therapy significantly reduced pain and improved sleep and quality of life. Evidence in support of the efficacy of each agent is described separately below. (See",
"    <a class=\"local\" href=\"#H352171902\">",
"     'Pregabalin'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H352171909\">",
"     'Gabapentin'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The pharmacologic properties of these medications are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=see_link&amp;anchor=H22#H22\">",
"     \"Pharmacology of antiepileptic drugs\", section on 'Drugs with other mechanisms of action'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H352171902\">",
"    <span class=\"h4\">",
"     Pregabalin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients unresponsive to or intolerant of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    and in patients with more severe sleep disturbance in addition to pain, we suggest the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    . We begin with a dose of 25 to 50 mg at bedtime before adjusting the dose upwards as tolerated to the recommended dose of 300 to 450",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    Some patients may respond to lower doses, such as 100 to 300",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    and do not require further dose escalation.",
"   </p>",
"   <p>",
"    The efficacy and safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    has been evaluated in randomized trials and in a systematic review and meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/56-60\">",
"     56-60",
"    </a>",
"    ]. In a meta-analysis involving three randomized trials and a total of 1890 patients, those allocated to receive pregabalin in any one of three doses (600, 450, and 300 mg daily) were significantly more likely to respond to treatment, defined as a &ge;30 percent reduction in pain score, compared with patients receiving placebo (odds ratios 1.7, 95% CI 1.27-2.29, 1.92, 95% CI 1.49-2.12, and 1.53, 95% CI 1.18-1.98, respectively). The trials also documented improvements in sleep, fatigue, health-related quality of life, and global well-being compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adverse events led to withdrawal from treatment in 25 percent of patients; these side effects included dizziness, somnolence, dry mouth, weight gain, and peripheral edema, and occurred with all three doses.",
"   </p>",
"   <p>",
"    The durability of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    was studied in a six-month trial during which patients initially were treated with increasing doses of pregabalin for six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/58\">",
"     58",
"    </a>",
"    ]. Among patients randomly assigned to pregabalin or placebo after initially responding to pregabalin, more of the patients continuing pregabalin maintained their response (68 versus 39 percent).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     Pregabalin",
"    </a>",
"    has also been compared indirectly with the dual reuptake inhibitors. (See",
"    <a class=\"local\" href=\"#H95200969\">",
"     'Comparison of dual reuptake inhibitors and other agents'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H352171909\">",
"    <span class=\"h4\">",
"     Gabapentin",
"    </span>",
"    &nbsp;&mdash;&nbsp;We use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    , for which evidence is more limited, as an alternative to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    in patients for whom cost of the medication or regulatory requirements limit the use of pregabalin. We begin with a dose of 100 mg at bedtime before titrating the dose upwards as tolerated and as required. The recommended dose is 1200 to 2400",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    based upon the study described below. As with pregabalin, some patients may respond to lower doses.",
"   </p>",
"   <p>",
"    The efficacy and safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    were assessed in a trial that randomly assigned 150 patients to receive gabapentin (1200 to 2400",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo for 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/61\">",
"     61",
"    </a>",
"    ]. A response was defined as at least a 30 percent decrease in the Brief Pain Inventory (BPI) score. A significantly greater proportion of patients receiving gabapentin were responders than were those in the placebo group (51 versus 31 percent, respectively), and the difference in the mean BPI scores between the two groups also favored gabapentin treatment. Gabapentin was generally well-tolerated, although dizziness, sedation, lightheadedness, and weight gain were reported significantly more often by those in the gabapentin group. There was no significant difference in the incidence of serious adverse events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H352171722\">",
"    <span class=\"h1\">",
"     TREATMENT FOR PERSISTENT SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients experience continued symptoms despite initial nonpharmacologic measures and treatment with a single pharmacologic agent at the maximum tolerated dose. There are several approaches we advise in such patients, depending upon patient preference and upon available resources and expertise. These interventions are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5786?source=see_link\">",
"     \"Treatment of fibromyalgia in adults not responsive to initial therapies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with fibromyalgia continue to have chronic pain and fatigue, although most longitudinal long-term studies of outcome in fibromyalgia have been from tertiary referral centers. One study of 538 patients followed at six referral centers found that pain, fatigue, sleep disturbances, anxiety, and depression were essentially unchanged over a follow-up period of approximately eight years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/62\">",
"     62",
"    </a>",
"    ]. Similarly, in the author&rsquo;s experience at a referral rheumatology center, there has been little change in the patients&rsquo; symptoms. However, two-thirds of patients reported that they were working full-time and that fibromyalgia interfered only modestly with their lives.",
"   </p>",
"   <p>",
"    In an observational study involving 1555 patients with fibromyalgia followed for up to 11 years by American rheumatologists, there was little clinically meaningful change in mean symptom severity, with patients reporting generally continuing high levels of symptoms and distress [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/63\">",
"     63",
"    </a>",
"    ]. There was a slight trend toward improvement, with approximately 25 percent of patients experiencing at least moderate improvement of pain over time.",
"   </p>",
"   <p>",
"    In contrast with the patient population studied from tertiary referral centers, patients treated by primary care physicians in the community have a much better prognosis. In one community survey of 141 fibromyalgia subjects, only 35 percent of those with chronic widespread pain at the initial assessment still had widespread pain two years later [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 10 to 30 percent of patients with fibromyalgia report that they are work disabled, a higher incidence than some other groups with chronic pain. In a Canadian study, for example, the incidence of disability was evaluated in 100 patients with fibromyalgia, 76 patients with widespread musculoskeletal pain, and 135 control individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/65\">",
"     65",
"    </a>",
"    ]. The proportions reporting being work disabled were 31, 11, and 2 percent, respectively. Fibromyalgia patients were also much more likely to be receiving a disability pension (26, 9, and 3 percent, respectively).",
"   </p>",
"   <p>",
"    Certain psychological factors may be associated with a better prognosis. This was illustrated in a study of 198 patients among whom the following were beliefs or sentiments that were more often shared by those with better outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/66\">",
"     66",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An increased sense of control over pain",
"     </li>",
"     <li>",
"      A belief that one is not disabled",
"     </li>",
"     <li>",
"      A belief that pain is not a sign of damage",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Behaviors that were associated with better outcomes included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Seeking help from others",
"     </li>",
"     <li>",
"      Decreased guarding during examination",
"     </li>",
"     <li>",
"      Exercising more",
"     </li>",
"     <li>",
"      Pacing activities",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Conversely, &ldquo;catastrophizing&rdquo; about the pain of fibromyalgia is associated with increased awareness of pain (as indicated by increased brain activation in response to painful stimuli in functional magnetic resonance images) and also is associated with worsening of, rather than improvement in, symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overall mortality rates do not appear to be increased in patients with fibromyalgia, but an increased risk of suicide may be present among such patients, as shown in other studies of non-cancer related chronic pain [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/68-70\">",
"     68-70",
"    </a>",
"    ]. In a study of 1361 Danish patients with fibromyalgia referred over a 16-year period, using the Danish Mortality Register, the standardized mortality ratios (SMR) for an increased risk of death from suicide was significantly increased (SMR 10.5, 95% CI 4.5-20.7) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     GUIDELINES OF PROFESSIONAL ORGANIZATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our approach is generally consistent with the recommendations of various expert panels and with the guidelines from professional organizations that have been proposed for treatment of adults with fibromyalgia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/15/14586/abstract/2,3,71\">",
"     2,3,71",
"    </a>",
"    ]. These guidelines preceded the regulatory approval of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/32/36358?source=see_link\">",
"     milnacipran",
"    </a>",
"    for fibromyalgia treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/20/43329?source=see_link\">",
"       \"Patient information: Fibromyalgia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?24/17/24854?source=see_link\">",
"       \"Patient information: Fibromyalgia (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment of fibromyalgia is directed at reducing the major symptoms of this disorder, including chronic widespread pain, fatigue, insomnia, and cognitive dysfunction. Treatment should be individualized and multidisciplinary, involving both nonpharmacologic measures and, in most patients, drug therapy. Some patients, particularly among those presenting initially to primary care physicians, may respond adequately to nonpharmacologic measures alone. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7185818\">",
"       'Overview of treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients should be educated regarding the diagnosis and treatment of fibromyalgia, the uncertainty regarding pathogenesis, and the patient&rsquo;s role in their own treatment. (See",
"      <a class=\"local\" href=\"#H352170621\">",
"       'Patient education'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H352170655\">",
"       'Effectiveness of patient education'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exercise can be of significant benefit for pain and function, and we recommend cardiovascular fitness training for patients with fibromyalgia (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Low impact aerobic activities such as fast walking, biking, swimming, or water aerobics are most successful. The type and intensity of the program should be individualized and should be based upon patient preference and the presence of any other comorbidities. (See",
"      <a class=\"local\" href=\"#H352172117\">",
"       'Exercise'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H352172356\">",
"       'Efficacy of exercise'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who do not have mild disease that responds to educational measures and exercise alone, we recommend the addition of medications (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"       amitriptyline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"       duloxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/32/36358?source=see_link\">",
"       milnacipran",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"       pregabalin",
"      </a>",
"      ) as the next step for the treatment of the symptoms associated with fibromyalgia, rather than nonpharmacologic measures alone (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). In general, drugs should be started at low doses and should be built up slowly. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest initiating therapy with a low dose of a tricyclic medication at nighttime (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"       amitriptyline",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The initial amitriptyline dose is usually 10 mg one to three hours before bedtime, increased by 5 mg at two-week intervals to the minimal dose required (eg, 25 to 50 mg). The dose may be limited by adverse side effects, especially in older adults. In patients with mild to moderate symptoms,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/60/13254?source=see_link\">",
"       cyclobenzaprine",
"      </a>",
"      is an alternative to amitriptyline. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Medications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Tricyclic antidepressants as initial drug therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Cyclobenzaprine as alternative initial drug'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who do not respond to trials of low-dose tricyclics or who have intolerable side effects, the choice of medications is guided by patient preference, by the patient&rsquo;s symptoms, and by comorbidities. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Medications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In those patients who have more severe problems due to fatigue, we suggest use of a dual uptake inhibitor (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Examples include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"       duloxetine",
"      </a>",
"      20 to 30 mg at breakfast, gradually increased to 60",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/32/36358?source=see_link\">",
"       milnacipran",
"      </a>",
"      12.5 mg each morning, gradually increased as tolerated to 50 mg twice daily. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Dual reuptake inhibitors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1979157\">",
"       'Duloxetine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1979168\">",
"       'Milnacipran'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with more severe problems with sleep, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"       pregabalin",
"      </a>",
"      taken at bedtime (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Treatment is initiated at a dose of 25 to 50 mg at bedtime and is adjusted upwards as tolerated to 300 to 450",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       Gabapentin",
"      </a>",
"      is an acceptable alternative for patients for whom cost or regulatory constraints limit the availability of pregabalin. (See",
"      <a class=\"local\" href=\"#H352171895\">",
"       'Anticonvulsants (alpha2-ligands)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H352171902\">",
"       'Pregabalin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H352171909\">",
"       'Gabapentin'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients unresponsive to a program including education, exercise, and drug monotherapy, we use additional interventions, such as drug combinations, psychological interventions, and supervised physical therapy, and may obtain additional consultation with other specialists. (See",
"      <a class=\"local\" href=\"#H7185818\">",
"       'Overview of treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5786?source=see_link\">",
"       \"Treatment of fibromyalgia in adults not responsive to initial therapies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The prognosis of fibromyalgia varies. Patients treated by primary care physicians in the community have a better prognosis than the population of patients seen in tertiary referral centers. Despite continued chronic pain and fatigue in the latter population, the majority of patients are not disabled from working. A better prognosis is associated with certain psychological factors and behaviors. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/1\">",
"      Hassett AL, Gevirtz RN. Nonpharmacologic treatment for fibromyalgia: patient education, cognitive-behavioral therapy, relaxation techniques, and complementary and alternative medicine. Rheum Dis Clin North Am 2009; 35:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/2\">",
"      Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA 2004; 292:2388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/3\">",
"      Carville SF, Arendt-Nielsen S, Bliddal H, et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 2008; 67:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/4\">",
"      Boomershine CS, Crofford LJ. A symptom-based approach to pharmacologic management of fibromyalgia. Nat Rev Rheumatol 2009; 5:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/5\">",
"      Schmidt-Wilcke T, Clauw DJ. Fibromyalgia: from pathophysiology to therapy. Nat Rev Rheumatol 2011; 7:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/6\">",
"      Busch AJ, Schachter CL, Overend TJ, et al. Exercise for fibromyalgia: a systematic review. J Rheumatol 2008; 35:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/7\">",
"      H&auml;user W, Bernardy K, Arnold B, et al. Efficacy of multicomponent treatment in fibromyalgia syndrome: a meta-analysis of randomized controlled clinical trials. Arthritis Rheum 2009; 61:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/8\">",
"      Glombiewski JA, Sawyer AT, Gutermann J, et al. Psychological treatments for fibromyalgia: a meta-analysis. Pain 2010; 151:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/9\">",
"      Burckhardt CS, Bjelle A. Education programmes for fibromyalgia patients: description and evaluation. Baillieres Clin Rheumatol 1994; 8:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/10\">",
"      Goldenberg DL, Simms RW, Geiger A, Komaroff AL. High frequency of fibromyalgia in patients with chronic fatigue seen in a primary care practice. Arthritis Rheum 1990; 33:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/11\">",
"      Aaron LA, Burke MM, Buchwald D. Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. Arch Intern Med 2000; 160:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/12\">",
"      Giesecke T, Williams DA, Harris RE, et al. Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors. Arthritis Rheum 2003; 48:2916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/13\">",
"      Arnold LM, Hudson JI, Hess EV, et al. Family study of fibromyalgia. Arthritis Rheum 2004; 50:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/14\">",
"      Hughes G, Martinez C, Myon E, et al. The impact of a diagnosis of fibromyalgia on health care resource use by primary care patients in the UK: an observational study based on clinical practice. Arthritis Rheum 2006; 54:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/15\">",
"      Annemans L, Wessely S, Spaepen E, et al. Health economic consequences related to the diagnosis of fibromyalgia syndrome. Arthritis Rheum 2008; 58:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/16\">",
"      Pfeiffer A, Thompson JM, Nelson A, et al. Effects of a 1.5-day multidisciplinary outpatient treatment program for fibromyalgia: a pilot study. Am J Phys Med Rehabil 2003; 82:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/17\">",
"      Luciano JV, Mart&iacute;nez N, Pe&ntilde;arrubia-Mar&iacute;a MT, et al. Effectiveness of a psychoeducational treatment program implemented in general practice for fibromyalgia patients: a randomized controlled trial. Clin J Pain 2011; 27:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/18\">",
"      Lera S, Gelman SM, L&oacute;pez MJ, et al. Multidisciplinary treatment of fibromyalgia: does cognitive behavior therapy increase the response to treatment? J Psychosom Res 2009; 67:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/19\">",
"      Rooks DS, Gautam S, Romeling M, et al. Group exercise, education, and combination self-management in women with fibromyalgia: a randomized trial. Arch Intern Med 2007; 167:2192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/20\">",
"      Bircan C, Karasel SA, Akg&uuml;n B, et al. Effects of muscle strengthening versus aerobic exercise program in fibromyalgia. Rheumatol Int 2008; 28:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/21\">",
"      Brosseau L, Wells GA, Tugwell P, et al. Ottawa Panel evidence-based clinical practice guidelines for strengthening exercises in the management of fibromyalgia: part 2. Phys Ther 2008; 88:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/22\">",
"      Gusi N, Tomas-Carus P. Cost-utility of an 8-month aquatic training for women with fibromyalgia: a randomized controlled trial. Arthritis Res Ther 2008; 10:R24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/23\">",
"      Tomas-Carus P, Gusi N, H&auml;kkinen A, et al. Eight months of physical training in warm water improves physical and mental health in women with fibromyalgia: a randomized controlled trial. J Rehabil Med 2008; 40:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/24\">",
"      Busch AJ, Webber SC, Brachaniec M, et al. Exercise therapy for fibromyalgia. Curr Pain Headache Rep 2011; 15:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/25\">",
"      Thomas EN, Blotman F. Aerobic exercise in fibromyalgia: a practical review. Rheumatol Int 2010; 30:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/26\">",
"      Sa&ntilde;udo B, Galiano D, Carrasco L, et al. Effects of a prolonged exercise program on key health outcomes in women with fibromyalgia: a randomized controlled trial. J Rehabil Med 2011; 43:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/27\">",
"      Sa&ntilde;udo B, Galiano D, Carrasco L, et al. Aerobic exercise versus combined exercise therapy in women with fibromyalgia syndrome: a randomized controlled trial. Arch Phys Med Rehabil 2010; 91:1838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/28\">",
"      H&auml;user W, Petzke F, Sommer C. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. J Pain 2010; 11:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/29\">",
"      H&auml;user W, Petzke F, &Uuml;&ccedil;eyler N, Sommer C. Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis. Rheumatology (Oxford) 2011; 50:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/30\">",
"      H&auml;user W, Bernardy K, U&ccedil;eyler N, Sommer C. Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis. JAMA 2009; 301:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/31\">",
"      Goldenberg DL, Felson DT, Dinerman H. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum 1986; 29:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/32\">",
"      Carette S, McCain GA, Bell DA, Fam AG. Evaluation of amitriptyline in primary fibrositis. A double-blind, placebo-controlled study. Arthritis Rheum 1986; 29:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/33\">",
"      Bennett RM, Gatter RA, Campbell SM, et al. A comparison of cyclobenzaprine and placebo in the management of fibrositis. A double-blind controlled study. Arthritis Rheum 1988; 31:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/34\">",
"      Carette S, Bell MJ, Reynolds WJ, et al. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. A randomized, double-blind clinical trial. Arthritis Rheum 1994; 37:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/35\">",
"      Tofferi JK, Jackson JL, O'Malley PG. Treatment of fibromyalgia with cyclobenzaprine: A meta-analysis. Arthritis Rheum 2004; 51:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/36\">",
"      Arnold LM, Keck PE Jr, Welge JA. Antidepressant treatment of fibromyalgia. A meta-analysis and review. Psychosomatics 2000; 41:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/37\">",
"      O'Malley PG, Balden E, Tomkins G, et al. Treatment of fibromyalgia with antidepressants: a meta-analysis. J Gen Intern Med 2000; 15:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/38\">",
"      Carette S, Oakson G, Guimont C, Steriade M. Sleep electroencephalography and the clinical response to amitriptyline in patients with fibromyalgia. Arthritis Rheum 1995; 38:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/39\">",
"      U&ccedil;eyler N, H&auml;user W, Sommer C. A systematic review on the effectiveness of treatment with antidepressants in fibromyalgia syndrome. Arthritis Rheum 2008; 59:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/40\">",
"      Clauw DJ, Mease P, Palmer RH, et al. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther 2008; 30:1988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/41\">",
"      Mease PJ, Clauw DJ, Gendreau RM, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. J Rheumatol 2009; 36:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/42\">",
"      Reynolds WJ, Moldofsky H, Saskin P, Lue FA. The effects of cyclobenzaprine on sleep physiology and symptoms in patients with fibromyalgia. J Rheumatol 1991; 18:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/43\">",
"      Quimby LG, Gratwick GM, Whitney CD, Block SR. A randomized trial of cyclobenzaprine for the treatment of fibromyalgia. J Rheumatol Suppl 1989; 19:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/44\">",
"      Moldofsky H, Harris HW, Archambault WT, et al. Effects of bedtime very low dose cyclobenzaprine on symptoms and sleep physiology in patients with fibromyalgia syndrome: a double-blind randomized placebo-controlled study. J Rheumatol 2011; 38:2653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/45\">",
"      Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004; 50:2974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/46\">",
"      Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005; 119:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/47\">",
"      Russell IJ, Mease PJ, Smith TR, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008; 136:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/48\">",
"      Vitton O, Gendreau M, Gendreau J, et al. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol 2004; 19 Suppl 1:S27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/49\">",
"      Gendreau RM, Thorn MD, Gendreau JF, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 2005; 32:1975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/50\">",
"      Branco JC, Zachrisson O, Perrot S, et al. A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. J Rheumatol 2010; 37:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/51\">",
"      Arnold LM, Gendreau RM, Palmer RH, et al. Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010; 62:2745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/52\">",
"      Branco JC, Cherin P, Montagne A, et al. Longterm therapeutic response to milnacipran treatment for fibromyalgia. A European 1-year extension study following a 3-month study. J Rheumatol 2011; 38:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/53\">",
"      Goldenberg DL, Clauw DJ, Palmer RH, et al. Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study. Pain Med 2010; 11:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/54\">",
"      Sayar K, Aksu G, Ak I, Tosun M. Venlafaxine treatment of fibromyalgia. Ann Pharmacother 2003; 37:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/55\">",
"      H&auml;user W, Bernardy K, U&ccedil;eyler N, Sommer C. Treatment of fibromyalgia syndrome with gabapentin and pregabalin--a meta-analysis of randomized controlled trials. Pain 2009; 145:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/56\">",
"      Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/57\">",
"      Mease PJ, Russell IJ, Arnold LM, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 2008; 35:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/58\">",
"      Crofford LJ, Mease PJ, Simpson SL, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain 2008; 136:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/59\">",
"      Tzellos TG, Toulis KA, Goulis DG, et al. Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis. J Clin Pharm Ther 2010; 35:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/60\">",
"      Arnold LM, Russell IJ, Diri EW, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 2008; 9:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/61\">",
"      Arnold LM, Goldenberg DL, Stanford SB, et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum 2007; 56:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/62\">",
"      Wolfe F, Anderson J, Harkness D, et al. Health status and disease severity in fibromyalgia: results of a six-center longitudinal study. Arthritis Rheum 1997; 40:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/63\">",
"      Walitt B, Fitzcharles MA, Hassett AL, et al. The longitudinal outcome of fibromyalgia: a study of 1555 patients. J Rheumatol 2011; 38:2238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/64\">",
"      Fitzcharles MA, Costa DD, P&ouml;yhi&auml; R. A study of standard care in fibromyalgia syndrome: a favorable outcome. J Rheumatol 2003; 30:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/65\">",
"      White KP, Speechley M, Harth M, Ostbye T. Comparing self-reported function and work disability in 100 community cases of fibromyalgia syndrome versus controls in London, Ontario: the London Fibromyalgia Epidemiology Study. Arthritis Rheum 1999; 42:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/66\">",
"      Nielson WR, Jensen MP. Relationship between changes in coping and treatment outcome in patients with Fibromyalgia Syndrome. Pain 2004; 109:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/67\">",
"      Gracely RH, Geisser ME, Giesecke T, et al. Pain catastrophizing and neural responses to pain among persons with fibromyalgia. Brain 2004; 127:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/68\">",
"      Dreyer L, Kendall S, Danneskiold-Sams&oslash;e B, et al. Mortality in a cohort of Danish patients with fibromyalgia: increased frequency of suicide. Arthritis Rheum 2010; 62:3101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/69\">",
"      Ratcliffe GE, Enns MW, Belik SL, Sareen J. Chronic pain conditions and suicidal ideation and suicide attempts: an epidemiologic perspective. Clin J Pain 2008; 24:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/70\">",
"      Gilbert JW, Wheeler GR, Storey BB, et al. Suicidality in chronic noncancer pain patients. Int J Neurosci 2009; 119:1968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/15/14586/abstract/71\">",
"      H&auml;user W, Thieme K, Turk DC. Guidelines on the management of fibromyalgia syndrome - a systematic review. Eur J Pain 2010; 14:5.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5627 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-481C146FAB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_15_14586=[""].join("\n");
var outline_f14_15_14586=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7185818\">",
"      OVERVIEW OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H352170621\">",
"      PATIENT EDUCATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H352170655\">",
"      Effectiveness of patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H352172117\">",
"      EXERCISE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H352172356\">",
"      Efficacy of exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Tricyclic antidepressants as initial drug therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H95201010\">",
"      - Comparative efficacy of amitriptyline",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Cyclobenzaprine as alternative initial drug",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95200155\">",
"      Inadequate response to tricyclics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Dual reuptake inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1979157\">",
"      Duloxetine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1979168\">",
"      Milnacipran",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5084764\">",
"      Venlafaxine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H95200969\">",
"      Comparison of dual reuptake inhibitors and other agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H352171895\">",
"      - Anticonvulsants (alpha2-ligands)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H352171902\">",
"      Pregabalin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H352171909\">",
"      Gabapentin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H352171722\">",
"      TREATMENT FOR PERSISTENT SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      GUIDELINES OF PROFESSIONAL ORGANIZATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/5627\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5627|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/54/24427\" title=\"table 1\">",
"      Stepwise FM therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30825?source=related_link\">",
"      Clinical features and diagnosis of chronic fatigue syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8056?source=related_link\">",
"      Clinical manifestations and diagnosis of fibromyalgia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7896?source=related_link\">",
"      Clinical manifestations and diagnosis of fibromyalgia in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35608?source=related_link\">",
"      Differential diagnosis of fibromyalgia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/28/14793?source=related_link\">",
"      Exercise and fitness in the prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6359?source=related_link\">",
"      Overview of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28394?source=related_link\">",
"      Overview of the benefits and risks of exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31031?source=related_link\">",
"      Pathogenesis of fibromyalgia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/17/24854?source=related_link\">",
"      Patient information: Fibromyalgia (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/20/43329?source=related_link\">",
"      Patient information: Fibromyalgia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=related_link\">",
"      Pharmacology of antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32554?source=related_link\">",
"      Restless legs syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5786?source=related_link\">",
"      Treatment of fibromyalgia in adults not responsive to initial therapies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_15_14587="Analgesia for sterilization";
var content_f14_15_14587=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drugs used during laparoscopic sterilization under local anesthesia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Time of administration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ibuprofen",
"       </td>",
"       <td>",
"        800 mg",
"       </td>",
"       <td>",
"        Oral 30 minutes before procedure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atropine",
"       </td>",
"       <td>",
"        0.4-0.6 mg",
"       </td>",
"       <td>",
"        Intravenous on arrival in operating room",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Midazolam HCl",
"       </td>",
"       <td>",
"        2.5 mg",
"       </td>",
"       <td>",
"        Intravenous in divided doses during preparation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fentanyl",
"       </td>",
"       <td>",
"        0.05-0.1 mg",
"       </td>",
"       <td>",
"        Intravenous during preparation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fentanyl or alfentanil",
"       </td>",
"       <td>",
"        0.5-1.0 mg",
"       </td>",
"       <td>",
"        Intravenous as needed for pain during procedure",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_15_14587=[""].join("\n");
var outline_f14_15_14587=null;
var title_f14_15_14588="Tips for sleeping better at night PI";
var content_f14_15_14588=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F67141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F67141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Tips for sleeping better at night",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        During the day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Exercise on a regular basis, even if it's only a 20-minute walk each day. Don't exercise in the evening.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Limit naps if you can. If you must nap, don't nap more than 30 minutes.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Before bedtime",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avoid alcohol, caffeine, chocolate, and nicotine (cigarettes) in the late afternoon and evening",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Limit liquids in the evening before going to bed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Turn off the TV 1 hour before bedtime. Listen to quiet music or take a warm bath.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If you worry or \"can't turn your brain off\" when you try to sleep, write out a list of the things you need to do before you go to bed. Then stop thinking about them.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        At bedtime",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Go to bed and get up at the same time every day, even on weekends",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A bedtime snack of warm milk, turkey, or a banana might make you sleepy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use your bedroom only for sleep and sex. Do not read, watch TV, or work in the bedroom.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If you are a \"clock watcher\", turn your clock so that you cannot see its face",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        To fall asleep, lie in the position that you are normally in when you wake up",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Go to bed at the same time as your spouse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        If you can't fall asleep",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If you haven't fallen asleep in 15 minutes, go to another room. Listen to quiet music or read a self-help book. Avoid watching TV or reading an exciting book. Go back to bed when you feel sleepy. If you still can't fall asleep, get up again and repeat as needed.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        If you wake up during the night",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If you can't get back to sleep, follow the steps above (under \"If you can't fall asleep\")",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_15_14588=[""].join("\n");
var outline_f14_15_14588=null;
var title_f14_15_14589="Diff dx GERD in CF";
var content_f14_15_14589=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80386&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80386&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of symptoms of gastroesophageal reflux in patients with cystic fibrosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        1. Regurgitation or vomiting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Central nervous system",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Psychogenic vomiting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Increased intracranial pressure (brain tumor, abscess)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vascular (migraine, severe hypertension)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vestibular disease, \"motion sickness\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Seizures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        (digoxin, theophylline), toxins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Pharyngeal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypersensitive gag reflex, thick secretions (sinusitis), large tonsils",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Gastric",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Inflammation (peptic ulcer disease)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dysmotility (gastroparesis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Obstruction (bezoar, pyloric stenosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Intestinal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Infection/inflammation (enteritis, appendicitis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dysmotility (diabetic neuropathy, intestinal pseudo-obstruction)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Obstruction (malrotation/volvulus, superior mesenteric artery syndrome, adhesions, intussusception, meconium ileus, distal intestinal obstruction syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nutrient intolerance (cow's milk, soy, gluten, eosinophilic enteropathy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Hepatobiliary or pancreatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Hepatitis, cholecystitis, pancreatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Cardiac",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Intestinal ischemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Renal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Pyelonephritis, hydronephrosis, calculi, glomerulonephritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Respiratory",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Post-tussive (pneumonia, common cold)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Miscellaneous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Sepsis, pregnancy; improper feeding techniques",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        2. Esophageal discomfort (dysphagia/heartburn/odynophagia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primary esophageal dysmotility (achalasia, diffuse esophageal spasm)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Esophagitis due to the other etiologies (candida, pill-induced)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pleural, mediastinal, cardiac, chest wall, or abdominal wall pain (cough-myalgia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Functional, malingering",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        3. Hematemesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemoptysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oral, nasal, or pharyngeal bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other esophageal bleeding sources (varices, Mallory-Weiss tear)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastroduodenal bleeding: peptic ulcer disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        4. Respiratory disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reactive airways (allergens - eg, aspergillosis; irritants - eg, cigarettes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infection (tuberculosis, mycoplasma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extrinsic compression (vascular ring)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Instrinsic obstruction (foreign body)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Ferry, G, Klish, WJ, Borowitz, D, et al, Consensus conference: Gastrointestinal problems in cystic fibrosis. In: Clinical practice guidelines foe cystic fibrosis, Vol II, Cystic Fibrosis Foundation, Bethesda, MD 1991.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_15_14589=[""].join("\n");
var outline_f14_15_14589=null;
var title_f14_15_14590="Deschamp ligature carrier";
var content_f14_15_14590=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F53873&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F53873&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Deschamp Aneurysm Ligature Carrier",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 229px; height: 457px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_15_14590=[""].join("\n");
var outline_f14_15_14590=null;
var title_f14_15_14591="Eval uni prenatal hydroneph";
var content_f14_15_14591=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74670&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74670&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 498px\">",
"   <div class=\"ttl\">",
"    Postnatal evaluation of unilateral prenatal hydronephrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 478px; height: 569px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Severity of the hydronephrosis is based upon the length of the renal pelvis diameter measured in the third trimester; mild &lt;9 mm, moderate 9 to 15 mm, and severe &gt;15 mm.",
"    <div class=\"footnotes\">",
"     US: ultrasound; VCUG: voiding cystourethrogram.",
"     <br>",
"      * If a ureter, ureterocele, thickened bladder, renal cysts, or renal echogenicity are demonstrated on prenatal ultrasound, evaluation with a postnatal ultrasound should occur before hospital discharge (&lt;48 hours of life).",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_15_14591=[""].join("\n");
var outline_f14_15_14591=null;
